

























γ‐secretase  is  a  membrane‐bound  proteolytic  complex,    formed  by  nicastrin,  APH1, 
presenilin  and  pen‐2, which  cleaves  over  sixty  known  substrates,  including Notch  and  E‐
cadherin, thus regulating cellular processes such as proliferation and adhesion. High  levels 
of nicastrin have been demonstrated  in 47.3 % (n=1050) high tumour grade breast tissues, 
whereas  it  is  absent  in  100%  normal  human  breast  (n=40). Although  the mechanism  for 
nicastrin  up‐regulation  in  breast  cancer  is  unknown,  preliminary  data  suggests  post‐
transcriptional  regulation.  Therefore,  γ‐secretase  is  an  important  therapeutic  target  in 
breast cancer. 
GSI1, a commercial γ‐secretase  inhibitor  is cytotoxic exclusively for breast cancer cell  lines, 
whereas  non‐tumourigenic  breast  cells  are  not  affected.  GSI1  triggers  G2/M  arrest, 
culminating  in apoptosis  through down‐regulation of XIAP, Bcl‐2, Bax and Bcl‐XL  in breast 
cancer cells.  In addition, similar cytotoxicity has been found  in a panel of cell  lines derived 
from  several  types  of  cancer. We  discuss whether  the  cytotoxic  effect  of GSI1  in  breast 
cancer cell lines is mediated through inhibition of γ‐secretase or the proteasome. 




Disseminated  and  circulating  tumour  cells  (CTCs)  are  clinically  used  as  indicators  of 
metastasis. Nicastrin has been found to be expressed by a rare population of cells  in bone 
marrow aspirates and in CTCs from breast cancer patients with high risk of relapse.  
Thus,  from  the  pharmacological  point  of  view,  nicastrin  represents  a  novel  therapeutic 






















Western  blotting  of  apoptotic  proteins  in  response  to GSI1,  endpoint  PCRs  for GSI1  and 
siRNA were performed by Dr Rajeshkumar Balasubramanian. Primers were designed by Dr 
Martin  Slade.  Optimisation  of  primers  was  conducted  between  Dr  Rajeshkumar 
Balasubramanian and I. 





Blood  samples  used  for  CTC,  PBMC  and  CTCscope  analysis were  collected  by  Dr  Adrian 
Zebrowski and Dr Jonathon Krell at Charing Cross Hospital, London.  
Blood for CTCscope were processed using Cellsearch™ by Rachel Payne.  
Blood samples processed  for CTCscope were processed by myself, and sent  to  the United 
States, where CTCscope RNA  in  situ hybridisation  and microscopy was performed by  Fay 
Wang at Advanced Cell Diagnostics. 
Flow cytometry acquisition was performed by Dr Yuan Zhou. 
Q‐RT‐PCR  experimentation  and  data  analysis  of  the  healthy  tissue  panel  was  done  in 
collaboration with Caroline Adams. 
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septa separating the  individual  lobes. The ducts are  internally  lined with  luminal epithelial 
cells which face the lumen and propagate lactation. The majority of breast cancers originate 
from  these  luminal  epithelial  cells.  The  periphery  of  the  ducts  is  lined  by a  layer  of 
myoepthelial  cells  (also  known  as  basal  cells),  which  are  adjacent  to  the  basement 
membrane, connected to the chest wall and have contractile properties that push milk from 















































normal  proliferation  and  apoptosis  to  activate  a  capacity  to  grow  infinitely,  as  well  as 
increase angiogenesis [2, 3].  
The  accumulation  of  genetic mutations  is  also  an  important  contributory  factor  in  the 
tumourigenesis  process.  Genetic  instability  increases  the  risk  of  developing  genetic 
mutations,  which  include,  gene  loss,  amplifications  or  chromosomal  translocations  [4]. 
Acquisition of  genetic mutations  can  result  in  gain‐of‐function  in proteins  (oncogenes) or 
loss‐of‐function  (tumour  suppressor genes  (TSGs)). Activation of oncogenes or absence of 
TSGs  fuels  the  tumourigenesis process.  For  instance, mutations  in  the BRCA1  and BRCA2 
TSGs  increase  susceptibility  to  breast  cancer  by  74  ‐  80%  [5].  Examples  of  selected 
oncogenes  and  TSGs  frequently  expressed  proteins  or mutated  genes  in  breast  cancer, 
which  increase the possibility of breast cancer formation, are  listed  in Table 1.1. There are 












































































by preventing  the aromatase enzyme  from catalysing androgens  into oestrogens  [19, 20]. 
For  instance,  exemestane  covalently  binds  to  aromatase  and  suppresses  its  activity  [21], 
whereas  letrozole  and  anastrozol  compete with  oestrogen  precursors  for  the  enzymatic 
active site. Some AI’s can reduce ER ligands [22], while fulvestrant can degrade ER itself [23]. 
Although AI’s are effective  in post‐menopausal women,  their use  is not  recommended  in 









is because  the  receptor  structures differ between  cell  types  [25].  Three  SERMS  are used 
clinically: tamoxifen, raloxifene and toremifene. Tamoxifen works by binding directly to the 
ER, thus preventing ligand interaction and consequent downstream signalling [19]. Because 





form of  the disease, and are associated with poor prognosis  [27].  Limitations  in available 
treatments hinder treatment and chemotherapy is usually the primary remedial action [28]. 
Cytotoxic chemotherapeutic agents reduce and/or kill cancerous growth through targeting 
DNA synthesis,  for example, by either cross‐linking DNA  (eg cyclophosphomide),  inhibiting 
mitotic  spindle  segregation  (for example, paclitaxel and docetaxel  [29]) or  inhibiting DNA 
topoisomerase II (for example, doxorubicin) [30, 31]. Despite administration of these drugs 




Since deregulation of growth  factor  signalling  is a  common hallmark of  cancer, drugs are 
being developed against  these pathways. For  instance, breast cancers are associated with 
elevated  epidermal  growth  factor  receptor  (EGFR) which  activates  the mitogen  activated 




cancer  proliferation  and  survival.  These  findings  have  been  exploited  to  develop  drugs 












































is  also  an  increased  risk  of  tamoxifen‐induced  endometrial  cancer,  as  it  mimics  the 
oestrogen effects in the uterus, and can cause thromboembolic complications [35]. A study 
of  19,000 women  comparing  a new  SERM,  raloxifene with  tamoxifen  reduces  the  risk of 
uterine cancer by 36% and blood clotting by 29% whilst being as effective  in reducing the 





ligand‐receptor  binding  (pertuzamab)  or  downstream  signalling molecules  (tipifarnib  and 
sorafenib)  (Figure 1.2). Some of  these new drugs  show effective  response  in clinical  trials 
with breast  cancers, whereas others  such as gefitinib and erlotinib had  shown  less effect 
[33].  In addition, some patients have an  inherent resistance  (de novo resistance) to drugs, 












decade.  The  γ‐secretase  complex  cleaves  over  sixty  known  proteins,  the  most  well 





Briefly,  the  γ‐secretase  complex  is  an  unusual  tetrameric  protease  protein  complex, 
comprised  of  nicastrin,  presenilin,  anterior  pharynx  defective‐1  (APH1)  and  presenilin 
enhancer  protein‐2  (pen‐2)  [45].  Presenilin within  the  complex  exists  as  two  associated 
fragments,  the  C‐terminal  fragment  (PS‐CTF)  and N‐terminal  fragment  (NTF)  (Figure  1.3). 
Cleavage  of  APP  and  Notch  produce  an  intracellular  domain  termed  AICD  and  NICD 

















active  γ‐secretase  complex  at  the  plasma  membrane.  Numbers  relate  to  the 
transmembrane domain. Presenilin undergoes endoproteolysis (indicated by *) to form and 




The  γ‐secretase  complex  has  been  classified  within  a  new  group  of  proteases  termed 
intramembrane –cleaving proteases (I‐CLiPs) which have the capacity to conduct regulated 
intramembrane proteolysis (RIP), that is, to cleave transmembrane domains of substrates by 
hydrolysis  within  a  hydrophobic  environment  like  the  lipid  bilayer  [38,  50].  However, 
proteins classed within  I‐CLiPs operate as single proteins, whereas  γ‐secretase  is a unique 
member  in  the  group  as  a  tetrameric  complex.  Nicastrin,  APH1,  PS‐CTF‐NTF  and  pen‐2 
proteins assemble  in a 1:1:1:1  ratio  in  the endoplasmic  reticulum  to  form  the  γ‐secretase 
complex  [51‐53].  Immature nicastrin associates with and stabilises one of  the  three splice 
variant homologues of APH1 in a sub‐complex [54‐57]. The enzyme component, presenilin, 





































































form  a  subcomplex  in  the  endoplasmic  reticulum  (A).  From  here,  the most  recognised 
biogenesis  theory  (1)  is  that  full‐length  presenilin  holoprotein  is  incorporated  to  form  a 
trimeric complex (B). Addition of pen‐2 triggers presenilin endoproteolysis  into PS‐CTF and 
PS‐NTF  fragments,  leading  to  nicastrin maturation  by  glycosylation  (C)  and  formation  of 
active  γ‐  secretase  (F),  which  is  transported  to  the  plasma  membrane.  An  alternative 
assembly  hypothesis  (2)  proposes  that  full‐length  presenilin  forms  a  sub‐complex 
independently of  the nicastrin‐APH1  complex, where endoproteolysis of presenilin occurs 







There  is  a  sense  of  co‐dependancy  and  co‐regulation  between  the  γ‐secretase  proteins, 
which  is  essential  for  γ‐secretase  assembly.  For  example,  NCSTN  RNAi  in  HEK293  cells 
reduces  presenilin  1  and  2  CTF  and NTF  fragments  [63]. Moreover,  absence  of  nicastrin 
protein in NCSTN ‐/‐ mouse embryonic fibroblasts (MEFs), results in proteasomal degradation 
of pen‐2, and proteasomal and lysosomal degradation of APH1a is [64]. In this model, APH1, 
pen‐2,  PS‐NTF  and  ‐CTF  fragments  are  reduced,  and  unprocessed  full‐length  presenilin 
protein increased [64], demonstrating decreased γ‐secretase assembly. Conversely, in PSEN 
‐/‐ null MEFs cells, mature nicastrin and pen‐2 protein  is ablated [51, 65]. RNAi knockout of 
PSEN  in HEK293  cells  also  causes  an  accretion  in  immature nicastrin,  [63]. This  is  further 
illustrated  in  PSEN1  ‐/‐  mouse  brain  lysates,  nicastrin  glycosylation  and  overall  protein 
expression  is dependent on  the presence of presenilin, as demonstrated by  the dramatic 




holoprotein  in  S2,  HeLa  and  neuronal  cells  [67].  Full‐length  presenilin  is  stabilised  by 
simultaneous  expression  of  APH1A  and  nicastrin  [67].Pen‐2  undergoes  proteasomal 
degradation  in  the  absence of presenilin  [68], whilst pen‐2  knockdown prevents nicastrin 
maturation  [65,  69].  These  findings  demonstrate  that  absence  of  one  of  the  γ‐secretase 






Experimental overexpression of nicastrin does not  simply  increase  the amount of mature 
glycosylated  nicastrin  [70],  but  increases  γ‐secretase  activity  on  APP  fragments  without 
impinging  on  PS1‐NTF  protein  levels  [71].  This may  indicate  that  nicastrin  is  perhaps  a 
limiting factor in γ‐secretase formation. This may be corroborated by several other findings. 
For  instance,  there  is  a  dose‐dependent  decrease  in  Aβ40  and  Aβ42  (products  of  APP 
resulting  from  γ‐secretase  cleavage,  see  section 1.4.2) of  levels  in  response  to NCSTN  +/+, 
NCSTN  +/‐  and NCSTN  ‐/‐ MEFs  [72].  Furthermore,  a protein  identified  in  zebrafish, nicalin, 
was  found  to  be  a  distant  homolog  of  nicastrin.  Nicalin  binds  in  a  complex with  nodal 
modulator  (NOMO)  and  transmembrane  protein  147  (TMEM147), which  regulates  nodal 






Despite  studies  examining  the  structure  of  the  γ‐secretase  complex,  elucidation  of  the 
composition  is made  difficult  by  the  fact  that  the  four  integral members  together  have 
nineteen transmembrane domains. The molecular weight of the complex  is debated  in the 
literature‐  suggested  weights  range  between  250‐2000  kDa,  which  may  be  due  to 
differential experimental methods and biological systems employed.  It may also be due to 
transitory protein  interactions between the γ‐secretase proteins. The varying glycosylation 






al  (Figure  1.5,  A,  C  [77]),  which  allowed  a more  sensitive  and  accurate  cryo‐EM  to  be 
performed  as  opposed  to  electron  microscopy.  Analysis  of  the  γ‐secretase  structure 
indicated a globular structure, containing a large hydrophilic cavity, and two pores. Through 
lectin  labelling, glycosylated nicastrin  is  located at the top of the complex, which can bind 
and present substrates within a  large central cavity. Presenilin TMD6 and 7 are postulated 
to reside  in the central cavity, which can sequester water from the environment to cleave 
substrates  that enter  the central pore  [77‐79]. Release of  the extracellular  fragments exit 
the  complex  through pore H1  to be  released  in  to  the extracellular  space, whilst  the  ICD 
fragment  is  released  into  the  cytosol  via  the  H2  pore  (Figure  1.5,  B  [77]).  Electron 
























rendering of 3D electron microscopy of  the  complex  in  the CHO  cell  line  (A, B)  reveals a 
globular  structure.  The  blue  belt  represents  the  putative  transmembrane  domain  of  the 
complex  (A).  Lectin  binding  indicates  nicastrin  is  located  on  the  top  surface.    Cross‐
sectioning of  (A)  reveals  two pores  (H1  and H2),  through which,  after  cleavage  in  the  γ‐
secretase central pore, substrate fragments may be released into the cytoplasm [77, 81]. 3D 
electron microscopy conducted by another group from γ‐secretase reconstituted in Sf9 cells 
shows a  less  compact and  flat heart‐shaped  complex, with pores on  the  surface  (C)  [80]. 
Astericises depict areas of low resolution in the experimental procedure (B). 
 
Electron microscopy by  Lazarov et al  suggested  γ‐secretase has a mass of ~230 kDa  [76], 
agreeing with the 1:1:1:1 stoichiometry [53], and is approximately the sum of the molecular 
weights  (Mr)  of  the  four  components  (PS‐NTF Mr:  ~20  kDa,  PS‐CTF Mr:  ~20  kDa, mature 










which  through  co‐immunoprecipitation  studies,  have  been  shown  to  associate  with  γ‐





Endoplasmic  control  appears  important  for  γ‐secretase  formation.    However,  only  the 
carboxyl  terminus  of  presenilin  1  [87]  and  TMD1  of  pen‐2  [88],  have  an  endoplasmic 
reticulum  retention motif, whereas nicastrin  is devoid of one  [89].  γ‐secretase  formation 
within  the endoplasmic  reticulum  is  regulated  through  the protein Rer1p  (retrieval  to  the 
endoplasmic reticulum). Rer1p  is a small cargo molecule  involved  in retrieval and shuttling 
of  membrane  proteins  between  the  Golgi  and  endoplasmic  reticulum  [90].  Immature 
nicastrin  is  retained  in  the endoplasmic  reticulum  through  interaction with Rer1p  via  the 
polar  residues  in  nicastrin  TMD  [91,  92].  This  interaction  is  enhanced  in  the  absence  of 
APH1a.  Through  competition  between  Rerp1  and  APH1a  for  the  same  binding  site  in 













whilst  γ‐secretase  is  found  assembled  in  the  early  compartments  of  the  endoplasmic 
reticulum [89, 93, 94]. This was termed the spatial paradox [95]. It was later discovered that 
γ‐secretase is actually transported to the trans‐Golgi network only after all four components 
are  assembled  in  the endoplasmic  reticulum  [89, 96] which  then migrates  to  the plasma 
membrane to execute substrate proteolysis. 
Although substrate processing by γ‐secretase occurs at the plasma membrane surface [94], 
active  γ‐secretase  complexes  are  found  in  other  cellular  locations.  Active  γ‐secretase 
complexes  can  be  found  in  the mitochondria  [97],  phagosomes  [98]  and  as  complexes 
embedded  within  lysosomal  membranes  rather  than  internalised  proteins  [99,  100]. 
Complexes have also been found by BN‐PAGE analysis  in brain, heart,  liver, spleen, kidney 
and  lung  of  the  wildtype  mouse  [84].  Interestingly,  it  has  been  found  that  although 















The  NCSTN  gene  is  comprised  of  seventeen  exons  located  on  the  sense  strand  of 
chromosome  1q23.  Chromosomal  abnormalities  in  this  region  have  been  reported  in  a 
variety  of  diseases,  such  as  systemic  lupus  erythematosus  [102]  and  hepatocellular 
carcinoma  [103].  Furthermore  chromosomal  gains  at  1q23 may  be  associated with  drug 





There  are  five  known  haplotypes  of  NCTSN  (A  to  E),  generated  by  single  nucleotide 






















































































In one study,  fourteen SNPs were  identified  in NCSTN, but none were associated with AD 
[108]. However, haplotype B constituted by  the simultaneous occurrence,  through  linkage 
disequilibrium, of  four SNPs  (one  silent C636 A/G  in exon 6 and  three  intronic mutations 
IVS6 + 18 C/G in intron 6, IVS10 – 5 C/G in intron 10 and IVS16 ‐ 119 G/C in intron 10) was 
increased in familial early onset Alzheimer’s disease (EOAD), when compared to the control 
and  late  onset Alzheimer’s  disease  (LOAD)  subjects  of Dutch  origin  [108,  117].  Increased 
frequency of haplotype B was also found in familial Alzheimer’s disease (FAD) and EOAD in a 









Contradictory  reports may  also  arise  from different  sample  sizes used  and  subsets of AD 
analysed. Nevertheless, more research is warranted in the contribution of NCSTN mutations 
to AD before any conclusions are drawn. 
The NCSTN gene promoter has been  located  ‐432  to  ‐133bp upstream of  the  start codon 






controls,  whilst  ‐436  showed  no  significance  in  AD  development  [110].  Although  the 
existence  of  the  ‐1216  C/A  and  ‐796  T/G  SNPS  was  confirmed,  the  finding  that  these 
mutations contribute to AD pathogenesis was uncorroborated in Italian AD sufferers [111].  
Bioinformatic  analysis  of  another  SNP,  ‐922  T/G  (rs10752637),  was  predicted  to  be  a 
transcriptional  factor  binding  site,  and  sixteen  putative  transcription  factors,  including 
NFĸB1,  were  predicted  to  interact  at  this  site.  Furthermore,  the  ‐922T  allele  increases 
luciferase  expression  compared  to  the  ‐922G  allele  and  binds  to  components  in  nuclear 
fractions whereas  ‐922G  cannot.  The  ‐922T  allele  also  increased  risk  in  SAD,  suggesting 
increased promoter activity results driven by the ‐922 T SNP may promote SAD [112].  
As of November  2010,  eighteen  splice  variants of  the NCSTN  gene were  recorded  in  the 
Ensembl database  [119],  six of which  are not  translated  (section  3.2.5.5,  Figure  3.2.8). A 
NCSTN splice variant lacking the entire exon 3 has been detected in rat embryonic and adult 
neuronal tissue but not other tissues. It was also observed  in the human neuronal cell  line 
LAN‐5 as a  lesser abundant  isoform to the  full  length NCSTN, which  failed  to produce any 
translated protein  [120]. Another  in‐frame splice variant  resulting  in deleted exon 16 was 








1.3.2 The nicastrin protein 
Nicastrin is a single-pass integral transmembrane glycoprotein [95, 122]. Human nicastrin is 
constituted by 709 amino acids containing sixteen potential glycosylation sites, and two 
potential intracellular phosphorylation residues. The architecture of nicastrin is comprised 
of a putative signal peptide (amino acids 1-33), a long extracellular domain (residues 33-
669), a single transmembrane domain (TMD) between residues 669-689, and a short 
intracellular domain at the c-terminus (amino acid residues 690-709) [123]. Within the large 
extracellular domain, residues 261-502 form the DAP domain [47], a region shown to have 
homology with the M28 aminopeptidase / transferrin receptor superfamily [124], homology 
being defined simply as sharing common genetic ancestry. This lead to speculation that 
nicastrin could have aminopeptidase activity. However, nicastrin has no B- and M- type 
aminopeptidase activity [124-126], but other types are yet to be investigated. Additionally, 
five amino acids, DYIGS (amino acids 336-340) is important for substrate binding and 














DYIGS (336-340) crucial for
substrate binding and interaction











Four  Cys  residues  (195,  213,  230  and  248),  each  spaced  16‐17  amino  acid  apart,  these 
residues are conserved amongst species, and are proposed to aid the structural formation 
of the DAP domain [123]. Adjacent to the DYIGS motif,  is residue E333 which  is critical for 
substrate  recognition  [47,  127].  Shah  et  al  [47]  proposed  that  through  recognition  and 





It has been demonstrated  that nicastrin  in C.elegans was unable  to co‐immunoprecipitate 
with  the  human  counterpart  γ‐secretase  proteins.  However,  by  creating  a  chimera  of 
c.elegans’  nicastrin  fused  with  human  nicastrin  residues  encompassing  the  TMD  and  c‐





TMD  renders  nicastrin  unable  to  participate  in  γ‐secretase  assembly,  whereas  the 
cytoplasmic tail is dispensable for this process [92]. More specifically, the one‐third of the N‐
terminal TMD  is sufficient to allow  incorporation of nicastrin  into the γ‐secretase complex. 
Helical  wheel  analysis  (software  that  examines  the  properties  of  protein  alpha  helices) 




into  the  γ‐secretase  complex  [130].  These  data  suggest  that  this  region  of  nicastrin  is 
important for interaction with other complex members 
Furthermore, electron microscopy revealed that glycoslyated nicastrin is found at the top of 
the  globular  structure  of  γ‐secretase  complex  (Figure  1.5).  Therefore,  nicastrin  has  been 












indicates  that glycosylation produces a  conformational  change  [131]. This mature  form  is 
the only one  that can associate with PS‐CTF and  form an active  γ‐secretase complex  [70]. 




secretase  activity  in  HEK  cells  stably  overexpressing  APPsw  (APP  containing  a  Swedish 
mutation which has  increased β‐secretase activity), presenilin, nicastrin, pen‐2, and APH1, 
[132]. However, phosphorylation of both nicastrin and presenilin by tumour necrosis factor‐




Nicastrin undergoes  S‐palmitoylation  at residue Cys  689.  S‐palmitoylation  is the 
covalent linkage of the fatty acid chain palmitate, via a thioester bond to cystiene residues. 
This post‐translational modification can allow protein association with  lipid rafts [134]. This 
may aid the  integration of the γ‐secretase complex  into the plasma membrane, but  is not 
required  for  complex  assembly  or  substrate  processing  [135].  However,  it  has  been 
demonstrated  that  in  mice  deficient  in  S‐palmitoylated  nicastrin  and  APH1a,  exhibited 





Overall, post‐translational processing of nicastrin may  contribute  to  the  cellular  transport 





study,  through  cloning  and  sequencing  of  cDNA,  compared  full‐length  human                           
nicastrin  against nicastrin  in mouse,  c.elegans, drosophila and Arabidopsis,  and  looked  at 
the percentage  identity (when two amino acids are  identical between species at the same 















Mouse   AF24069  89  93 
c.elegans  Q23316  22  41 
Drosophila  AF240470  30  48 














the E333 and DYIGS motifs,  crucial  for  substrate  recognition and binding were  conserved 







The  E333  residue  (purple  box)  is  conserved  in  all  eleven  species.  The  DYIGS  motif  is 
conserved  amongst most  species  (red  box)  except  the  in  Arabidopsis  thaliana.  The  Y  is 
conserved in all species (blue arrow)). Taken from [126] 
 
The  conservation  by  similarity  and  identity,  may  indicate  evolutionary  mechanisms  to 
conserve  nicastrin  amongst  species,  and  may  indicate  nicastrin’s  functional  relevance.  
Expression of human nicastrin  can  rescue  the  lethal nicastrin null phenotype  in C.elegans 






APP  substrates  [47,  126].  Deletion  in  regions  of  the  nicastrin  ectodomain  prevents 
maturation [131]. Within this domain, the DYIGS motif has been shown to be  instrumental 





accumulation  of  uncleaved  APP  product,  and  disrupts  maturation  of  the  γ‐secretase 
complex,  although  nicastrin  does  not  execute  the  cleavage  [55,  123,  138].  Co‐
immunoprecipitation  experiments  with  Δ312‐340 mutants,  which  encompasses  the  DAP 
domain,  eradicates  substrate  interaction  and  inhibits  γ‐secretase  activity  [47,  123]. 
Furthermore,  deletion  of  312‐369  results  in  an  accretion  of  immature  nicastrin  in  the 
endoplasmic  reticulum,  indicating  retention  and  a  lack  of  maturation, 
consequentlypreventing  its  association  with  the  other  γ‐secretase  components  [122]. 
Therefore,  the  DAP  domain  appears  critical  for  nicastrin  maturation,  a  requisite  for 
incorporation  into  the  functional  γ‐secretase  complex  to promote  substrate  cleavage  [47, 
123]. More  specifically within  the DAP  domain, mutation  of  E333  exhibits  a  reduction  in 
substrate  recognition, and  reduced APP  cleavage  [47, 127]. E333 also  crucially  recognises 
the  free N‐terminus of  γ‐secretase  substrates,  and  is postulated  to present  substrates  to 
presenilin  for  cleavage  [47, 127]. Double point mutations  in D336A/Y337A  increase Aβ40 
and Aβ40 secretion [123], suggesting nicastrin can regulate γ‐secretase activity. 
 
A model  of  nicastrin’s mode  of  action  within  the  active  γ‐secretase  complex  has  been 
proposed: After ectodomain shedding of substrates (Figure 1.9 B), the E333 nicastrin residue 
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Figure  1.9:  Postulated  mechanistic  action  of  nicastrin  within  active  γ‐secretase.  After 
transport from the Golgi, γ‐secretase integrates in the plasma membrane, within the vicinity 
of  a  substrate  requiring  processing  (A).  The  majority  of  the  substrate’s  ectodomain  is 
cleaved by a sheddase (B). Nicastrin rotates to bind to the substrate (C). Whilst still bound to 
the  substrate, nicastrin  rotates again  to present  the  substrate  to presenilin  (D). Substrate 
cleavage  releases  the  extracellular  domain  towards  the  extracellular  matrix,  and  the 













Nicastrin  also  has  anti‐apoptotic  effects which  are mediated  through  down‐regulation  of 
both  p53  gene  and  protein.  Over‐expression  of  nicastrin  reduces  caspase‐3  levels  in 
staurosporine‐induced apoptosis, p53 gene transcription and protein activity in HEK293 cells. 
Conversely,  caspase‐3,  p53  gene  and  protein  all  increase  in  NCSTN  ‐/‐  double  knockout 




Although  there  is accumulating evidence  illustrating nicastrin’s  involvement  in  γ‐secretase 
substrate  recognition  and  function,  a  publication  recently  emerged,  challenging  the 
requirement  of  nicastrin  in  γ‐secretase.  It  was  demonstrated  that  effective  γ‐secretase 
cleavage  of Notch  and APP was  unaffected  in NCSTN  ‐/‐ MEFs,  but  not  in  PSEN  ‐/‐ MEFs, 















amongst  23  species  and  is  required  for  interaction  between presenilin  1  and  pen‐2. 
However, TMDs 1,‐3, 5 and 6 are  required  for  γ‐secretase activity but are dispensable  for 
pen‐2  interaction  [144]. Pen‐2  then  triggers  the endoproteolysis  of  presenilin  [145,  146]. 
This occurs in the cytoplasmic loop connecting TMD 6 and 7 to generate PS‐CTF (16 kDa) and 
PS‐NTF  (27 kDa) which closely associate  together  in 1:1  ratio  [146, 147]. The most critical 
residues in presenilin 1 are Asp 257 and Asp 385, and the equivalent in presenilin 2, Asp 263 




component  [51].  The  catalytic Asp  385  residue  in presenilin  1  is  part  of  a  highly 
conserved GxGD motif that contributes to the catalytic activity of presenilin, as well as being 
suggested as a  recognition  site of  γ‐secretase  substrates  [149]. A  PAL  sequence exists at 
residues 433‐435 also contributes to γ‐secretase activity [150]. 
 
Presenilin  can  also  function  independently  of  the  γ‐secretase  complex,  and  is  able  to 







In  humans,  two  genes, APH1a  located  at  chromosome  15,  and APH1b  on  chromosome  1 
encode  two  APH‐1  isoforms  with  approximately  50%  homology.  APH1a  can  undergo 
alternative splicing at the c‐terminus to produce a longer variant of 265 amino acids (APH1a‐
L) or a shorter variant of 247 amino acids (APH1a‐S) [156]. APH1a is the predominant form 
incorporated  into  active  mammalian  γ‐secretase  complexes  [84,  157].  APH1  adopts  a 
topology comprising of seven TMDs [158]. Within the fourth TMD (residues 122‐126) exists 
a highly  conserved  GXXXD motif,  where  X  can  be  any  amino  acid  [156,  159].  A  G122D 
mutant results in an inability of APH1a to co‐immunoprecipitate with the other γ‐secretase 
components  and  inhibits  the  cleavage  activity  of  the  complex  [159].  However,  the 
established role for APH1 in γ‐secretase is to provide stability to the structure [54]. 
The  PSENEN  gene  (chromosome  19)  encodes  a  101  amino  acid  peptide  (pen‐2)  with 
two TMDs which adopt a hairpin‐like structure within the membrane. The pen‐2 protein  is 
highly conserved amongst species. Like APH1, pen‐2 also provides structural support to the 
γ‐secretase  complex,  but  its  prime  function  is  to  bind  to presenilin  via  TMD1  [59].  This 
association initiates the endoproteolysis of presenilin and stability of the PS‐NTF and PS‐CTF 













There  does  not  appear  to  be  any  sequence  consensus  between  the  substrates  that 
determines  cleavage  by  the  γ‐secretase  complex.  The  only  known  pre‐requisites  of  a 
substrate to be cleaved by γ‐secretase are that it is 1) a type I integral membrane protein, 2) 
it  undergoes  a  process  termed  as  ectodomain  shedding,  where  the  majority  of  the 
ectodomain  is  cleaved off  by  α‐  or  β‐secretases,  and  3)  the  size  of  the  resulting  cleaved 
intracellular  domain must  not  exceed  50  amino  acids  [160].  Ectodomains  larger  than  50 
amino acids cannot be cleaved by the complex, as substrate size  is  inversely correlated to 
the  efficacy  of  γ‐secretase  [38,  160].  However,  there  appears  no minimal  size  limit  for 
cleavage  [127].  Cleavage  by  α‐  or  β‐secretases  generates  a  free  N‐amino  terminal  stub 
recognisable by nicastrin to ultimately facilitate γ‐secretase processing [47].  
 
There  is  a  rapidly  growing  list  of  substrates  of  γ‐secretase.  To  date,  there  are  sixty 
recognised  substrates  (for  a  comprehensive  substrate  list:  [38,  161]).  Other  substrates 
include  ErbB4  [162],  E‐cadherin  [163],    and  p75  [164] which  regulate  numerous  cellular 
functions  including  proliferation,  cell  cycle,  cell  adhesion  and  apoptosis  [38].  More 








APP  can  undergo  processing  through  a  non‐toxic  or  toxic  (amyloidogenic)  pathway,  the 
latter in whichis a major contributory factor in AD senile plaque formation. In the non‐toxic 
pathway  (Figure  1.10,  A),  APP  undergoes  ectodomain  shedding  (a  pre‐requisite  for  γ‐
secretase  to  cleave  a  type  I  protein)  by  cleavage  from  α‐secretase  (ADAM10  or  TNF‐α 
converting enzyme (TACE). This results in a soluble APP fragment (sAPPα), which is released 
into  the  extracellular matrix).  Embedded  in  the  membrane  is  an  83‐residue  C‐terminal 























   
   









   
   






   
   









   
   
   





















Figure  1.10:  The  amyloid  precursor  protein  (APP)  non‐toxic  (A)  and  toxic,  Alzheimer’s 
disease (AD) (B) processing pathways. In the non‐toxic pathway (A) APP (middle) undergoes 
ectodomain  shedding  via  cleavage  by  α‐  (ADAM10  and  TACE)  resulting  in  soluble  APP‐α 
(sAPPα). A residual membrane C83 (83 amino acid C‐terminal APP) fragment, results from α‐
secretase  cleavage.  γ‐secretase  cleavage  of  the  C83  fragment    releases  the  APP 
intracellullular domain  (AICD) and 3 kDa protein  into  the extracellular matrix.  In  the  toxic 
pathway (B), APP ectodomain cleavage is conducted by β‐secretase (BACE), resulting in C99 
(99 amino acid C‐terminal APP). γ‐secretase cleaves the C99 fragment to release AICD  into 




The  γ‐secretase  complex  is  responsible  for  cleaving  the  four mammalian Notch  isoforms 
(Notch 1‐4). Notch architecture comprises EGF‐like repeats, Lin‐2 and CD10/ankryn repeats 
and a PEST and RAM23 Domain [171]. A primary Notch glycosylation is conducted by fringe 
glycotransferases  between  EGF‐like  repeats  11‐12  (termed  site  1).  This  produces  two 






is  initiated via  interactions between cell surface  ligands (jagged (Jag) ‐1, ‐2, delta‐like ‐1, ‐2 
and  ‐4)  [47] and Notch heterodimer  receptors present on an adjacent cell. This  induces a 
conformational change to reveal a cleavage site (site 2) for TNF‐α converting enzyme, which 
leaves  a  12  amino  acid NECD  stub  on  the  plasma membrane  [173,  174].  A NECD‐ligand 
complex  is released via endocytosis  into the signal transducing cell [175]. Consequently, γ‐
secretase  recognises  the  residual  NECD  ectodomain  stub  and  cleaves  the  NTMD, which 
releases  the NICD  [49, 174]. NICD  then  translocates  to  the nucleus where, via  its RAM23 
repeats  and  ankryn/cdc10  domain,  binds  to  CSL  DNA  binding  proteins  (CBF1/RBPJ‐κ  in 
mammalian  cells,  Su(H)  in  Drosophila,  and  LAG‐1  in  C.  elegans)  [176,  177].  Upon  the 
presence of NICD, co‐repressor SMRT usually bound to CSL disassociates, and co‐activators 
mastermind‐like‐1,2,3  and  p300  [178,  179]  are  recruited  to  initiate  gene  transcription  of 
target genes including hes, hey [180], c‐myc [181], p21 [182] and cyclin D1 [183] to regulate 






receptors.  Ligand‐Notch  receptor  interaction  stimulates  cleavages  by  TNFα‐converting 
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185].  Several  studies have  implicated Notch hyper‐activation  in breast malignancies.  This 
was  first  identified when  insertion  of mouse mammary  tumour  virus  (MMTV) within  the 
Notch 4 locus incited tumour formation in mice [186]. Since then, increased Notch signalling 
in breast malignancy has been  illustrated by an accumulation of N1ICD and protein over‐

















independence)  of  MCF‐7  cells  [43].  Immumohistochemistry  demonstrated  that  reduced 
levels of numb  in 50% of breast cancer tissues  inversely correlates with tumour size  [193] 
and  a  higher  probability  of  secondary  metastasis  [194].  Another  study  [195]  analysed 
191/241 primary  invasive breast cancer tumours  illustrated  increased numb expression, of 
which  a  high  proportion  negatively  correlated  with  the  breast  cancer  stem  cell marker 





Increased expression of mRNA and protein  involved  in Notch signalling  is also prevalent  in 





agar  growth whereas  the  opposite  effect was  observed with  N2ICD  in medullablastoma 
[196]. Moreover, 97 breast cancer tissues examined displayed increased Notch1 which was 










and  up‐regulation  of mRNA  and  protein  of  Notch  signalling molecules  induce  oncogenic 

































































































































and protein  levels  in  the ovarian  cancer  cell  line A2780,  reduces proliferation and  colony 
formation through induction of apoptosis [214]. Moreover, in the ERBB2 breast cancer neuT 
mouse model, use of MRK‐003 decreased  tumour number and  size, with  concommintant 




of  other  chemotherapeutic  drugs,  for  instance,  synergistic  treatment  of  DAPT  and 
doxorubicin  in multiple myeloma  xenografts  reduces mouse  tumours  to  a  greater  extent 
than each drug separately [216]. This effect  is also observed when DAPT and paclitaxel are 




cancer  cell  lines,  combined use of MRK‐003 with AG1478  (an EGFR  inhibitor)  significantly 
enhanced the anti‐proliferative effects of MRK‐003 alone in soft agar colony formation [217]. 
Additional benefits of combined MRK‐003 with rapamycin  in T‐ALL cell  lines and xenograft 




secretase  inhibitor  treatment  that may be beneficial  to suppressing carcinogenesis.  In  the 





















Table  1.5:  The  effect  of  γ‐secretase  inhibitors  on  several  malignancies:  compounds 
modulate  the Notch pathway  to  incite  reduced  signalling,  increased apoptotic proteins  to 
induce of apoptosis, and reduce proliferation. + indicates an observed γ‐secretase inhibitor 
effect. 


















+      [191] 
GSI1  +      [184] 













DAPT  +    +  [222] 
Kaposi  
Sarcoma 
GSI1  +  +    [223] 
Multiple 
Myeloma 
GSI‐12  +  +  +  [216] 
DAPT  +    +  [199] 
Melanoma  GSI1    +    [224] 
T‐ALL 
 
Compound E  +      [220] 













There  are  currently  sixteen  ongoing  clinical  trials  exploring  the  effects  of  γ‐  secretase 
inhibitors  in  cancer  and  an  additional  three  that  have  been  completed.  Table  1.6 
summarises  a  selection  of  trials.  The majority  explore  the  clinical  benefits  of  γ‐secretase 
inhibitors in AD and leukaemia [36]. In AD, the IDENTITY trial using LY450139 (Semagacestat) 






tumour  size  in A549 mouse  xenografts, and  reduces  colony  size  formed by MDA‐MB‐468 
breast  cancer  cells  [227].  MRK‐003  in  T‐ALL  mouse  xenografts,  reduced  tumour  size, 
increased  apoptosis  (measured  by  TUNNEL  and  activates  caspase‐3  on  tumour  sections), 
alongside a down‐regulation of hes genes. Aβ40 secreted  in serum was ablated three days 
post  treatment  with  administered  MRK‐003,  but  elevated  back  to  near‐normal  levels 
thereafter [228]. In T‐ALL cell lines, MRK‐003 causes a G0G1 cell cycle blockade, reduces cell 










Clinical  trials  examining  the  use  of  γ‐  secretase  inhibitors  in  T‐ALL  patients  resulted  in 
chronic  gastrointestinal  side  effects.  The  γ‐  secretase  inhibitors  PA‐03084014  and 






003  suggesting  that  the  efficacy  of  γ‐  secretase  inhibitors may  be  restricted  to  certain 
patient cohorts [217]. Unfortunately in August 2010, 2,600 recruited AD patients were told 
to cease taking LY450139, as preliminary data showed a decline  in cognition and ability to 




















































understood.  The  expanding  list  of  substrates  that  are  processed  by  the  complex  already 
features molecules such as Notch that are widely expressed in cancers, and inhibition of γ‐
secretase has shown some effectiveness in suppression of tumorigenic models and in Phase 
trials.  However,  adverse  clinical  effects  of  currently  available  γ‐secretase  inhibitors, 























The use of  γ‐secretase  inhibitors DAPT and DBZ has been  shown  to  reduce breast cancer 
stem cells (CSCs) through inhibition of Notch [184, 232]. CSCs are a rare population of cells 
that have been implicated in driving metastasis [166, 184, 233]. Metastasis is the recurrence 
or  clinical  relapse  of  cancer  after  clinical  intervention.  Metastasis involves  a  series  of 
processes which  tumour cells must undergo. These  steps  include progressive growth of a 
primary  tumour,  angiogenesis,  invasion  of  surrounding  tissue,  cell  detachment  from  the 
tumour and survival in the vascular system, escape from the blood, attachment to capillary 
bed and permeation of a foreign organ by evading immune response to finally propagate of 
growth  [3,  234].  The metastatic  process  can  culminate  in  a  secondary  tumour,  clinically 















primary  tumour,  which  evade  the  cytotoxic  effects  induced  by  adjuvant  therapy  [236]. 
These tumour cells are found in peripheral blood as circulating tumour cells (CTCs), or in the 
bone marrow and  lymph nodes, as disseminated  tumour  cells  (DTCs). DTCs and CTCs are 
often single cells that may be retained  in a quiescent state under a G0‐G1 cell cycle arrest 
and  are  therefore  considered  dormant  (reviewed  in  [241]).  Dormant  cells  can  persist  in 
patients  up  to  22  years  post  surgery  [242]. DTCs  and CTCs may  exit  their  dormant  state 
through oncogenic or external stimuli to form secondary metastatic lesions [241]. CTCs are a 







Several  studies  have  shown  that DTCs  are  associated with  increased  tumour  size,  lymph 
node  involvement and  tumour grade, decreased overall and distant disease‐free  survival. 
Therefore, DTCs  are  indicative of poor prognosis  [243‐246].  The presence of DTCs  in  the 








A  large  study of 964  samples  from eleven  types of cancers  including breast, prostate and 
colorectal, found ≥ 2 CTCs in all samples but not in healthy subjects [248]. Detection of ≥ 5 
CTCs per 7.5 ml of blood  is frequently observed  in breast cancers, which  is considered the 
threshold  for  breast  cancer  prognosis,  whereas  CTCs  are  very  rarely  found  in  healthy 
individuals with benign breast disease [249‐251]. Detection of ≥ 5 CTCs per 7.5 ml of blood 





















DTCs  and  CTCs.  Immunocytochemistry  and  RT‐PCR  are  the  most  commonly  employed 








Hypaque  gradient  centrifugation,  filtration  or  immunomagnetic  separation  to  eliminate 









(FDA)  approved method  for CTC  isolation  in metastatic breast  and prostate  cancers,  and 










purified  population  for  the  epithelial  markers  cytokeratins  8,  18  and  19  (pan‐CK),  all 
conjugated to R‐phycoerythrin, CD45 conjugated to allophycocyanin (APC), which is used to 
distinguish contaminating  leukocytes, and stains nuclei with 4',6‐diamidino‐2‐phenylindole 
(DAPI)  (Figure  1.12, D).  The machine  also  has  an  extra  FITC  channel  to  detect  additional 
proteins (optimised Her‐2 and EGFR antibodies are available from CellSearch™). The stained 
sample  is  placed  into  a magnetic  cartridge which  through magnetic  attraction  pulls  the 
EpCAM  coated  cells  to  the  surface  (Figure 1.12, E). CTCs  can  then be manually visualised 
with the AutoTracks Analyser which present images of stained cells in a gallery for operator 
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into  the carousel platform of  the CellSearch™ machine  (A). EpCAM expressing CTCs  (large 
brown  circle)  are  retrieved by  addition of  EpCAM nanoparticles  to  the blood  sample  (B). 
Magnet  application  positively  selects  CTCs  bound  to  EpCAM  nanonparticles,  whilst 




transferred  to a MagNest, a magnet which attracts EpCAM coated cells  to  the surface  for 
microscopic analysis. The images are presented in a gallery for the operator to examine and 











adaption  of  RNA  ISH,  and  based  on  the Quantigene  assay  by  Panomics  [256],  and  is  an 
emerging  technology  developed  by  Advanced  Cell  Diagnostics.  CTCscope  is  a  novel 
(proprietary)  technique  allowing  detection  of  mRNA  transcripts  by  multiplex  in  situ 
hybridisation.  Principally,  the  system  is  designed  with  various  types  of  oligonucleotide 
molecules that construct a scaffolding network around target mRNA sequences to amplify 
fluorescent  signals. This essentially allows  the detection of mRNA  transcripts  in  individual 
cells. 
 
Firstly, multiple oligonucleotide  sequences,  that  are  complementary  to  the mRNA  target, 
called  target probes, are generated  to  span and hybridise  to  the mRNA  sequence  (Figure 
1.13,  B).  The  target  probes  are  also  designed  to  complementarily  hybridise  to 
oligonucleotide  sequences  called  pre‐amplifier  molecules  (Pre‐AMP).  The  Pre‐AMP 
molecules  generate  a  scaffold  structure  to  which  another  group  of  complementary 

















B. Hybridisation of 
oligonucleotide probe pairs 

















slides.  Specific  oligonulcleotide  probes  are  hybridised  to  the  target  mRNA.  Pre‐amp 
molecules hybridise to the oligonucleotide probes, and in turn, AMP molecules bind to the 
Pre‐AMP molecules. Fluorescent probes attach to the AMP molecules, creating a fluorescent 
signal  detectable  through  microscopy.  Modified  from 
http://www.acdbio.com/whats_rnascope.html [257].  
 


















designing  mRNA  specific  targeting  probes  and  detection  using  alexafluor  647.  The 




The CTCscope  technique can be applied  to clinical  samples  (peripheral blood or  formalin‐
fixed  paraffin  embedded  tissue),  and  has  several  advantages  over  conventional 
methodologies  for detecting CTCs. CTCscope  is designed  to ensure  low background whilst 
maintaining  high  specificity.  Thus,  enrichment  steps  which  can  result  in  CTC  loss  are 
minimised. Transcripts are detectable  in  individual  cells which are morphologically  intact. 










and  evaluated  as  an  indicator  of  normal  biological  processes,  pathogenic  processes,  or 
pharmacologic responses to a therapeutic intervention”. Identification of molecules that are 





risk  of  metastatic  disease,  which  are  mainly  based  on  clinical  pathological  features  of 
tumours.  These  include  examination  of  tumour  size,  histological  grade,  steroid  receptor 
status  and  auxillary  lymph  node  involvement  [236].  These  can  be  detectable  by  physical 
examination radiographic imaging and ultrasound [235].  Her‐2, ER and PgR are also used as 





therefore  has  not  been  completely  embraced  clinically  as  reliable  diagnostic  tools. 










serum  product  of  the  MUC1  gene.  Elevated  CA15‐3  levels  in  conjunction  with  Her‐2 
expression and  lymphovascular  invasion are associated with early disease recurrence after 
the  treatment of  local breast  cancer  [266]. Despite  this,  there  are many pitfalls  to  these 
markers. CK19, MUC‐1 and CEA mRNA is expressed in the blood and lymph nodes of healthy 
patients, thus compromising the specificity when using these as markers  [267]. Moreover, 
antibodies  against  pan‐CK  used  in  immunocytochemistry  have  displayed  some  degree  of 
non‐specificity,  perhaps  contributed  to  by  the  fact  normal  cells  express  low  levels  of 
cytokeratin  [268]. Moreover, measuring  CK‐19  by  RT‐PCR  risks  detection  of  cytokeratin 
pseudogenes  in genomic DNA  [269],  thus  increasing  the  likelihood of  false positives being 




Approximately  80%  of  patients  receive  precautionary  adjuvant  therapy,  and  this  therapy 
fails in half of these patients who relapse regardless [236]. This highlights the lack of reliable 
diagnostic tools and the persistence and aggression of metastatic cancer cells. Therefore the 



















two  independent methods have been used:   chemical  inhibitors and siRNA (Results 
section 3.1, 3.2). 
 




have attributed  to  the  formation of AD  [107]. Additionally  the double mutation  in 
nicastrin at  residues D336A/Y337A by  site directed mutation  increases  γ‐secretase 
activity.  It  was  hypothesised  that  a  mutation  in  the  gene  sequence  encoding 














5) Increased  expression  of  γ‐secretase  substrates,  such  as Notch,  EpCAM,  CD44  and 
MUC‐1 have been associated with breast cancer metastasis, and γ‐secretase activity 
is  present  in  breast  cancer  metastasis  models  [166,  184,  232,  271].  Thus,  the 




6) As disseminated and circulating  tumour cells are used as surrogates  for metastatic 
disease,  the  hypothesis  that  nicastrin  is  expressed  in  these  tumour  cells  and may 
possibly be used as a biomarker of metastatic disease will be explored using a variety 
of  cellular  and  molecular  techniques.  As  a  proof  of  concept  study,  nicastrin 
expression will be examined  in bone marrow aspirates and blood  samples derived 













above. MCF10A were grown  in DMEM with 5% horse  serum, 100 ng/ml cholera  toxin, 10 
μg/ml  insulin, 500 ng/ml hydrocortisone  and 20 ng/ml hEGF. Non‐tumorigenic 226‐L‐U19 
and 226‐L‐TS4 breast cell lines, kindly provided by Parmjit Jat were grown in DME: F12, 10% 
FCS, 5  μg/ml  insulin, 1  μg/ml hydrocortisone, 10 ng/ml hEGF and 10 ng/ml cholera  toxin. 
The immortalized non‐tumourigenic breast cell line 184A1 (CRL‐8798; ATCC) was cultured in 
basal mammary epithelial cell growth medium (Promocell, UK), supplemented with bovine 
pituitary  extract  (13  µg/ml),  epidermal  growth  factor  (10  µg/ml),  hydrocortisone  (500 














was made  in  the  skin prior  to  sampling. Using a disposable 1.8 mm marrow‐ gauge bone 
marrow  aspirate  needles  (Rocket Medical),  2‐5 ml  aspirates were  collected  into  syringes 
containing heparin  (CP Pharmaceuticals)  to prevent coagulation.   Samples were added on 
top of 20 ml Ficoll‐Hypaque, centrifuged without a brake, at 1200 g for 30 minutes. PBMCs 
were collected from the buffy  layer PBS was added to cells to a final volume of 50 ml, and 
they were  centrifuged at 800 g  for 10 minutes. The  supernatant was discarded and  cells 
were  resuspended  in  3‐5  ml  red  lysis  buffer  (Sigma  Aldrich)  to  eliminate  erythrocytes. 
Following 3 minutes incubation, the volume was made up to 50 ml with PBS and centrifuged 
at 800 g  for 10 minutes. The cell pellet was  resuspended  in PBS  for cell counting using a 







Blood  (5mls) was collected  in EDTA tubes to prevent coagulation,  from healthy volunteers 
within  the  department  or  from  metastatic  breast  cancer  patients.  For  every  1  ml  of 
peripheral  blood,  2 ml  of Ficoll‐Hypaque was  used  to  extract  PBMCs.  In  a  15 ml  falcon 







centrifuged at 1300 g  for 30 minutes  at  room  temperature. This  created  a  separation of 
erythrocytes at the bottom of the tube, covered by the  layer of Ficoll‐Hypaque. On top of 
this was a layer of buffy coat containing the lymphocytes, lying under a layer of plasma. The 









have  detectable  CTCs  by  CellSearch™  processing.  Samples  were  collected  under  Ethical 
approval  at  Charing  Cross  Hospital.  Samples were  processed within  4  hours  after  initial 
blood collection. Two ACCUSPIN tubes (Sigma Aldrich) per patient sample were warmed to 
room  temperature  and briefly  centrifuged prior  to use.  The blood  sample was  separated 
(3.5 ml)  and placed  into  an ACCUSPIN  tube,  and  centrifuged  in  a  swing out  rotor  for  20 
minutes,  800  g  without  a  brake.  The  upper  plasma  layer  was  aspirated,  leaving 
approximately 0.5 ml above the PBMC layer. The PBMC layer from both tubes were carefully 
collected and added to a 15 ml Falcon containing 10 ml of 1 x BSA/EDTA/PBS (0.4% BSA+1 










ml micro‐centrifuge  tube. The  sample was  incubated  for 40 minutes at 37  °C on a  roller. 
PBMCs were pelleted by  centrifugation at 5000 g  for 1 minute, and  the  supernatant was 
carefully removed  from the cell pellet. Post‐fixation buffer  (1 ml) was added to cells. Cells 
were mixed by vortexing  for 3 seconds,  inversion three times and vortexing  for another 3 
seconds.  The  sample was  then  centrifuged  for  1 minute  at  500  g,  and  the  supernatant 
discarded, and 1 ml of post‐fixation was added and the consequent steps repeated. To the 





Peripheral  blood  from  patients  diagnosed  with  metastatic  breast  cancer  was  taken  by 














and  permeabilised  using  proprietary  reagents. Ferrofluid  containing mouse  monoclonal 
EpCAM  antibodies  coated  nanoparticles  was  added  to  the  blood,  and EpCAM  positive 
epithelial cells were separated from the blood upon the application of a magnet. Residual, 
unbound blood  components are aspirated. To  stain  the putative CTCs, antibodies against 
pan‐CK‐PE, CD45‐APC  and counterstain DAPI  were  added  in  a  buffer  containing  a 
proprietary permeabilisation  reagent.  A  second  magnetic  separation  was  performed 
following  antibody  incubation.  Cells  in  ~400  µl  of  suspension  buffer  (proprietary)  were 
transferred  into  a MagNest  cartridge.  Once  manually  retrieved  from  the  CellSearch™ 




The CellTracks  analyser  allows  automated  image  generation  of  cells  present  in MagNest 
cartridges.  Parameters  of  the CellTracks machine were  first  calibrated  using  a  calibration 
cartridge  prior  to  use.  Optimal  parameters  are  then  applied  to  samples  present  in  the 












by  allowing  the  cells  to  detach  from  the  surface  overnight.  The  cartridge  stopper  was 
carefully removed using tweezers. Carefully but thoroughly, using an elongated thin Pasteur 






For  control  samples, MDA‐MB‐231  and  NCSTN  ‐/‐ MEF  cells were  harvested  from  tissue 
culture  flasks  using  5 minute  washes  with  0.02%  EDTA  (Sigma  Aldrich)  to  preserve  the 
integrity of nicastrin,  as  immature nicastrin  is  tryspin  sensitive, whilst mature nicastrin  is 
resistant  [131]. Cells were  not  allowed  to  exceed  ~70%  confluency  before  use. An  equal 










DAPT  (N‐(N‐(3,5‐Difluorophenacetyl‐L‐alanyl)))‐S‐phenylglycine  t‐butyl  ester,  Compound  E 
(2S)‐2‐{[(3,5‐Difluorophenyl)acetyl]amino}‐N‐[(3S)‐1‐methyl‐2‐oxo‐5‐phenyl‐2,3‐dihydro‐1H‐





Cells  (2.5 x 103) were seeded  in  triplicate and allowed  to adhere  for 24 hours. The media 






The  sulphorhodamine  B  (SRB)  assay was  used  to  screen  for GSI1  cytotoxicity  [274].  The 
assay relies on the ability of SRB to bind to protein components of cells that have been fixed 
to tissue‐culture plates by trichloroacetic acid (TCA). SRB is a bright‐pink aminoxanthene dye 
with  two  sulphonic  groups  that  bind  to  basic  amino‐acid  residues  under  mild  acidic 







determine  the  effect  of  GSI1  on  cell  number  over  time,  SRB  assays were  performed  as 
described. Cells were seeded with six replicates  in flat‐bottomed 96‐well plates (3000 cells 
per well). The cells were allowed to adhere for 24 hours, and then media containing GSI1 (0, 












1640  medium  containing  5%  foetal  bovine  serum  and  2  mM  L‐glutamine.  Cells  were 
inoculated into 96‐well microtiter plates in 100 ml at plating densities ranging from 5000 to 
40,000  cells  per well,  depending  on  the  doubling  time  of  individual  cell  lines.  After  cell 








drug addition  (Time  zero  (Tz)). GSI1  in  complete medium  containing 50 µg/ml gentamicin 
was added to the cell lines and the plates were incubated for an additional 48 hours at 37°C, 
5%  CO2,  and  an  SRB  assay  was  performed.  Using  the  seven  replicates  of  absorbance 
measurements at Tz, growth of DMSO control cells (C), and test growth  in the presence of 









Three  dose–response  parameters  were  calculated  for  each  experimental  agent.  Growth 
inhibition  of  50%  (GI50) was  calculated  as was  the  drug  concentration  resulting  in  total 
growth inhibition (TGI) is calculated from Ti = Tz. The LC50 (concentration of drug resulting in 
a 50%  reduction  in  the measured protein at  the end of  the drug  treatment as  compared 



















Briefly,  cells  were  washed  twice  with  ice‐cold  PBS,  harvested  in  the  proprietary  cell 
extraction buffer, and incubated on ice for at least 10 minutes. Lysates were centrifuged at 
10 000 g for 1 minute and supernatants were collected with a total protein yield of 0.5–1.0 























proteasome subunit  for 15 minutes at room  temperature. Then,  the enzyme‐inhibitor mix 
was  added  to  1x  assay  buffer  (25mM  HEPES,  4‐(2‐hydroxyethyl)‐1‐
piperazineethanesulphonic acid, pH 7.5, 0.5mM EDTA, 0.05% (v/v) NP‐40 and 0.001% (w/v) 
sodium dodecyl sulphate (SDS)), and  incubated with the proteasomal substrate N‐succinyl‐












and 5 µM GSI1, MG132 or DAPT  for 4 hours. A DMSO  vehicle  control was also  included. 
Adherent cells were washed in cold PBS twice. Cells were scraped in cold PBS, collected and 
centrifuged  170  g  for  5  minutes  at  4˚C.  The  pellets  were  resuspended  in  50  µl  of 
proteosome lysis buffer (50 mM HEPES, pH 7.5, 5 mM EDTA, 150 mM NaCl and 1% triton X‐
100).  Following  incubation  on  ice  for  30 minutes, with  vortexing  at  10 minute  intervals, 
lysates were centrifuged at 14000 g  for 15 minutes at 4˚C. The supernatant was collected 
containing  19S  and  20S  crude  proteasomal  extracts  and  were  used  for  analysis  by 
simultaneous  protein  determination  (Bradford  method,  section  2.8.2)  and  proteasome 
activity. Lysates (10 l) were incubated with 180 l 1x assay buffer (50 mM HEPES pH 7.5, 5 
mM EDTA, 150 mM NaCl, 1% Triton), and 10 l 1:20 diluted fluorogenic substrate (suc‐LLVY‐




During  the  course of  this  thesis,  two methods were used  to  transfect  siRNAs  into breast 
cancer  cells. Oligofectamine  (Invitrogen) was used  at  the beginning of  the  thesis but  the 










washed  with  100  μl  Opti‐MeM  (Invitrogen),  and  replaced  with  fresh  100  μl  Opti‐MeM. 
Oligofectamine (Invitrogen) was diluted in Opti‐MeM. siRNAs (Dharmacon) targeting APH1A, 
NCSTN, PSEN1, and PSENEN were mixed with Oligofectamine and transfected for four hours 
to  a  final  concentration  of  40  nM.  Controls  used were: mock, Oligofectamine  only,  non‐





Table  2.1:  Anti‐human  siRNA  duplexes  used  against  γ‐secretase  complexes  in  RNAi 












































was performed as  follows. Cells were trypsinised and washed once  in PBS. Pellets  in were 








vigorously  for 15  seconds.  Samples were  incubated on  ice  for 15 minutes.  Samples were 
then  centrifuged  at  14000 g  (maximum  speed)  for  15 minutes  at  4  °C, which  creates  an 
interphase protein  layer.  The  layer  above  the  interphase was  collected, with  care not  to 
disturb  the protein  layer. An equal volume of  isopropanol was added  to  the upper phase 
and mixed by  inversion several times. Following  incubation on  ice for 15 minutes, samples 
were  centrifuged  at  14000  g  (maximum  speed)  at  4°C.  The  supernatant  is  removed  and 
100µl 75%  slowly ethanol was  added  to  the pellet  (without mixing).  The  tubes were  left 
open,  on  ice,  to  allow  the  ethanol  to  evaporate.  Pellets  were  resuspended  in  10µl 








Reverse  transcription of 2  μg  total RNA was  synthesized with Moloney Murine  Leukemia 
Virus (MMLV) reverse transcriptase and random hexamers. The cDNA mix was made using 
6.3  μl  (200  U/μl) MMLV  reverse  transcriptase  (Invitrogen)  and  3.2  μl  (40  U/μl)  RNasin 













K4008‐1) was  quantified  using  the  NanoDrop  spectrophotometer  (Thermo  Scientific  ND‐


















make PCR reactions was also used for determining presence of spice variants. The second 
method was quantitative real-time PCR (Q-RT-PCR) by Taqman which later became available 
and was switched to, as it was a more informative method. 
 
2.7.3.1 PCR method 1: End-point PCR using LightCycler (Roche Diagnostics) 
(Used in sections 3.1.11, 5.7). End-point PCR was performed on a LightCycler (Roche 
Diagnostics) using LightCycler DNA FastStart SYBR Green 1 kit (Roche Diagnostics). Primers, 
MgCl2 concentrations and thermal cycling PCR conditions are summarized in Table 2.2. 





Table 2.2: Primers and optimal conditions used for cDNA amplification with the Roche Lightcycler. aAn initial step (hot start) of 95°C for 10 





Gene Forward primer 
(5’ to 3’) 
Reverse primer 




 °C /s 
Annealing 
°C / s 
Elongation  





NOTCH1 gcaacagctccttccacttc ccacgaagaacagaagcaca 3  95/25 59/27 72/25 34 499 
NOTCH2 atgactgccctaaccacagg ctggagtacaggaggcgaag 2  95/15 59/20 72/15 25 264 
APH1A ccgctttgcctactacaagc ccaaaaggtatggagcagga 3  95/20 58/20 72/20 27 265 
NCSTN caaagcaccttcagcatcaa cgagctgccaatgtagtcaa 3  95/25 58/25 72/25+86/2 28 315 
PSEN1 gttccacttcgtatgctggt gcgaggatactgctggaaag 3  95/20 60/15 72/20 23 314 
PSEN2 ctgcccaggagagaaatgag cagtcaagggaggctcaaag 3 95/25 61/25 72/25 25 198 
PEN2 tcccttgtcccagcctacac ggtcctttattgggggatgt 3  95/20 59/20 72/20 32 329 
JAG1 ctcctgtcgggatttgttta ccacagacgttggaggaaat 3 95/30 58/30 72/30 28 414 
JAG2 gtcaaggtggagacggttgt atcctcgtcctcctcatcct 2 95/30 60/30 72/30 25 345 
NUMB agccagcccatactgctcta acaggctgagaggtgaggaa 2 95/30 60/30 72/30 30 346 
GAPDH tctcatcaccatcttcca  catcacgccacagtttcc 2 95/30 54/30 72/30 32 380 





2.7.3.2 PCR method 2: End-point PCR for NCSTN sequencing 
PCR reactions were made using an Expand High Fidelity PCR system (Roche diagnostics, cat 
no 04 738 268 001). cDNA (2 ng) synthesised using method 2 (section 3.2.5), and diluted 1 in 
4, as a working concentration. Each PCR reaction was comprised of: 5 µl primer mix, 14.5 µl 
autoclaved AnalaR water, 2.5 µl 10 x buffer with 15 mM MgCl2, 0.5 µl of 10 mM dNTP, 0.5 µl 
expand high fidelity taq polymerase and 2 µl cDNA (equivalent of 0.05 ng cDNA per 
reaction). Autoclaved AnalaR water used in PCR reactions were used as NTCs, to detect 
possible contamination in PCR reactions. Thermal cycling (Table 2.4) was performed on a G-
storm PCR machine. Four replicates per sample were run per primer pair. Samples were run 
by agarose gel electrophoresis. 
 
2.7.3.3 Agarose gel electrophoresis 
Agarose gel was prepared to a 1.8% concentration by dissolving agarose in 1x tris-acetic acid 
EDTA solution (TAE: Severn Biotech Ltd). The PCR reaction (3 l) was mixed with 2 µl of 5x 
DNA loading red buffer (Bioline). TrackIt 100 bp ladder (Invitrogen) was used to determine 
the size of the amplified fragments. 
 
2.7.4 PCR method 3: Taqman quantitative real-time PCR (Q-RT-PCR) 
All Q-RT-PCR reactions were performed in a PCR laminar air flow cabinet, using sterilised 
filter tips (Starlab). Dilutions of neat, untreated MDA-MB-231 cDNA was used to create a 





cDNA was serial diluted 1:10 and 1:100 to give standards of 10% and 1% respectively. Neat 
cDNA was considered as 100% (see section x for preparation of neat cDNA).  
Sensimix (Quantace, QT-605-02), containing Sybr® green I, 6mM MgCl2, heat activated DNA 
polymerase and ultra pure dNTPs, was used in Q-RT-PCR reactions. Per reaction, 5 µl 
Sensimix and 0.5 µl primer mix were added together. Mastermixes were made for multiple 
reactions, vortexed and dispensed into MicroAmp® Fast Optical 96-Well Reaction Plates 
(Applied Biosystems Ltd, cat no 4346906). To this, 4.5 µl of either test samples or autoclaved 
AnalaR water for no template controls was added. The final volume of Q-RT-PCR reactions 
was 10 µl. All samples, standards and NTC were performed in triplicate.  
Thermal cycling was performed on a Taqman 7900 Applied Biosystems Ltd machine. All 
primers were designed to have an annealing temperature of 60°C, and all primers were 
optimised to work under the same conditions to allow multiple primers to be run on the 
same plate. A dissociation curve was run during optimisation to ensure there were no 
primer dimer formations that may interfere with accurate quantification. 
Thermal cycling conditions were: 95 °C for 10 minute hotstart, 95 °C for 30 seconds 
denaturation, 60°C for 30 seconds annealing, 72°C for 30 seconds elongation. The 
denaturation to elongation steps were repeated for 40 cycles.   
For every test sample, alongside test genes, Q-RT-PCR reactions were conducted for a 








Table 1.3: Primer pairs used for Q-RT-PCR analysis 
Primer pair name Forward primer 
(5’ to 3’) 
Reverse primer 
(5’ to 3’) 




RPS6 agggttatgtggtccgaatca tgccccttactcagtagcagg 
RPS14 tcaccgccctacacatcaaact ctgcgagtgctgtcagagg 
 
2.7.5 Taqman Q-RT-PCR data analysis 
Q-RT-PCR analysis was performed using SDS 2.3 Taqman software. The cycle threshold (Ct) 
values were automatically set by the software. Ct is defined as the point at which amount of 
accumulated fluorescence produced by the generation of PCR amplicons crosses the pre-
defined threshold limit.  Standard producing a curve with a gradient of -3.32 indicate 100% 
efficiency in DNA amplification. Experiments where the standard curve exceeded the 
boundaries of -3.2 and -3.45 were discarded and repeated. The software allowed automatic 
calculation of DNA quantity, mean values between replicates and the standard deviation 
(STD) of the mean. Outliers were omitted from data analysis to prevent skewing of the data. 
To normalise the gene expression of test genes, the values were used only from the same 
derived cDNA.  The value of the DNA quantity mean of the test gene was divided by the DNA 
quantity mean of normaliser gene. These ratios are the values plotted as presented in the 
results chapters. 
The STD was recalculated accordingly:  






2.7.6.1 Purification of PCR products 
PCR products were generated using the primers and optimised thermal conditions described 
in Table 2.4. Products were run of agarose (described in section 2.7.3.3). PCR products were 
purified using GE Healthcare illustra microspin DNA purification columns. Briefly, the resin in 
column was resuspended by vortexing, and spun for 1 minute at 600 g and PCR products 
(maximum 50 µl per column) loaded onto the column, and centrifuged at 600 g for 2 






Table 2.4: Primers and thermal conditions used to generate PCR products for sequencing. The sequencing primers correlate with the diagram 




(5’ to 3’) 
Reverse primer 
(5’ to 3’) 
Denaturation  
Temp (°C)  
/ time (Sec)  
Annealing  
Temp  
(°C) / time 
(s)  
Elongation  
Temp (°C)  






UTR aggccgctaacagacaggag gggagctgttttatttaagg 
 
94/30 46.5/30 72/30 35 201 
Nica1 agacggtgtcagtggtagcc gccacattccagaaaaagga 94/30 54.6/30 72/50 35 954 
Nica2 cacatgcatgctgtcatcag 
 
gggatcagcctgaactgtgt 94/30 51.4/30 72/30 30 888 
Nica3 gctgagccctgaagagga atcccaaaatctggcatgag 95/30 36.8/30 72/30 30 970 








in Table 2.5. All  sequencing  reactions were performed by  Ivan Andrew  (Medical Research 
Council, Clinical Sciences Genomics Laboratory, Hammersmith Hospital). Cycle Sequencing 















































3  ccttctgtctttctgcgtcc    181‐200 
4    tctccctttcagcttctcca  477‐466 
5  atacagtggaattcgctggg    608‐627 
6    ttgatgctgaaggtgctttg  833‐852 
7  tcctttttctggaatgtggc    980‐999 
8    tctgtgtgcatccaaagctc  1247‐1266 
9  gacgggcctcttcaacatta    1766‐1785 
10    gctttggcattgatgcagta  2186‐2205 
11  agcttttcttgccagctcag    2265‐2284 
12    atcccaaaatctggcatgag  2484‐2503 
13  gcccttcaggacccttctac    2558‐2577 
















Proteins were  determined  by  staining with  the  Bradford  reagent  (Pierce  Biotechnology). 
Bovine serum albumin  (BSA) at 0, 3.125, 6.25, 12.5, 50 and 100 μg/ml  in deionised water 
with  10  μl/ml western  lysis  buffer were  used  as  standards.  Samples were  diluted  1/50, 




Samples  (20  μg protein/μl) were denatured  in 2x protein  sample buffer  (125 mM tris, 4% 
SDS, 0.2% bromophenol blue, 200 mM DTT, 20% glycerol, pH 6.8) at 100°C for 10 minutes. 





molecular weight proteins and 15%  for  lower sized proteins. Kaleidoscope  ladder  (Biorad) 
was  run as  a molecular weight marker, and gels were  subjected  to electrophoresis at 60 
volts through the stacking gel, and 100 volts through the running gel using a 1:10 dilution of 
10x running buffer  (0.5 M  tris, 1 M glycine, 1% SDS, pH 8.3). Proteins were  transferred  to 
nitrocellulose  (Millipore) at 100 volts  for 1 hour using 1:50 dilution of 50x  transfer buffer 
(0.25  M tris, 1  M  glycine,  pH  8.3).  Following  brief  incubation  with  ponceau  to  check 
sufficient  protein  transfer,  membranes  were  washed  in  0.1%  TBS‐Tween  (TBST),  and 
incubated  in 5% BSA  in 0.1% TBST on a rocker shaker at 4°C for 1 hour. Membranes were 
probed  for  antibodies  diluted  in  5%  BSA  in  0.1%  TBST  overnight.  Antibodies  used  are 
























































and  left  to  adhere  for  24  hours.  Cells were  treated with  0,  2  and  5  μM GSI1.  Cell  cycle 
profiles were analysed after 24 and 48 hours GSI1 treatment after propidium iodide staining. 
Briefly, media was collected to capture any dying or non‐viable cells in the media. Adherent 
cells  were  trypsinised,  added  to  the  previously  collected  media  and  pelleted  by 
centrifugation at 168 g for 5 minutes at 4°C. Cells were vortexed during addition of 1 ml ice‐
cold 70% methanol and kept one hour at 4°C. Samples were washed twice with 5 ml PBS. 
RNAase  (100  μl  of  100  μg/ml) was  added  to  sample  pellets  and  incubated  at  4°C  on  an 
orbital shaker for 15 minutes. Propidium iodide (900 μl of 50 μg/ml) was added to cells and 
left overnight at 4°C on a roller. Samples were  filtered  through a 71 μm pore nylon mesh 
before  analysis  on  a  FacsCanto  Analyser  (Beckton  Dickinson,  USA)  to  determine  the 
proportion of cells at each stage of the cell cycle.  
 
For  siRNA‐transfected MDA‐MB‐231  cells  the  supernatant  was  collected  48  hours  post‐
transfection and added to trypsinised cells. Cells were counted and 60,000 cells were lysed 









with  either  primary  nicastrin  antibody  only  (1/500)  or  1%  BSA/PBS  (for  the  secondary 
antibody blank) at 4˚C on a roller. PBMCs were washed once with 1 ml 1% BSA/PBS  for 5 
minutes,  and  cells  pelleted  by  centrifugation  at  240  g  for  5 minutes.  All  samples were 
incubated with secondary alexafluor 647 antibody (1/300) for 30 minutes at 4˚C on a roller. 




























3.3.4), but a Sigma Aldrich antibody was  found  to have  less background  staining and was 
used at 1/500 with 1/300 alexafluor 488 for all other nicastrin staining. 
In  order  to minimise  the  effects  of  non‐specificity  of  the  nicastrin  antibody,  it was  pre‐
purified prior  to use  in  the  immunofluorescence  staining. Protein  lysates  from untreated 
NCSTN  ‐/‐ MEF  cells were prepared  as described  in  section 2.8. A 1  cm  x 1  cm  square of 
nitrocellulose membrane was placed  into a well of a 24 well plate. This was hydrated with 
1ml of 1 x PBS for 5 minutes. The membrane was then saturated with NCSTN ‐/‐ MEF protein 










A  1  cm  x  1  cm  square  was  made  using  liquid  blocker  around  cytospun  cells. 
Immunofluorescence was conducted  inside a moist‐chamber  slide box at RTP.   Cells were 
hydrated with  100  µl  PBS  for  5 minutes.  Lymphocytes  and  bone marrow  samples  (and 
corresponding  control  cells) were not permeabilised  in order  to detect membrane bound 
nicastrin, which would correlate with active γ‐secretase complexes at the plasma membrane 
[94]. Cells were then blocked by  incubation with 0.5% BSA (100 µl) for 3 hours. Cells were 
incubated with 100 µl of  the purified nicastrin antibody  (section 2.10.2.3)  for 1 hour  [94]. 
The negative control  included 0.5% BSA  instead of primary antibody.   Samples were  then 
washed three times with 100 µl of PBS for 5 minutes. The secondary anti‐rabbit alexafluor 
488 antibody  (Invitrogen) against the nicastrin  (100 µl) was  incubated for 1 hour. Samples 
were  then washed  100 µl of PBS  for  5 minutes  three  times. Powdered DAPI  (Invitrogen, 
D9542)  was  solubilised  to  in  double  distilled  water,  were  freshly  diluted  to  a  working 
concentration of 1:10,000 in PBS. This was added to the samples (100 µl) for 5 minutes, and 
washed  off with  100  µl  PBS  for  5 minutes.  Before  slide mounting,  a  drop  of mounting 
medium (Sigma Aldrich) was placed onto the slides, and a coverslip positioned on top of the 
cells. Excess mounting media was removed by gently applying pressure to the coverslip with 








































fibronectin).  Sequences  are  presented  in  appendix  Tables  5.1.1‐5.  The  oligonucleotide 










Hybridization  Buffer  A  [6X  saline‐sodium  citrate,  25%  formamide,  0.2%  Lithium  Dodecyl 
Sulfate,  blocking  reagents]  for  3  hours  (buffers  are  proprietary  information).  PreAMP  in 


























Massachusetts).  Overlapping  signals  from  different  fluorophores  were  separated  by 





















Further experiments  aimed  to elucidate  the mechanism by which  the  chosen  γ‐secretase 
inhibitor exerts its effects. 
The most  commonly  studied  γ‐secretase  inhibitors  in  cancer  are DAPT, Compound  E  and 
GSI1,  since  they  have  been  shown  to  be  effective  in  reducing  proliferation,  inducing 
apoptosis  and  down‐regulating  the Notch  pathway  [42,  43,  184,  220]  (see  Section  1.4.4, 
Table 1.4). Thus, we decided  to assess  their ability  to  reduce breast cancer cell growth. A 





MCF‐7, MDA‐MB‐231 and T47‐D cells were  treated  for 48 hours with one of  the  three  γ‐
secretase  inhibitors  at  concentrations  ranging  between  0.01‐50  µM  (Figure  3.1.1). 







there was a 30‐34% decrease  in  cell number  (p <0.001). However,  the effect of  the drug 
reached a plateau  in T47‐D cells,  suggesting enzyme  saturation  (Figure 3.1.1, C).  In MDA‐
MB‐231 cells, Compound E had no effect,  (Figure 3.1.1, B). Conversely, DAPT  reduced cell 
numbers more effectively than Compound E in MDA‐MB‐231 cells (1 µM DAPT reduced cell 
numbers  by  33%;  p  <  0.001). At  the  highest  concentration  used  (50 µM), DAPT  reduced 
MDA‐MB‐231 cell numbers by 60% (p <0.001), whereas Compound E had no effect (Figure 





DAPT  in  any  cell  line  reduced  cell  numbers  on  average  of  21%  and  43%,  respectively. 
Furthermore, MCF‐7 cells were sensitive to just 0.1 µM GSI1, which reduced cell numbers by 
36%  compared  to  the  vehicle  control  (p  <0.0001), whereas  this  concentration  of  either 
Compound E or DAPT was ineffective. 
















































































































231, CAL‐51) cell  lines, as well as non‐tumourigenic breast epithelial cell  lines  (226‐L‐U19, 
226‐L‐TS4).  GSI1  was  titrated  to  concentrations  of  0,  0.5,  0.75,  1,  2  and  5  µM  in  the 
aforementioned cell lines, and growth curves were obtained through measurement by SRB 
staining at two day intervals for a period of ten days. 
Overall,  increasing  concentrations  of GSI1  inhibited  proliferation  in  a  dose‐dependent 
manner  in  breast  cancer  cells,  regardless  of  the  ER  status  of  the  cell  lines,  although  the 
degree  of  potency was  cell  line  dependent. In  all  cancer  cell  lines,  excluding  T47‐Ds,  cell 
growth gradually decreases over time with  increasing concentrations of GSI1 up to 0.5 µM 
GSI1 in MCF‐7 and MDA‐MB‐231 (Figure 3.1.2, A, B), 0.75 µM GSI1 in CAL‐51 (Figure 3.1.2, C) 
and  1 µM GSI1  in  ZR‐75‐1  (Figure  3.1.2,  E),  and  between  1 µM  and  2 µM GSI1,  a  sharp 
decrease  in  cell  growth  was  observed.  In  T47‐D  cells  however,  with  increasing  GSI1 

























































































































status.   Black arrows  represent vehicle control  (DMSO), orange arrows 0.75 μM GSI1  (the 
tested  concentration  closest  to  the  mean  tumourigenic  IC50  value)  and  the  red  arrow 











lines  tested  (MCF‐7, MDA‐MB‐231, CAL‐51, T47‐D and ZR‐75‐1 Figure 3.1.2), GSI1  induced 
cytotoxicity  at  ≥  2 μM,  resulting  in  minimal  or  no  growth.  However,  using  the  same 
concentrations, 2‐5 μM GSI1 had no affect the proliferation of the non‐tumourigenic breast 
cell  line 226‐L‐U19  (Figure 3.1.3, A). GSI1 was  therefore  titrated  to higher  concentrations 
(10‐ 60 μM) in 226‐L‐U19, as well as an additional non‐tumourigenic breast cell line, 226‐L‐
TS4, to determine the difference in IC50 values between tumourigenic and non‐tumourigenic 
cells.  IC50  values  (Table,  3.2.1)  indicated  that  in  the  two  non‐tumourigenic  cell  lines 

































































































cell  lines  (Figure  3.1.2:  vehicle,  0.5,  0.75,  1,  2  and  5  μM)  were  tested  in  the  non‐
















as  the  growth  curves  in  the  tested  cell  lines  had  differentiated  enough  to  observe  a 
difference  in  response  to  GSI1  titration.  IC50  was  defined  as  the  concentration  of  drug 
required  to  inhibit  growth  by  50%.  Although  later  time  points  illustrate  the  sustained 
inhibition  of  cell  growth,  plateau  effects  in  the  vehicle  controls  (most  notably  in MCF‐7, 

















Table  3.1.1:  IC50  values:  Tumourigenic  cell  lines  are more  sensitive  to  GSI1  than  non‐
tumourigenic breast cell lines.   IC50 values were calculated at day 6 from the growth curves 




















To  test  whether  inhibition  of  γ‐secretase  by  GSI1  induced  anti‐growth  effects  on  other 
cancer  types,  the  National  Cancer  Institute’s  (NCI)  panel  of  sixty  cancer  cell  lines  were 
treated with GSI1 (10 nm, 100 nM, 1, 10, and 100 µM, the equivalent of  log10  ‐8,  ‐7,  ‐6,  ‐5 
and  ‐4  respectively)  for 24 hours  (Figure 3.1.4). To measure cytotoxicity SRB  staining was 
performed.  Data  is  presented  as  percentage  growth  (Figure  3.1.4),  using  the  calculation 
described in section 2.3.4. 
GI50  was  considered  by  the  NCI  as  “50%  growth  inhibition”  and  LC50  as  “50%  lethal 





vehicle  controls  [275]. GI50,  LC50 and TGI  values,  calculated by NCI are  found  in appendix 
Figure 5.2. 
With increasing GSI1 concentrations, a decrease in cell number was seen in all 60 cell lines 
with the mean  log10 GI50 of −6.13 ± 0.007 M (1 µM). The mean  log10 LC50 calculated  for all 
sixty  cell  lines was  −4.41 ± 0.011 M (100 µM). When  the  screen was  repeated,  the values 
obtained were −6.41 ± 0.005 M  (1 µM)  for the  log10 GI50, and −4.49 ± 0.12 M  for  the  log10 
















effect  of  GSI1  (10,  100 nM,  1,  10,  100 μM  ,the  equivalent  of  log10  ‐8,  ‐7,  ‐6,  ‐5  and  ‐4 
respectively)  on  cancer  cells  was  determined  by    SRB  staining  after  24  hours  of  drug 













cancer  Figure  3.1.4,  I),  after  an  initial  growth  decrease  to  10  µM,  growth  increased. 





Since GSI1  inhibited cell growth and  induced cytotoxic effects  in multiple cancer types, the 
hypothesis was  tested  that  its effect  in breast  cancer was due  to  induction of  cell death 
through apoptosis. For this, cell cycle analysis using flow cytometry was performed in three 
breast cancer cell  lines  (MCF‐7, MDA‐MB‐231 and ZR‐75‐1)  treated with 0.75, 2 and 5 μM 
GSI1, for 24 and 48 hours. At 0.75 μM GSI1, there was no significant change in any cell cycle 
phase in any cell line, at either 24 or 48 hours (Figure 3.1.5, A). However, after 24 hours of 
treatment with 5 μM GSI1  cells  showed  a  shift  into G2/M which progressed  to  apoptosis 
(16.5%, 73.6% and 58.5%  in respective cell  lines, Figure 3.1.5, B, appendix Table 5.6) by 48 
hours  in  all  three  cell  lines.  The  number  of  S‐phase  cells  also  increased  at  24  hours  in 
response to treatment with 5 μM GSI1  in MDA‐MB‐231 and ZR‐75‐1 cells by 6.8% and 20% 









was  a  decrease  in  cells  in  the  G1  phase  by  32.8%  and  45.6%  respectively  at  24  hours 
compared to the controls, and this was further reduced by 48 hours. 
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As  discussed  in  section  1.5.1,  γ‐secretase  inhibitors  have  shown  to  induce  apoptosis  in 
various cancer  types  [42, 214, 277]. More specifically, GSI1 has been previously shown  to 
induce  apoptosis  [219]. A  panel  of  proven  anti‐apoptotic markers  (Bcl‐XL,  Bcl‐2,  Bax  and 





for 48 hours,  and  the  anti‐apoptotic Bcl‐XL protein expression was measured by western 
blot analysis. This concentration was used as it was nearest to the IC50 determined from the 
growth curves (Table 3.1.1). In MDA‐MB‐231 and ZR‐75‐1, Bcl‐XL expression was decreased 
in  response  to  GSI1  (Figure  3.1.6,  A).  MCF‐7  cells  were  further  treated  with  various 
concentrations  of  GSI1  (0,  0.75,  2,  and  5)  for  48  hours,  and  protein  expression  of  anti‐
apoptotic markers XIAP, Bcl‐2, Bax and Bcl‐XL were analysed by western blotting. XIAP was 

































Figure  3.1.6:  GSI1  triggers  apoptosis  through  down‐regulation  of  apoptotic  proteins. 
Breast  cancer  cell  lines  MDA‐MB‐231,  MCF‐7  and  ZR‐75‐1  were  treated  with  the  IC50 
concentration of 0.75 µM  for 48 hours  (A). Bcl‐XL protein expression was decreased by  γ‐


















the  control  cells,  actin  was  dispersed  throughout  the  cytoplasm,  and  had membranous 
localisation that clearly defines the cellular periphery (Figure 3.1.7, A). After treatment with 
0.75 µM GSI1,  the  cells became  irregular  in  shape,  some enlarged, others multinucleated 
(Figure 3.1.7, B, C). GSI1 also induced cytoskeletal disorganisation through the formation of 
stress  fibres  and  filapodae  (Figure  3.1.7,  B,  C,  white  and  green  arrows).  GSI1  at  a 
concentration  of  2  μM  severely  reduced  the  number  of  MCF‐7  cells.  However, 
immunofluorescence analysis did not allow quantitative analysis  to demonstrate  this. The 
cellular  integrity  of MCF‐7  cells  treated with  2  μM was  poorly  defined, with  some  cells 
completely  losing  the  plasma membrane  boundary.  These  cultures  also  featured  syncitia 
(Figure  3.4  C  and  E). Multinucleated  cells were  not  seen  in  the  untreated,  control  cells. 
Attached  MCF‐7  cells  were  completely  lost  with  5  µM  GSI1,  thus  microscopy  was  not 
achievable.  This  was  observed  in  three  independent  experiments.  This  experiment  was 





























and  γ‐ secretase  activity  measured  using  three  assays:  a  commercially  available  kit 
measuring  APP  cleavage,  the  measurement  of  protein  levels  of  N1ICD,  and  an  CBF1‐
luciferase reporter assay [47, 280, 281].  
The  first  assay  was  conducted  using  a  commercially  available  γ‐  secretase  activity  kit. 
Essentially, the methodology involves extraction of cell membranes encompassing active γ‐
 secretase  complexes  (if present),  and  incubation with  an APP  substrate. Cleavage of  the 
APP peptide substrate, (GVVIATVIV)  is conjugated to fluorogenic peptide (EDANS/DABCYL), 
releases  the  two molecules, measurable  by  fluorescent  emission.  This  fluorescence  is  a 
surrogate for γ‐ secretase cleavage of APP and therefore activity. This assay demonstrated 
an  inverse  correlation  between  increasing  GSI1  concentration  and  a  dose‐dependent 
reduction  in  γ‐ secretase activity  in MCF‐7 cells  (Figure 3.1.8).   At 0.75 µM GSI1 showed a 








Figure 3.1.8: GSI1 down-regulates γ-secretase activity in breast cancer cells. MCF-7 cells 
were treated with GSI1 for 24 hours and cleavage of APP was used as a surrogate 
measurement for γ-secretase activity. Bars indicate the average γ-secretase activity ± SD of 
three independent experiments. * indicates P<0.05 statistical significance calculated by T-
Test analysis. Adapted from Rasul et al [276]. 
 
In order to confirm the observed inhibition of γ- secretase activity by GSI1 further assays 
were carried out to demonstrate effects on Notch signalling. To do this, the γ-secretase 
cleaved product of Notch, N1ICD, was examined using western blot analysis of whole lysates 
from MCF-7 cells treated for 24 hours with 0, 2 and 5 µM GSI1 (Figure 3.1.9). Corroborating 
the inhibition of γ- secretase activity observed, N1ICD protein was dramatically reduced 
when cells were treated with 2 and 5 µM GSI1. However, the levels of inhibition were 
relatively equal, unlike the dose-dependent reduction observed in the APP γ- secretase kit 













178].  A CBF‐1  based  luciferase  reporter was  used  to measure  activation  of Notch  by  γ  ‐
secretase,  as previously described  [280]. Mirroring  the  reduction  in APP  cleavage, MCF‐7 
cells treated with GSI1 also reduced the luciferase activity of the CBF‐1 reporter  in a dose‐
dependent manner  (p< 0.05,  Figure 3.1.10).  Interestingly,  the  inhibitory effect of GSI1 on 
CBF‐1‐driven luciferase  transcription  was  lower  than  the  corresponding  inhibition  of  γ  ‐
secretase activity on APP (Figure 3.1.8‐9). At 2 µM GSI1, there was an 80% APP γ‐ secretase 
activity  inhibition  (Figure  3.1.10),  although  there was  50% CBF‐luciferase  gene  inhibition. 
With 5 µM GSI1 treatment, inhibition of APP cleavage was completely effective, whilst there 
















Previous  results  showed a decrease  in N1ICD protein  levels when cells were  treated with 
GSI1 (Figure 3.1.9). To determine alterations  in the expression of Notch1 mRNA as well as 
that of other Notch genes, ligands and γ‐secretase components, analysis of gene expression 
by  semi‐quantitative  PCR was  carried  out  on  four  breast  cancer  cell  lines  (MDA‐MB‐231, 
MCF‐7,  ZR‐75‐1  and  T47‐D).  The  examined  genes  included  those  of  the  γ‐ secretase 
components  (NCSTN, APH1A, PSEN1, PSEN2, PSENEN), Notch  receptors  (Notch1, Notch2), 
associated ligands (Jag1, Jag2) and the Notch inhibitor Numb. GAPDH was used as a loading 










cells. However, both T47‐D and MCF‐7  cells expressed higher  levels of  Jag2  compared  to 
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As  in  vitro  experiments  do  not  take  into  consideration  the  uptake  of  drugs  by  cells,  the 
proteasome activity  in vivo was measured  (Figure 3.1.13). Extracts  from MCF‐7 and MDA‐
MB‐231 cells following four hours treatment with either GSI1 or MG132 were prepared and 
proteasome  activity  determined. GSI1  reduced  proteasome  activity  in  a  dose‐dependent 
manner,  in both cell  lines. MG132 was marginally a more potent  inhibitor, concurring with 

























































lower  concentrations  than GSI1  (Figure 3.1.14). This  is  reflected by  the  IC50  values  (Table 
3.1.2) where  in MCF‐7 a 77%  lower  concentration of MG132  (0.1 µM)  compared  to GSI1 
(0.45 µM) reduced cell growth by 50%. Similarly in MDA‐MB‐231 cells the IC50 of MG132 (0.2 


























































Figure 3.1.14: MG132 is more cytotoxic to breast cancer cells than GSI1. MCF-7 (A) and 
MDA-MB-231 (B) cells were treated with increasing GSI1 or MG132 concentrations for 4 
hours and the cytotoxic effect determined after staining with SRB. Data represent the 











Overall  in both  the  in vivo and  in vitro experiments,  the pattern of proteasome  inhibition 
between  both  GSI1  and  MG132  was  similar,  except  a  higher  concentration  of  GSI1  is 







Furthermore, breast  cancer  cells were more  sensitive  to  the effects of GSI1  compared  to 














GSI1 was  found  to be efficient  in  reducing breast cancer cell growth  through  induction of 
apoptosis and, possibly,  through a potent off‐target effect on proteasome activity.  In  this 
respect, as discussed in section 1.1.6, other γ‐secretase inhibitors have been shown to have 
off‐target effects as clinical side effects, such as gastrointestinal toxicity [230]. Therefore, it 




The  γ‐secretase  components  are  heavily  co‐dependent  on  each  other  to  form  active 






secretase  complex  were  silenced  by  RNA  interference.  Previously,  siRNA  mediated 
knockdown  of  individual  components  has  been  shown  to  result  in  decreased  protein 
expression of other  γ‐secretase  components  in a HEK293  cell  line  [47], but had not been 








oligofectamine)  and  non‐targeted  siRNA  transfected  cells  were  included  in  these 
experiments.  siRNA mediated knock down of Glyceraldehyde 3‐phosphate dehydrogenase 
(GAPDH)  was  also  used  as  a  positive  control  for  targeted  gene  knockdown.  GAPDH  is 
involved  in  the catalysis of glucose  for energy production,  therefore  it was expected  that 
silencing would reduce cell growth. As can be seen in Figure 3.2.1, there was little effect on 
cell growth following treatment with negative controls (mock and non‐specific RNA). siRNA 
screening of  all  the  γ‐secretase  components  showed  that NCSTN  knockdown  significantly 
reduced cell growth at day 4, which increases to 55% by day 6 (p < 0.0001). This is the same 
level of  growth  inhibition obtained with  the positive GAPDH  control  knockdown. Overall, 
compared with the non‐specific control, the rate and amount of cell growth became more 
impaired with time in the NCSTN knockdown. Silencing of the other γ‐secretase components 
also  reduced  cell  growth  at  day  6,  but  not  as  effectively  as  induced  by  NCSTN  gene 
knockdown: PSENEN reduced growth by 30%, APH1A by 26% and PSEN1 by 19% at day 6, 

























Figure  3.2.1: Gene  knockdown of NCSTN  in MCF‐7  cells  reduces  cell  growth. Cells were 
treated with  siRNA  against  genes  encoding  proteins  of  the  γ‐secretase  complex  (PSEN1, 
APH1A,  NCSTN  and  PSENEN).  Negative  controls  of  untreated  cells,  mock  (transfection 
control)  and  non‐specific  siRNA  and  positive  control  of  GAPDH  were  included  in  the 
experiment. SRB assays were performed 2, 4, and 6 days post transfections to measure cell 
growth.  Data  is  representative  of  two  experiments.  Error  bars  indicate  ±  SD.    Statistical 





The  gene  knockdown  of NCSTN  reduces  cell  growth  in  the  breast  cancer  cell  line MCF‐7 
which  mirrors  the  effect  of  GSI1.  As  GSI1  was  shown  to  reduce  cell  growth  through 
induction  of  a  G2/M  arrest  and  apoptosis,  it  was  investigated  whether  NCSTN  gene 
knockdown  produces  the  same  effect.  Both MCF‐7  and MDA‐MB‐231  cells were  treated 
with NCSTN  siRNA or  a  siRNA  against  EGFP, used  as  a negative  control.  The non‐specific 









(Figure 3.2.2, A), although there  is one notable change  in S‐phase  in MCF‐7 cells at day 3: 







protein  levels  of  nicastrin  and  the  anti‐apoptotic  protein  XIAP,  previously  shown  to  be 
reduced  by  GSI1, were measured  in MCF‐7  and MDA‐MB‐231  cells,  3  days  post‐  siRNA 
treatment. Gene knockdown of NCSTN was sufficient to reduce both immature and mature 











































lines. MCF‐7  and MDA‐MB‐231  breast  cancer  cell  lines were  transfected with NCSTN  or 
EGFP  (non‐specific)  siRNA. Cell  cycle analysis by  flow  cytometry was performed at days 3 
and 6 post‐transfection  (A). No change  in  the cell cycle profile was observed  in either cell 
line or time point, when compared to the EGFP control. Percentage values of flow cytometry 








Using  immunohistochemistry  analysis  of  tissue microarrays,  our  laboratory  has  recently 
demonstrated,  ,  that  nicastrin  is  not  expressed  in  normal  breast  tissue  derived  from 
reduction mammoplasty  procedures  (n=40),  but  is  expressed  in  47.5%  of  breast  cancers 
(n=1050)  [284].  It was  therefore postulated  that nicastrin may be up‐regulated during  the 
tumourigenic  transformation  process,  which  eventually  contributes  to  the  metastatic 
phenotype. To investigate this, cell lines were used as models to represent different stages 









NCSTN  gene  expression  in  untreated  cell  lines  of  approximately  70%  confluency,  was 
measured by Q‐RT‐PCR. NCSTN expression was normalised against  the gene expression of 
ribosomal  protein,  RPS6.  The  non‐tumourigenic  cell  lines  had  the  same  level  of  gene 
expression  as  the  metastatic  breast  cancer  cell  lines  MCF‐7  and  CAL‐51.  However, 









was detectable gene expression,  there appeared  to be  little nicastrin protein. Despite  the 
non‐tumourigenic hTERTs expressing  similar  levels of NCSTN  to 184A1  and MTMEC  lines, 
nicastrin protein was more abundant, and expressed  to similar  levels as  the  tumourigenic 
cell  lines, MCF‐7, CAL‐51 and T47‐D’s.  Interestingly, although T47‐D had  the highest gene 
expression, MDA‐MB‐231 appeared to have the highest nicastrin protein levels of all the cell 
lines examined. Overall, these results may have higher nicastrin expression in breast cancer 
cell  lines  compared  to  non‐tumourigenic  breast  cell  lines,  at  both  gene  expression  and 
protein levels. Importantly, since NCSTN mRNA did not correlate with protein levels it is very 






















































































tumourigenic  (blue  bars)  and  tumourigenic  (red  bars)  breast  cell  lines  was  used  to 





Interestingly,  Ensembl  shows  the NCSTN  gene  is  located  on  chromosome  1q23  between 
160,313,062‐160,328,742 bp, thereby overlapping with the COPA gene located between loci 
160,258,777‐160,313,354 bp on  the anti‐sense  strand  [119]. The COPA gene encodes  the 




components  in COPI secretory vesicles. Further, the  incorporation of nicastrin protein  into 













Overlapping  genes  occur  frequently  in  viral,  prokaryotic  and  mitochondrial  genomes. 
However until recently, it was believed that they were rare in eukaryotic nuclear genomes. 
With  the  completion  of  the  human  genome  sequence,  it  has  become  evident  that 
overlapping genes are relatively common. In one of the first analyses reported, 774 pairs of 
overlapping genes were  found  in  the human genome  [288, 289].     Genes  that overlap  in 
such a manner have demonstrated co‐regulation, for example, the MDR1 gene encoding the 
ABC drug  transporter, P‐glycoprotein, overlaps with  the poorly  characterized RPIP9  gene. 








cell  lines  as  used  in  Figure  3.2.3.  COPA  expression  was  normalised  against  the  gene 
expression  of  RPS6.  In  general,  COPA  expression was  higher  than NCSTN  in  all  cell  lines 
(Figure 3.2.5). COPA expression was similar in all cell lines tested, in both non‐tumourigenic 
and  tumourigenic,  apart  from  T47‐D, where  the  expression was  significantly  higher.  The 

































































designed  in  one  coding  exon  and  the  reverse  in  the  next  adjacent  exon  so  that  the 
intervening  intronic  region would not be amplified. One primer pair generated a 213 kbp 
product to sequence the 5’UTR region. Four of the primers pairs were designed to produce 
four  products  of  approximately  1  kbp.  The  products  had  a  minimum  100  bp  overlap 











Nica 1 product size: 954 bp
Nica 2 product size:  888 bp
Nica 3 product size: 970 bp
Nica 4 product size: 892 bp
B








1       3                          5                     7 9 11               13                
2          4                    6                      8                                                            10       12             14
Stop codon
UTR product size: 213 bp
Forward strand, chromosome 1q23, 15.68KB. Accession number NM015331
 
Figure  3.2.6:  PCR  and  sequencing  primer  design  to  sequencing  NCSTN  cDNA  for 
polymorphisms. Schematic of NCSTN exon positions, accession number NM_015331.2 taken 




Five  PCR  primers  pairs  (UTR,  Nica1,  Nica2,  Nica3  and  Nica4)  were  designed  to  amplify 
products  spanning NCTSN  coding  exons  (B).  Each  primer  (depicted  by  coloured  boxes)  is 
aligned to the position in the NCSTN gene sequence. Each vertical line represents 250 kb of 
the mRNA sequence. Alignment of amplified PCR products against the NCTSN sequence (C). 
Nested  sequencing  primers were  generated  to  read  sequences  at  least  once  in both  the 





were used  to  test  for NCSTN polymorphisms. MCF10A  is  a widely utilised model of non‐
tumourigenic  breast  cells.  Sequences  were  aligned  to  NM_015331.2,  the  NCBI  NCSTN 
reference  sequence, using  two  independent analyses  software  (Gene Tool and NCBI blast 
[290]).   High quality  sequence  chromatograms were obtained which had  low background 
signals, an example of which is shown in Figure 5.4 (appendix Figure 5.4). Sequencing of the 
five PCR products  in  all  three  cell  lines  created  similar  runs,  all  aligning  to  the prototype 
nicastrin mRNA   sequence (Genbank accession number NM_015331.2),  indicating wildtype 
NCSTN  is present  in both  the non‐tumourigenic and  tumourigenic  cell  lines  sequenced. A 
diagrammatic  representation  of  how  the  sequencing  products  obtained  aligned  to  the 
prototype  sequence  is  shown  in  Figure  3.2.7  using  MCF‐7  as  an  example.    Sequence 




































association  in reported mutations and the disease  is debated, as discussed  in section 1.3.1 
[108, 110, 111, 116, 117]. However, there were four published exonic mutations detectable 
in AD patients [108], but were not associated statistically with AD. Therefore, the presence 









(MCF10A) showed no mutation  in  the coding region of NCSTN, previously  reported  in AD. 
Corresponding  translated  protein  residues  are  noted  in  brackets  (under  reported  SNP 
mutation column). 
 
Reported SNP Mutation   Location   link with AD   Sequencing of MCF‐
7, MDA‐MB‐231, 
MCF10A 













Several  mutational  studies  have  identified  amino  acid  residues  that  regulate  nicastrin 
protein  function  and  activity  as  discussed  in  section  1.3.6.  In  particular,  site  directed 
mutagenesis mutations to amino acids within the DAP domain abrogate the protein’s ability 
to bind to presenilin and substrates of the γ‐secretase complex  [47, 123]. Most notably, a 
double point mutation  (D366A/Y337A)  increases  γ‐secretase  activity  as measured by APP 
cleavage  [123].  After  sequencing MCF10A, MCF‐7  and MDA‐MB‐  231,  the  regions  in  the 
chromatograms were  then  specifically  looked  at  for  SNPs,  insertions  or  deletions  at  the 
corresponding  gene  locations  encoding  the  protein  residues  targeted  by  site  directed 


















































































Alternative  splicing  of  a  single  gene  can  give  rise  to  numerous  proteins which may  have 
different  biological  functions.  Mircoarray  analysis  of  a  panel  of  52  different  cancers, 
examining every exon‐exon  junction  in over 10,000 genes, showed 74% of the genes were 
alternatively spliced [291]. Splice variants in cancer specific genes have been identified, for 
instance, WT1  (in Wilms  tumours), and  the gene KLK3 which encodes  the prostate cancer 
marker  prostate  specific  antigen  (PSA),  may  be  contributory  to  cancer  or  be  used  as 
surrogate biomarkers to monitor disease [270]. In particular, several splice variant forms of 
the  γ‐secretase  substrate,  CD44  have  been  reported  in  cancers.  A  literature  review  of 
studies using monoclonal antibodies of  the  splice variant CD44V6  in ~10,000 primary and 
metastatic samples of various tumours showed frequently detectable levels of CD44V6 [292]. 
Presence  of  CD44V6  splice  variant  is  associated  with  lower  5‐year  survival  rates  in 




variants of NCSTN on the Ensembl database [119].    In published  literature, a splice variant 
with exon 16 deleted was detected  in a  small cohort of autopsied brains of FAD patients 
[121]. Furthermore, a splice variant lacking exon 3 was identified in rat NCSTN, resulting in a 





















NCSTN-203 16 2835 305
NCSTN-204 17 2747 689
NCSTN-202 18 3039 232
NCSTN-201 14 2526 571
NCSTN-008 9 958 320
NCSTN-012 7 659 219
NCSTN-011 7 824 275
NCSTN-010 2 545 No product
NCSTN-009 11 1246 No product
NCSTN-007 4 448 134
NCSTN-006 7 776 255
NCSTN-005 4 490 No product
NCSTN-004 6 726 No product
NCSTN-013 2 856 No product
NCSTN-003 7 702 232
NCSTN-014 4 592 No product
NCSTN-002 18 3031 689
NCSTN-001 17 2936 709
 
Figure  3.2.8:  Ensembl  recorded  splice  variants  of NCSTN  gene  (September  2010)  [119]. 
Right of  table  illustrates  the eighteen  reported NCSTN  splice  variants.  Filled  in  red boxes 
representative of exon coding gene regions, the empty boxes are untranslated exons, and 
connecting  red  lines  are  intronic  regions.  The  arrows  lead  to  information  in  the  table 
regarding sequence length, the number of exons present, and the amino acid length of the 
translated protein. The red arrow from NCSTN‐001 shows wildtype NCSTN, corresponding to 
NM_015331.2.  The  purple  box  depicts  PCR  primer  design  used  to  generate  products  for 





In  order  to  test  the  hypothesis  that  splice  variants may  be  present,  the  PCR  products 




bands  were  observed  aside  from  those  expected  from  the  reference  sequence  thus 







0 1000 2000 2944 Kb
UTR product size: 213 bp
Nica 1 Nica 2 Nica 3 Nica 4
5’ UTR
1   2   3   4
200 bp-
1000 bp-
1   2   3   4 1   2   3   4 1   2   3   4 1   2   3   4
 
Figure  3.2.9:  No  splice  variants  are  detectable  in  non‐tumourigenic  and  tumourigenic 
breast  cells. NCSTN  from MCF‐7  (2), MDA‐MB‐231  (3), and MCF10A  (4) was amplified by 
PCR  using  the  primers  pairs.  Sample  1  is  the  blank  control,  to  indicate  specificity  of 












Gene  knockdown  of  NCTSN  reduces  breast  cancer  cell  growth,  but  the  mechanism  is 
independent of apoptosis. No NCTSN gene SNPs or splice variants exist in non‐tumourigenic 
or tumourigenic breast cancer cells. A post‐ transcriptional or translational mechanism may 
control  nicastrin  protein  expression  between  non‐tumourigenic  and  tumourigenic  breast 






in  tissue  microarray  sections  from  forty  reduction  mammoplasties  and  1050  samples 
obtained  from patients with  invasive breast cancer. Nicastrin was absent  in normal breast 
tissue samples; however  it was present    in 47.5% of the  invasive breast cancer tissues and 
showed an association with cytokeratin 18 expression  (p <0.001) and    inverse correlation 
with cytokeratins 5/6  (p = 0.01). Furthermore, NCSTN knock‐down not only decreased cell 
proliferation in MCF‐7 cells (Figure 3.2), but also decreased the invasive infiltration capacity 
and  motility  of  breast  cancer  cell  lines  in  Matrigel.  This  was  associated  with  a  down‐
regulation  of  genes  controlling  epithelial‐to‐mesenchymal  transition  (EMT)  such  as  twist, 
resulting in an increase in the γ‐secretase substrate and adhesion protein E‐cadherin [284]. 
Thus, nicastrin may be implicated in the metastatic properties in breast cancer cells. 
Cancer  treatments  are  moving  towards  personalised,  tailored  therapies.  For  example, 




particular  gene expression may  influence  treatment  regimes,  and predict  response  [294]. 
DTCs and CTCs are indicators of metastatic disease, and are being used as a tool to facilitate 





allow more  frequent  sampling and  is  less  invasive  than  tumour biopsies or bone marrow 
aspirates.  There  is  also  a  need  for more  available markers  to monitor  disease.  Thus,  as 
nicastrin may be a putative biomarker of metastatic disease, and CTCs are used as a way to 
monitor metastasis, it was therefore hypothesised that nicastrin may be expressed on CTCs, 




There  were  several  problems  encountered  in  order  to  detect  nicastrin  in  CTCs.  Firstly, 





















































Standard  (briefly:  fixation,  30  min 
blocking  with  10%    human  AB 
serum, 1 hour primary, antibody, 1 
hour secondary antibody, DAPI)  
Too  much  background,  cells  were 
detaching.  Improved  by  coating 
slides with poly‐L‐lysine  







Reduced  background  further  with 
0.5% BSA  
Length  of  blocking  time  (1,  2,  3 
hours)  
3  hours  blocking  at  room 
temperature  
Three different Nicastrin antibodies 

















antibody  only were  used  as  blanks  to  confirm  specificity  of  staining  and  to  subtract  any 
background staining and/or autofluorescence when using confocal microscopy (Figure 3.3.1, 
B, D). The optimal staining conditions were considered as a primary and secondary antibody 
concentration  combination  that  stained MDA‐MB‐231  cells but not  the NCSTN ‐/‐ MEFs or 
the  secondary  on  blank  controls.  The  optimised  staining  (nicastrin  antibody:  1/500, 













and  1/300  alexafluor  488  secondary  conjugate,  or  B:  secondary  only  (blank).  Nicastrin 
expression was negligible in NCSTN ‐/‐ null MEF (C), which was comparable to the secondary 















Until now,  the expression of nicastrin was unknown  in both DTCs and CTCs. As a  starting 
point,  bone marrow  aspirates were  obtained  from  a  small  sample  of  five  patients with 
primary breast cancer with high‐risk disease status, which may harbour a rare population of 
DTCs.   High‐risk  patients  are  defined  as  those with  cancer  cells  detectable  in  ≥  3  lymph 
nodes at the time of surgery, and have a high‐risk of metastatic relapse than  low‐risk T1N0 
patients  (patients with  lowest  graded  tumours, with no  involved  lymph nodes). High‐risk 












The  samples  used  here  were  previously  known  to  have  DTCs  detectable  by 
immunocytochemistry  detection  for  pan‐CK  (Table  3.3.2).  Interestingly,  the  number  of 
nicastrin positive cells found per patient, was similar to the amount of pan‐CK positive cells 
detected by  immunocytochemistry (Table 3.3.2), although the number of nicastrin positive 
cells  detected  per  sample was  always  greater  than  the  number  of  pan‐CK  positive  cells 
identified  by  immunocytochemistry.  This  suggests  that  the  nicastrin  positive  cells  could 
possibly  be  the  DTC  population.  However,  without  distinguishing  the  pan‐CK  epithelial 
marker, this is speculative. Additionally, as the samples are rich in PBMCs, a CD45 marker is 


















marrow  aspirates  derived  from  high‐risk  patients  (n=5)  were  stained  for  nicastrin  by 


























Although  no  pan‐CK  or  CD45  staining  was  used  in  the  bone  marrow  staining,  it  was 
interesting  that  only  a  few  nicastrin  cells  were  detectable,  and  appeared  to  be  similar 
numbers to those detected by immunocytochemistry using a pan‐CK marker. However, the 
focus  in detection of micrometastases  is gearing towards blood based techniques, as bone 
marrow  samples  are  painful  to  the  patient,  and  cannot  be  taken  as  frequently  as  blood 
samples.  This  severely  limits  the  opportunities  for  sequential  sampling,  which  in  turn, 
restricts the monitoring of disease progression or therapeutic efficacy. 
However,  as  nicastrin  appeared  to  be  detectable  in  a  rare  population  of  cells  in  bone 
marrow aspirates from patients at high‐risk of relapse, it was then investigated whether this 
was true in blood samples from highly metastatic patients. In order to detect CTCs in patient 







from  inside  the  Cellsearch™  cartridge was  attempted, which  has  never  been  undertaken 
before. The purpose of this experiment was not to recapitulate the rarity of CTCs, but to test 
whether a)  the method of cell  retrieval  is  feasible and b) cells could be  stained  to detect 
nicastrin expression.  
Therefore,  two million MDA‐MB‐231  cells, used  as  surrogates  for CTCs, were  spiked  into 
healthy  blood.  The  spiked  sample  was  processed  in  the  Cellsearch™  system.  Briefly, 
epithelial cells were first immunomagnetically separated from blood, then stained with the 
CTC marker pan‐CK  (PE), the  leukocyte marker CD45  (APC) and DAPI to  identify nucleated 















NCSTN                   Pan-Cytokeratin DAPI                       COMPOSITENicastrin Pan-CK                               DAPI                          omposite
 
Figure 3.3.4: Nicastrin is detectable in cancer cells in the blood. Two million MDA‐MB‐231 
cells were spiked  in healthy blood, processed  through  the Cellsearch™ machine,  retrieved 






To  test whether  the  optimised  staining  protocol  (as  described  in  section  3.3.2)  could  be 
implemented  for  staining  patient  samples,  a  blood  sample was  obtained  from  a  patient 
known to be highly metastatic (patient 11) . One sample was processed by the CellSearch™ 
which  detected  34  pan‐CK  positive,  CD45  negative, DAPI  positive  cells  (Table  3.3.3).  The 
CellSearch™‐processed  cells  were  carefully  retrieved  from  the  cartridge,  cytospun,  and 
immunofluorescence of nicastrin was performed.  
A pan‐CK negative  cell  in  the nicastrin blank was used  to  set  the  confocal parameters  to 




cells  from  one  high‐risk  patient  sample  that  were  pan‐CK  positive,  DAPI  positive  and 







were  retrieved  from  the  cartridge,  cytospun  and  stained  for  nicastrin  by 























To substantiate  the possibility  that nicastrin was expressed  in CTCs, nicastrin mRNA  levels 
were  analysed  by  using  CTCscope.  Our  group  is  using  the  CTCscope  to monitor mRNA 
expression of EGFR  in metastatic breast cancer patients treated with  lapatanib. Use of this 
pioneering mRNA  ISH  technology has several benefits.  It allows  the detection of mRNA  in 
samples without  the use of a purification  step, as used  in  the Cellsearch™ machine,  thus 
minimising  the  loss  of  cells.  In  addition,  processing  of  the  samples  onto  slides  and 
microscopic  analysis  allows  visualisation  of  cells  within  a  field  of  cells  to  allow  direct 
comparison.  CTCscope  also  enables  detection  of  lymphocytes  by  using  CD45  probes. 
Therefore, CTCs can be directly compared against  the  lymphocytes  in  the blood, and was 






to epithelial  to mesenchymal  (EMT)  transition which  is a vital process contributing  to  the 
invasiveness  of  cancer  cells,  a  characteristic  of  CTCs.  Since  there  is  no  single marker  to 
identify CTCs, all of these were used. Probes against CD45 mRNA were used to distinguish 
leukocytes from CTC cells, whilst DAPI was used to differentiate staining of cells from non‐






were  spiked  into  healthy  blood  (one  MDA‐MB‐231  cell  per  1000  peripheral  blood 
mononuclear  cells),  as  surrogates  of  CTCs,  and mRNA  ISH was  performed. MDA‐MB‐231 
cells  from  the earlier experiments are known  to express nicastrin mRNA and protein, and 
were used as controls in the immunofluorescent staining (Figure 3.3.6).  
In the example shown, the pan‐CTC marker (Figure 3.3.6, C, green) clearly stained a single 
cell  that was nucleated  (DAPI positive) and negative  for CD45  (Figure 3.3.6, B, white) and 
therefore  was  not  a  leukocyte,  and  likely  to  be  an MDA‐MB‐231  cell  (Figure  3.3.6,  C). 
Nicastrin  (Figure  3.3.6,  A,  red)  evidently  co‐localised  where  pan‐CTC  marker  mRNA 
transcripts were detectable. In the field of view in Figure 3.3.6, C, it was also evident that 16 
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MB‐231  cells  were  spiked  into  healthy  blood  and  probed  for  Pan‐CTC  markers  (CK 








To  compare  the  CTCscope with  the  immunofluorecence  staining  of  nicastrin,  two  blood 
samples were obtained from three patients with metastatic breast cancer. CTC enumeration 
was performed using CTCscope  in one  sample,  and  the  second by Cellsearch™.  The  cells 






CTCs,  in  patient  9,  one  pan‐CTC  positive  (green)  cell was  detected  but  did  not  express 
nicastrin (red) nor CD45 mRNA (Figure 3.3.7, A), and therefore was considered a CTC (green 
box). Likewise in patient 10, there was a single pan‐CTC cell, and very weak nicastrin staining 
was detectable  (Figure 3.3.7, B,  red box).  In patient 11, a single pan‐CTC positive cell was 
detectable which expressed NCSTN mRNA  (Figure 3.3.7, C,  red box). Patient 11  (the same 
patient  used  in  section  3.3.5)  also  had  34  detectable  CTCs  determined  by  Cellsearch™ 
analysis,  and  eight  pan‐CK  positive,  nicastrin  positive  cells  (Table  3.3.3).  Furthermore,  a 
positive  control  was  also  simultaneously  used  of MDA‐MB‐231  cells  spiked  into  PBMCs 
derived  from healthy blood  (1 MDA‐MB‐231  cell per 1000 PBMCs, Figure D). The  level of 







inconsistencies.  Both  the  CTCscope  and  nicastrin  immunofluorescence  staining  showed 
lower  detectable  numbers  of  putative  nicastrin  positive  CTCs  (Table  3.3.3).  In  all  three 
patients,  the  CTCscope  method  always  detected  lower  numbers  of  CTCs  than  the 









cell  in patient 9, as depicted by  the green box  (Figure A). N NCSTN mRNA  is expressed  in 
pan‐CTC (green) positive, CD45 negative (white) cells in patient 10 (B) and patient 11 (C) as 
depicted by the red boxes. A positive control of MDA‐MB‐231 cells spiked into healthy blood 
was used  (D). NCSTN mRNA  is also expressed  in CD45 positive PBMCs  (white boxes). The 
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Patient 9  1  None  4 No cells found in blank
Patient 10  1  1 (?)*  1 No cells found in blank




It was  important to establish the expression of nicastrin  in PBMCs, as  if these cells express 
the protein, especially  if  the expression  levels are  indistinguishable  to  cancer  cell  lines or 
CTCs, then nicastrin may not be a suitable metastatic biomarker  in the blood. PBMCs from 
two healthy volunteers and seven metastatic breast cancer patients (four not shown) were 




Figure  3.3.8  illustrates  the  immunofluorescent  staining  of  PBMCs  from  two  healthy 
volunteers and examples of three metastatic breast cancer patients. All samples showed a 
weak  membranous  staining  in  a  small  population  of  PBMCs,  when  compared  to  the 




There was  no  difference  in  the  staining  pattern  in  nucleated  cells  between  healthy  and 
metastatic patients.  
CTC analysis by CellSearch™ was also performed on blood from the metastatic breast cancer 
samples  (Table 3.3.3).  It was unknown whether CTC numbers present  in  the blood would 
influence nicastrin expression in the PBMCs, in which case would increase the likelihood of 
false positives being detected. Therefore, patient samples were chosen with either no CTC 






all analysed  samples  (Figure 3.3.9,  red box,  shows an enlarged example). However,  these 
artefacts were un‐nucleated, and it was unclear whether these signals originated from cells, 
from remnants of broken membranes, or were due to autofluorescence. The  fact that the 
staining  was  not  evident  in  the  secondary  antibody  blank  controls,  indicated  that  the 
staining was specific. Furthermore, the punctuated staining was absent in the MDA‐MB‐231 
and  NCSTN  ‐/‐  null  MEFs  controls.  As  the  controls  were  not  processed  through  Ficoll‐
Hypaque  gradient  centrifugation  and  thus  have  no  blood  content,  the  staining  might 
originate  from either a blood constituent or an artefact of  the PBMC extraction protocol. 
However, this pattern of staining was not detectable in the Ficoll‐Hypaque processed bone 




















cells.  PBMCs  were  obtained  by  Ficoll‐Hypaque  gradient  centrifugation  from  healthy 
volunteers (A and B) and metastatic breast cancer patients (C, D and E). Nicastrin expression 
was  detected  by  immunofluorescence  (green  signal).  Nuclei  were  stained  with  DAPI.  A 
secondary‐only antibody was used as a negative control. For MDA‐MB‐231 positive cells see 
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volunteers and metastatic breast cancer patients.  It was  important  to  further corroborate 
this  using  an  independent  methodology,  as  if  nicastrin  is  expressed  in  the  blood,  the 
suitability of nicastrin as a blood‐based biomarker of metastatic disease is questionable. 
PBMCs  were  extracted  using  ficoll‐Hypaque  gradient  centrifugation  from  whole  blood 
derived from a healthy volunteer. Cells were then stained and analysed by flow cytometry, 
using the same antibody and concentration (1/500) as used in immunofluoresence staining 
(Figure  3.3.1).    The  secondary‐only  control  (alexafluor  647)  demonstrated  that  the 
leukocytes gated within gate P1, were not stained (histogram, Figure 3.3.10, A). Within the 
P1  gated  PBMC  population,  three  distinct  subpopulations were  apparent  in  the  forward 
scatter (FSC) versus side scatter (SSC). Distinguishable by the cell size (FSC) and granularity 
(SCC), putative  lymphocytes (L:  low SSC and FSC), monocytes (M:  low SSC, higher FSC) and 
granulocytes (G: high SSC, intermediate FSC) are depicted on Figure 3.3.10, A. In the PBMCs 
stained  with  nicastrin  (Figure  3.3.10,  B),  the  gated  leukocyte  population  as  a  whole 
demonstrated  that  a  proportion  of  cells  (41%)  expressed  nicastrin.  To  further  gate  the 
subpopulations  of  cells  demonstrated  in  Figure  3.3.10,  B,  95%  putative  granulocytes 
expressed nicastrin  (Figure 3.3.10, C, histogram). However,  these cells only  represented a 
low population of  the overall  sample  (2.4%).  In  lymphocytes  (Figure 3.3.10, D, histogram) 
and monocytes  (Figure 3.3.10, E histogram), nicastrin was not expressed  in all cells  (41%). 
Further  experiments  are  required, with  additional markers  to  definitively  confirm which 




















Figure  3.3.10:  Nicastrin  is  expressed  in  the  blood.  PBMCs  from  healthy  blood  were 
extracted by Ficoll‐Hypaque gradient, and stained for nicastrin. The secondary‐only control 
(alexafluor  647)  showed  no  background  staining  (A).  Three  blood  subpopulations  were 
evident: putative granulocytes (G), lymphocytes (L) and monocytes (M). Gated leukocytes as 
a whole in nicastrin‐stained PBMCs showed a population of cells expressed nicastrin (B). The 








RT‐PCR was performed  for  three control, housekeeping genes  (RPS6, RPS14  together with 
NCSTN). Data analysis was performed as described in section 2.7.5. NCSTN gene expression 
relative  to  two  normalisers,  RPS6  and  RPS14  showed  the  most  consistent  pattern  of 
expression within individual tissues and were considered as reproducible. Compared to the 
CAL‐51 cells, many of the healthy tissues expressed NCSTN to a similar level (Bone marrow, 
fetal  brain,  prostate,  skeletal muscle,  spleen,  thymus,  uterus,  breast  and  lymphocytes). 
NCSTN expression  is approximately  twice  the amount of CAL‐51  in  fetal  liver and  kidney. 
Furthermore, liver, thyroid gland and trachea have three times the amount of NCSTN gene 



































































































































In summary, proof‐of‐principle experiments  indicate that nicastrin  is expressed  in CTCs but 
more samples need to be analysed in order to make statistically valid conclusions. Nicastrin 
may not be a suitable blood‐based marker as nicastrin is expressed in the blood at both the 
mRNA  and  protein  levels,  but  may  still  be  of  clinical  benefit  when  examined  by 





















explored.  Three different  synthetic  compounds  (Compound  E, DAPT  and GSI1) previously 
shown  to  inhibit  cell growth and  induce apoptosis  in different  carcinomas were  tested  in 
breast cancer cell lines to determine the most effective to reducing cell growth [38, 42, 161, 
193,  219].  Whilst  10  μΜ  DAPT  has  previously  been  shown  to  reduce  growth  of 
mammosphere cultures by 22% [298] and breast cancer stem cells numbers [232], DAPT has 
minimal effect in reducing breast cancer cell growth. Of the compounds tested, GSI1 (z‐leu‐
leu‐norleu‐CHO), was most  effective  in  reducing  breast  cancer  cell  number.  In  a  similar 
study,  Han  et  al  [299]  compared  the  effect  of  three  structurally  distinct  γ‐secretase 
inhibitors, DAPT, GSI1 and L‐685,458. DAPT was confirmed to induce minimal effect, whilst 
GSI1 significantly reduced cell growth. Whether the uptake of these compounds by breast 
cancer  cells or  their half‐lives  (either  in  the  culture medium or  intracellularly)  is different 
and modulates their potency, remains to be established. 
GSI1  potently  reduced  cell  number  and  increased  death  in  all  tumourigenic  cells  at 
concentrations  that were  ineffective  to  non‐tumourigenic  breast  cell  lines.    Additionally, 
anti‐growth effects of the γ‐secretase inhibition were regardless of ER and Her‐2 expression 
in cell lines and therefore makes this a promising drug target, as current drug therapeutics 






targeting  cancer  cells  with  negligible  or  no  effect  on  non‐tumourigenic  breast  cells.  
However,  considering  the  adverse  side  effects  induced  by  γ‐secretase  inhibitors  on 
gastrointestinal  tract and  thymus  [230, 231, 300]  the effect of  γ‐secretase suppression on 
other normal cell types remains to be established. 
Differential  responses  between  tumourigenic  and  non‐tumourigenic  cell  lines  can  be 
explained by the expression of the Notch negative regulator, Numb. Breast cancer cell lines 
express N1ICD, and  lack Numb, whereas there  is an  inverse correlation  in non‐tumorigenic 
cell  lines  [43].  Furthermore,  low  nicastrin  expression  was  detected  here  in  the  non‐
tumourigenic  cell  line,  184A1.  This  suggests  lower  or  absent  γ‐secretase  activity  in  non‐
tumourigenic cells, rendering cells insensitive to GSI1. Whether GSI1 affects the cleavage of 
other  γ‐secretase  substrates  involved  in  non‐proliferation  processes  in  non‐tumourigenic 
cells, is yet to be explored. 
An NCI60 screen demonstrated GSI1 was cytotoxic in nine different tumourigenic origins. γ‐
secretase  inhibition using other γ‐secretase  inhibitors also have anti‐cancerous effects,  for 
instance,  DAPT  reduces  proliferation  and  colony  formation  in  ovarian  cancer  [214]  and 
tumour  growth  in  renal  cancer  xenografts  [301].  MRK‐003    reduces  cell  growth  and 
neurosphere formation in glioblastoma cell lines [302] and reduces tumour size induced by 
the  leukaemic  [277]  and  lung  cancer  cell  lines  [217].  GSI1  also  reduces  Kaposi  Sarcoma 
mouse  xenograft  volume  [223]. However, DAPT  increased  the  sensitivity  of  colon  cancer 
xenografts to paclitaxal, but had no effect on tumour growth [42], whereas the NCI60 colon 
cancer  cell  lines  were  sensitive  to  the  cytotoxic  effects  of  GSI1.  Therefore  structural 









NCI/ADR‐RES, multidrug‐resistant  cells  overexpressing  the  ABC  transporter  ABCB1  [303], 
and prostate PC‐3 cells, which also express PgP [304], are the least susceptible of all the cells 
in  the NCI60 cell panel, drug substrates of PgP are mostly planar, hydrophobic molecules, 





APP  and  Notch  cleavage,  and  CBF‐1  gene  transcription,  the  target  of  NICD.  This  was 
consistent with previous findings [184, 219]. GSI1 increases full‐length Notch‐1 [219], which 




promotes  downstream  transcription  of  gene  targets which  include  Hes‐1;  this  has  been 







Inhibition of  γ‐secretase using GSI1  causes  a G2/M  cell  cycle  arrest  leading  to  apoptosis, 
with a concomitant down regulation of the anti‐apoptotic proteins, bcl‐2, XIAP, and Bcl‐xl. 
Accordingly, GSI1  has  been  previously  shown  to  increase  p53,  p21  and  cleaved  PARP  in 
breast cancer  [219]. Moreover, other  γ‐secretase  inhibitors can  induce apoptosis  in other 
cancer  types  [223, 224, 306]. The mechanism by which  γ‐  secretase  is  linked  to  the anti‐
apoptotic proteins Bcl‐xl and XIAP,  is uncertain. However, as these proteins are controlled 
by PI3K/Akt  signalling,  thus, GSI1 could act via Akt  to elicit apoptosis  in breast cancer, as 
DAPT  can  reduce Akt  signalling  [307]. A  diagrammatic  representation  of  how GSI1  could 
exert  the  anti‐growth, pro‐apoptotic  and  cytoskeletal defects  are proposed  in  Figure 4.1. 
Firstly,   NICD‐CBF‐1  interaction  promotes Hes1  gene  transcription  [176,  177,  180], which 
binds  to  the  Pten  promoter  to  inhibit  transcription  of  the  TSG  PTEN  [220]. As  PTEN  is  a 
negative regulator of Akt, PTEN down regulation by Hes1 allows Akt signalling to promote 
cell survival and  inhibition of apoptotic mechanisms.  It can therefore be postulated that γ‐
secretase  inhibition  down‐regulates  NICD  and  consequently  Hes1, which  increases  PTEN 
leading to an inhibition of Akt, thus reducing cell survival and promoting of apoptosis.  
Furthermore,  Bcl‐2  forms  an  anti‐apoptotic  complex with  presenilin  1, which  dissociates 
upon apoptotic stimuli [154].  Several γ‐secretase inhibitors bind directly to presenilin [308, 








Actin  is  cleaved  by  caspases  during  apoptosis  [310]  and  a  dose‐dependent  increase  in 
caspase 3/7 activity was observed in MDA‐MB‐231 cells upon GSI1 treatment (performed by 
Dr Balasubramanian, data not  shown). However, MCF‐7  cells do not express endogenous 
caspase‐3,  but  can  induce  apoptosis  through  caspase  9,  7  and  6  [311].  Thus,  actin 
disorganisation in these cells may be through cleavage by another caspase or via a caspase‐
independent mechanism  (Figure  4.1). Additionally, GSI1 may  act  as  a mitotic  inhibitor  to 
prevent  dissociation  of  dividing  cells,  thereby  inhibiting  proliferation.  This  hypothesis  is 
supported by the observation of multinucleated MCF‐7 cells treated with GSI1. 
Cyclin D1 and c‐myc are downstream transcriptional targets of the NICD/CBF‐1 complex [183, 
312],  and  their  transcribed  proteins  are  involved  in  proliferation  [313,  314].    A  possible 
route  of  proliferation  suppression  may  be  through  decreased  Cyclin  D1  and/or  c‐myc, 
downstream  targets  of NICD which  can  be  oncogenic  in  breast  cancer  [313,  314]. GSI1’s 



























Figure  4.1:  Postulated mechanism  of  GSI1: GSI1 may  decrease  proliferation  and  induce 
anoikis  and  apoptosis  through  down‐regulation  of  Akt.  This  thesis  demonstrates  GSI1 
inhibits  the  γ‐secretase  complex  to  reduce NICD  and  CBF‐1, with  induction  of  apoptosis 
(concurrent  down‐regulation  of  XIAP  and  Bcl‐XL)  and  reduced  cell  proliferation  in  breast 
cancer  cells. Using previously  characterised  signalling pathways, a mechanism of  affected 











whilst  overexpression  of  Akt  in  the  breast  non‐tumourigenic  cell  line  MCF10A,  confers 
resistance to anoikis and evasion from  cell death [318]. Therefore, inhibition of γ‐secretase 




also  be  examined  following GSI1  treatment  in  SKBR3, which  highly  express Her‐2, which 
activates  Akt  signalling.  If  γ‐secretase  inhibition  through  GSI1  mediates  via  Akt,  this 





and  the  CBF‐1  gene  promoter,  yet  this  concentration  inhibits  breast  cancer  cell  growth 




vitro,  later  confirmed by Han  et al  [299]. Whether proteasome  inhibition  is  an off‐target 
effect  of  GSI1  or  as  consequence  of  inhibiting  γ‐secretase  remains  uncertain.  Structural 





inhibition.  For  example,  the  structurally  unrelated DAPT  had  no  effect  on  cell  growth  or 
proteasome activity but  still  reduced  γ‐secretase activity  in breast  cancer  cell  lines  [299]. 
Moreover,  like  GSI1, MG132  also  induces  G2/M  arrest  and  apoptosis with  loss  of  Bcl‐2 
expression is osteocarcinoma cells [321].  Therefore, proteasome inhibition by GSI1 may be 
a non‐specific effect. 
Han  et  al  [299]  later  corroborated  our  findings  that  GSI1  induces  cytotoxicity  in  breast 
cancer cells, but suggested  this was due  to proteasome  inhibition  rather  than  γ‐secretase 
inhibition.    Firstly,  they  showed GSI1  inhibits  cell proliferation  at  concentrations when  γ‐
secretase  activity  is  not  inhibited. Moreover, DAPT  and GSI1  inhibited  the  generation  of 
NICD in six and four breast cancer cell lines, respectively. Furthermore, FLAG‐labelled NEXT 
was  expressed  in  two  breast  cell  lines, which  is  the  Notch  processed  form  ready  for  γ‐
secretase cleavage. Both DAPT and L‐685,458 prevented  intracellular  localisation of NICD, 
inferring  γ‐secretase  inhibition.  However,  GSI1  did  not  completely  prevent  nuclear 
localisation  of NICD.  Furthermore, GSI1  and MG132,  abrogated  proteasomal  activity  and 
caused an accumulation of ubiquitinated proteins, whilst DAPT did not. This  suggests  the 
cytotoxic effects  are due  to  the  structural  similarity of GSI1  to  the proteasomal  inhibitor 
MG132. Although Han’s group results agree with previous studies  in that GSI1  targets the 
proteasome, only Notch 1 was used as a  surrogate measurement  for  γ‐secretase activity, 
and effects of GSI1 on other Notches and γ‐secretase substrates should be examined before 
completely ruling GSI1 out as a γ‐secretase inhibitor. Furthermore, targeting γ‐secretase by 




reduce  breast  cancer  cell  proliferation  [284].  Therefore,  γ‐secretase  is  a  valid  target  to 
inhibit, although GSI1 may not be the best inhibitor to use.  
Overall, our  results and  those expanded  later by Han’s group highlight  the  importance of 
both γ‐secretase and GSI1  in breast cancer and open the possibility of targeting either the 
proteasome  or  the  γ‐secretase  complex  with  small  molecules  amenable  to  the  clinical 
practice.  In  these  lines, work  in  our  Department  is  focused  now  on  a  novel  γ‐secretase 
inhibitor developed by Pfizer. 
It may  also be possible  cross‐talk mechanisms between  the  γ‐secretase  complex  and  the 
proteasome  pathway  may  exist,  but  only  limited  information  is  available.  Competition 
between  the  proteasome  and  γ‐secretase  exists  for APP  cleavage  [322].  Five  structurally 
distinct proteasome inhibitors (lactacystin, ALLN, expoxoicin, MG132 and MG262) tested in 
HEK‐293  cells,  all  decreased  PS1‐NTF  and  PS2‐NTF  protein  levels  [323].  Furthermore, 
nicastrin,  APH1  and  pen‐2  undergo  proteasomal  degradation  in  the  absence  of  other  γ‐
secretase  components  [64,  283,  324].  This  suggests  that  proteasomal  involvement may 
contribute to γ‐secretase activity and formation. 
Proposals of γ‐secretase functioning as a “proteasome of the membrane” have been made, 












the  proteasome  [328],  akin  to  nicastrin  within  the  γ‐secretase  complex,  as  shown  by 
electron microscopy  [77].  Furthermore,  the 19S RP  recognises ubiquitinated proteins and 
ushers them into the catalytic core of the 20S. Equally, nicastrin recognises NH2 residues of 
γ‐secretase substrates and ushers substrates into the complex’s central cavity for presenilin 
cleavage  [47, 77]  (section 1.2.5). The 20S  structure  is  reminiscent of  γ‐secretase: 20S  is a 
cylindrical  structure  with  a  cavity  containing  the  catalytic  core  particle  with  trypsin‐, 




bind between  the  two  complexes.  Low‐resolution electron microscopy of  the  γ‐secretase 
































Figure  4.2:  Similarities  between  γ‐secretase  and  protesasome.  The  26S  proteasome  is 
comprised  of  a  19S  lid  and  20S  catalytic  core  particle  (A).  Ubiquitin  molecules  are 
conjugated  on  to  target  proteins  by  enzymes,  for  proteolysis  by  the  proteasome,  for 
degradation  or  generation  of  functional  fragments  (B).  Type  I  substrates  undergo 
ectodomain  shedding before  cleavage by  γ‐secretase  to  release  intracellular domains and 
fragments for degradation. Adapted from [77, 325].   
 
Whether proteasomal  inhibition  is an off‐target effect, or due  to  inhibition of putative  γ‐
secretase‐proteasome  cross‐talk,  the  effect may  not  be  negative.  The  therapeutic  use  of 
proteasome inhibitors is also being considered in cancer treatment [332, 333]. For instance, 
the proteasome inhibitor Bortozemib, reduces cell growth measured on a NCI60 panel, and 
is  clinically  used  to  treat  multiple  myeloma  [275].  Bortozemib  increases  sensitivity  of 




p27 protein  levels  [334]. Furthermore, PC3 prostate  cancer  cells  treated with bortozamib 
have a decreased number of cells in G1, and arrest in G2/M, a similar effect to that observed 
with  GSI1  [335].  Therefore,  it  has  also  been  proposed  that  γ‐secretase  and  proteasome 
inhibitors could be used synergistically in cancer therapeutics [336]. 
Interestingly, PgP  is a  cell  surface protein  that  functions as an efflux pump  for drugs and 
toxins. Expression of PgP is associated with chemoresistance. In HEK293 cells, MG132 causes 
an accretion of  immature PgP  in which cell surface  localisation  is prevented and therefore 
drug efflux  [337]. Moreover,  the  gene encoding PgP, MDR1,  is  a  transcriptional  target of 
NFκ‐B  [338]. Thus,  inhibition of  the proteasome may prevent degradation of  IκB, allowing 
sequestration of NFκ‐B,  consequently preventing  transcription of MDR1. This may  reduce 
levels of PgP and therefore render cells more sensitive to MG132. As MG132 is structurally 
similar  to  GSI1,  this may  be  a  possible mechanism  through which  GSI1  acts  to mediate 
cytotoxic effects. 
Additionally, the human KB carcinoma cell line, KB 8‐5 cells overexpress PgP. In these cells, 
MG132  caused  a  dose‐dependent  accumulation  of  daunorubicin,  as  measured  by 
fluorescence.  As  PgP  functions  to  efflux  drugs  out,  it  was  therefore  proposed  that 
proteasomal  inhibition by MG132 blocked PgP  function  [339].    Furthermore, MG132 also 
prevents PgP maturation and transport to the cell surface in HEK293 cells [337], which may 
prevent multi‐drug  resistance. Due  to  the  structural  similarity between MG132 and GSI1, 







It  is demonstrated here  that  γ‐secretase  inhibition  through use of GSI1  is detrimental  to 
breast  cancer  cell  growth  and  viability  by  inducing  apoptosis  and  cytoskeletal 
disorganisation. GSI1 is also effective in reducing cell growth in other cancers. However, the 
actual target of GSI1  is questionable due to the  inhibitory effects on the proteasome [299, 
336].  It  is now widely acknowledged  that  γ‐secretase  inhibition  is a valid  target  in cancer, 
supported  by  the  expanding  list  of  clinical  trials.  However,  the  adverse  side  effects  of 
currently available γ‐secretase inhibitors, such as abnormalities in the gastrointestinal tract, 
thymus and spleen observed  in rodents need to be addressed [231, 340, 341]. Side effects 
could  be  due  to  a  number  of  reasons.  Firstly,  γ‐secretase  inhibitors  directly  target  the 
endoproteolysis  of  presenilin.  Presenilin,  independently  of  γ‐secretase,  is  involved  in  a 
multitude of  cellular  functions,  and  it  is unknown whether different pools of  the protein 
exist for the complex and the independent roles. Therefore, adverse effects may occur due 
to  affecting  other  cellular  pathways  rather  than  γ‐secretase.  Secondly,  the  complete 
elucidation of the γ‐secretase complex formation by electron microscopy will greatly aid the 
design  of  more  specific  compounds  target  the  complex.  Furthermore,  six  possible  γ‐
secretase  complexes  that may  exist  on  different  cell  types,  and  the  complex may  confer 
preferential cleavage  to selective substrates.   For example, haemopoetic cells may have a 









Such negative  regulatory domains  in other  γ‐secretase  substrates are yet  to be explored. 





It  is demonstrated here  through  sequencing of  the  coding  region of  the nicastrin gene  in 
breast tumourigenic  and  non‐tumourigenic  cells  that  both  expressed wildtype  nicastrin, 
with no detectable mutations or alternative slice variants from the wildtype. 
In  some  ways,  it  was  surprising  that  no  mutational  differences  in  NCSTN  were  found 
between the non‐tumourigenic and tumourigenic cell lines, as there was a clear increase in 
nicastrin protein expression  in  invasive metastatic breast  cancer patients  compared  to  in 





the Catalogue Of  Somatic Mutations  In Cancer   database have  reported no mutations  in 






and upper digestive  tract  (n=3). APH1A was  analysed  in  four  tissue  types. No mutations, 
gene fusions or splice variants were observed [344].  
Although  mutations  in  the  coding  region  of nicastrin  were  not  detected,  this  does  not 
exclude  the  possibility  of intronic mutations within  genomic DNA. However, most  of  the 
reported mutations in the nicastrin gene are intronic, and only one (IVS6+18C/G) out of nine 
intronic mutations may have a debatable  link  to AD  (Table 1.2)  [108].   More  significantly 
perhaps,  four  substitution mutations  have  been  reported  in  the  NCSTN  gene  promoter, 
three of which (‐1216 C/A, ‐922 T/G and ‐796 T/G) may have an association with AD [110‐





As there  is an evident up‐regulation of nicastrin protein  in breast cancer tumours  [284],  it 
was  important  to  determine  at  what  stage  of  the  tumourigenic  process  is  nicastrin 
expression  up‐regulated. A  panel  of  breast  non‐tumourigenic  and  tumourigenic  cell  lines 




non‐tumourigenic breast cell  lines, and  three  tumourigenic breast cell  lines. Furthermore, 
nicastrin protein  levels do not  correlate with mRNA expression,  for example,  in  the non‐






breast  cells,  unlike  in  immunohistochemical  analysis  of  breast  tissue  samples  [284]. 





expression  of  MDR1  [287].  It  is  therefore  possible  that  post‐transcriptional  regulatory 
mechanism(s) control cellular nicastrin protein levels. Structural elements present in mRNA 
sequences are often  instrumental  in  regulating  transcriptional control. For example,  there 
are  hairpin‐like  structures  and  pseudoknots  which  can  block  translation  [345].  These 
structures may influence tumourigenesis [346], for instance, the BCRA1 mRNA transcript in 
sporadic  breast  cancer  has more  hairpin  secondary  structures  than  in  non‐tumourigenic 
breast cell lines [347]. A hairpin loop at the 5’ region of the multidrug resistance gene MDR‐
1  encoding  PgP  inhibits  translation  in  K562  leukaemic  cells  treated with  cytotoxic  drugs 
[348]. Hairpin loops also exist in mRNA of c‐myc, which controls the perinuclear localization 
of  the mRNA  [349].    To  identify whether  hairpin  structures  exist  in  NCSTN mRNA,  RNA 
mapping could be performed. 







for  the  discordance  between  nicastrin  mRNA  and  protein  expression.  Accumulating 
evidence  demonstrates  microRNA  expression  contributes  to  cancer  promotion  [352]. 
Interestingly,  loss of the microRNA cluster, miR‐29a/b‐1,  increases BACE expression  in AD. 
BACE  is  responsible  for  ectodomain  shedding  of APP  before  γ‐secretase  cleavage  (Figure 
1.10 [353]).  Therefore loss of microRNAs may also contribute to AD pathogenesis [354]. As 
microRNAs  contribute  to  cancer,  it  is  possible  that microRNAs  regulate  nicastrin  protein 
expression.  
Below,  two  software packages were used  to predict  the binding of microRNAs  to NCSTN 




to  have  an  oncogenic  role  in  MCF‐7  cells  and  xenograft  tumour,  as  inhibition  of  this 














Figure  4.3:  MicroRNAs  predicted  to  bind  to  NCSTN  mRNA  using  predictive  software 
available at www.microRNA.org (A) or www.targetscan.org (B) [355, 356]. Fifteen different 
microRNA  sequences  were  predicted  to  bind  NCSTN  mRNA  using  www.microRNA.org. 
www.targetscan.org  (B) predicted  the binding of  three microRNAs, of which miR‐140 was 






One question  to ask  in  the near  future  is whether  these miRs are differentially  regulated 
between the non‐tumourigenic and tumourigenic breast cell line models. Should this be the 




Considering  there  may  be  a  putative  link  between  the  γ‐secretase  and  proteasome 
complexes  (as  discussed  section  4.1.3),  proteasome involvement may  also  contribute  to 
regulation  of  nicastrin  protein  levels.  Increased  protein  turnover  rate  by increased 
proteasomal degradation of the nicastrin may exist  in cell  lines that have  low nicastrin.   It 
has also previously been demonstrated that immature nicastrin that is not incorporated into 
active  γ‐secretase  complexes  has  been  shown  to  be  degraded  by  the  proteasome 
[359]. Nicastrin  has  to  undergo glycosylation  to  be  converted  from  immature  to mature 
forms which have shorter and longer (> 24 hour) half lives respectively [58]. Thus it may be 
postulated  that  in cells with  low nicastrin  levels, glycosylation may not occur,  resulting  in 
high protein  turnover  and/or  proteasomal  degradation.  However,  the nicastrin  antibody 
used  for western blotting  in this particular experiment  (Figure 3.2.3) detects the centre of 
the  protein,  and  therefore mature  and  immature nicastrin  could  not  be  examined  here. 
Thus,  to  test  these  hypotheses,  the  following  experiments  can  be  conducted.  Inhibiting 
protein synthesis with cyclohexamide and performing western blot analysis with a nicastrin 
antibody with detects both  immature and mature nicastrin, protein stability can be tested. 
To  determine  whether nicastrin  protein  stability  is  regulated  through proteasome 




or lactacystin  to  allow  total  endogenous  protein  to  be  measured.  Additionally,  by 
radioactively  labelling  nicastrin,  pulse‐chase  experiments may  be  performed  over  a time 
course  to  study both  the  stability and  the  cellular  location of  the protein  in different  cell 





translation.  Polysomes  are multiple  groups  of  ribosomes which  are  attached  todifferent 
positions spanning a single mRNA strand to promote efficient protein translation. However, 
translation  may  be  inhibited  when  polysomes  move  along  mRNA  molecules.  One 
mechanism  by which  polysome  translational  suppression  can  occur  is  through microRNA 




An  interesting  finding  from  preliminary  data  was  that  using  the  same  panel  of  non‐
tumourigenic and  tumourigenic breast  cell  lines analysed  for NCSTN gene expression,  the 
COPA gene followed a similar pattern of expression as NCSTN; COPA expression is highest in 





The  NCSTN  and  COPA  genes  are  positioned  on  the  sense  and  anti‐sense  strands  of 
chromosome  1q23,  and  share  an  overlap  of  69965  bp  (using  www.ensembl.org)  [119]. 
Overlapping  genes  are  detectable  in  humans,  for  instance,  one  study  identified  774 
overlapping  gene  pairs  out  of  34,604  genes  analysed  [289].  Co‐regulation  between  the 
NCSTN and COPA genes may occur, a phenomenon previously observed in breast cancer in 
the MDR1 gene and an overlapping gene RPIP9 [288].  
COPA  encodes  the  COPA  protein  (alias:  HEP‐COP),  the  α‐subunit  of  COPI  (non‐clathrin‐
coated  vesicular  coat  protein)  coated  vesicles.  COP  vesicles  are  important  for  protein 




γ‐secretase  assembly  [91].  As  the  preliminary  data  suggests  a  putative  co‐expressional 
pattern between NCSTN  and COPA,  the  regulation between  the proteins  linked by Rer1p 
may have  some  significance  in modulating  γ‐secretase. For  instance, mutated HEP‐COP  in 
yeast results  in the mistargetting of Rer1p [90], whilst down‐regulation of Rer1p results  in 
increased γ‐secretase activity [91]. This is a mechanism beneficial for γ‐secretase inhibition: 
over‐expression  of  Rer1p,  may  out‐compete  APH1  for  binding  to  nicastrin,  thereby 
preventing  γ‐secretase  formation  and  activity.  To  test  this  hypothesis,  Rer1p  can  be 
overexpressed in a breast cancer cell line, and consequent experiments performed including: 
1)  co‐immunoprecipitation  and western  blotting  between Rer1p  the  γ‐secretase  complex 








To  elucidate whether one  or more  of  the  γ‐  secretase  components were  responsible  for 




of  their  respective  isoforms.  It was  slightly  surprising  that  gene  knockdown  of  especially 
PSEN1 had  the  least effect on proliferation, especially as presenilin  is the catalytic core of 
the  γ‐secretase  complex  [149].  Additionally,  knockout  of  PSEN1  [362],  APH1A  [363]  are 
embryonically  lethal  in mice, whilst knockout of PSENEN  in zebrafish causes deformities  in 
somatogenesis  and  neuronal  loss  [364],  suggesting  these proteins modulate  cell  survival. 
However,  the  RNAi  experiments  suggest  that  these  proteins may  not  be  vital  for  breast 
cancer cell growth. This may be due to differential experimental techniques and cell types.  
The significant  reduction  in cell growth  induced by gene and protein knockdown suggests 
nicastrin  is crucial to breast tumourigenesis. Concurrently, NCSTN knockout produces non‐
viable embryos  in C.elegans  [123]  and  is embryonically  lethal  in mice  [140]. Here, partial 
gene knockdown was sufficient to significantly reduce nicastrin protein levels. As nicastrin is 
initiates γ‐secretase assembly [47], decreased nicastrin protein may consequently reduce γ‐






PS‐CTF  and  –NTF  fragments  decrease,  whilst  full‐length  presenilin  increases  [64,  273], 
indicating nicastrin  is vital to the stability of the complex. Gene knockdown may therefore 
essentially  act  to  inhibit  γ‐secretase  assembly  and  activity.  To  test  this  hypothesis,  co‐
immunoprecipitation  experiments  with  nicastrin,  presenilin,  APH1A  and  pen‐2  could  be 
performed  following  siRNA  of  NCSTN  may  confirm  whether  γ‐secretase  assembly  is 
disturbed.  
Furthermore, it may be hypothesised that cleavage of substrates such as Notch involved in 
cell  survival  may  be  reduced,  as  nicastrin  is  responsible  for  substrate  recognition  and 
presentation  into  the  catalytic  cavity  of  the  γ‐secretase  complex  [47,  77].  Reduction  of 
Notch cleavage may contribute to the reduced cell growth. Our laboratory has consequently 
demonstrated that NCSTN siRNA in MCF‐7 reduces E‐cadherin cleavage [284], so it possible 




suggested  for  GSI1  (section  4.1.2).  However,  there  is  one  caveat  in  this  hypothesis:  no 
significant cell cycle changes were detectable when cell growth was most reduced at day six. 
This observation may show some similarity to GSI1; as NCSTN siRNA reduces cell growth by 
50%, the  IC50 concentration of GSI1  (0.75 μM) has no effect on cell cycle profiling  in three 
different breast cancer cell lines. This may infer that this is a plausible effect of γ‐secretase 




where  caspase‐3  was  not  activated,  whereas  nicastrin  knockdown  affected  other  γ‐
secretase  components  [365].  Furthermore,  shRNA  of  NCSTN  in  breast  cancer  cell  line 
HCC1806 only induced apoptosis with synergistic Gefitinib treatment [366]. 
 
In  NCSTN  ‐/‐  mice,  embryonic  lethality  is  associated  with  increased    apoptosis  [140]. 
Additionally,  nicastrin,  independently  of  the  presenilin,  has  also  a  protective mechanism 
against p53, PI3/Akt and caspase mediated cell death in HEK293 cells [141]. Over‐expression 
of  nicastrin  abrogated  the  staurosporine‐induced  apoptotic  response. However,  nicastrin 
resistance  to  staurosporine‐induced  apoptosis was  circumvented  in  p53  and  p19ARF  null 
fibroblasts, and Akt inhibitors, suggesting that the protective, anti‐apoptotic role of nicastrin 
is mediated through p53 and Akt. Moreover, nicastrin mutants previously shown to increase 
(D336A/Y337A), or  reduce  (Δ312‐340)  γ‐secretase activity had no effect on  the protective 
mechanism  against  apoptosis,  compared  to  wildtype  nicastrin  [141].  These  experiments 
suggest  loss  of  nicastrin  would  increase  cell  susceptibility  to  apoptotic  mechanisms, 






It  is  acknowledged  that  as  end‐point  PCR  was  used  to  validate  gene  knockdown,  a 
quantitative value of silencing could not be established. Therefore, a more efficient stable 











the negative non‐specific siRNA control,  there  is more growth at day six compared  to  the 
cell  number  at  day  zero.  To  test  this  hypothesis  a  BrdU  staining,  detectable  by  flow 






Although  there were no detectable mutations  in  the coding  region of  the NCSTN gene or 
splice  variants, post‐transcriptional  and  /or  translational  regulatory mechanisms probably 
play  a  role  in  nicastrin  synthesis.  Gene  knockdown  of  NCSTN  resulted  in  decreased  cell 
growth  in  breast  cancer  cells.  Consequently,  our  group  have  shown  further  that  gene 
knockdown  of  NCSTN,  reduces  the  invasive  and motile  capacity  of MDA‐MB‐231  breast 
cancer  cells  (as  measured  by  Matrigel  infiltration  and  live  imaging),  and  may  prevent 
epithelial‐to‐mesenchymal  transition by  increasing E‐cadherin expression and p120 at  cell 




tumours  [284].  Furthermore,  NCSTN  siRNA  in  colon  and  breast  cancer  cells  improves 
chemosensitivity  to Oxaliplatin  and Gefitinib  [366, 367]. Thus, nicastrin  inhibition may be 
advantageous therapeutically as a target or as a sensitising agent in breast cancer. 
As siRNA of NCSTN reduces proliferation in vitro, if mouse modelling systems prove nicastrin 
knockdown  has  anti‐tumourigenic properties,  gene  therapy may  be  a  future  approach  in 
targeting in vivo. However, in vivo siRNA gene therapy is a developing area of research, and 
not  yet  approved  for  clinical  use. Monoclonal  antibodies  represent  a  directed  approach 
to targeting specific proteins. Over 100 Phase trials are undergoing clinical testing, with four 
FDA approved monoclonal antibodies in use for cancer therapy: Trastuzumab, Bevacizumab, 
Cetucimab  and  Panitumumab  [368].  Trastuzamub,  in  particular binds  to  the  extracellular 
portion of Her‐2, blocking the receptor from heterodimerising with EGFR ligands to promote 
cell signalling. This has revolutionised the treatment of patients with high expressing Her‐2 
positive  breast  cancers,  as  it  increases  sensitivity  to  chemotherapeutics  and  increases 
survival [369]. Our group have sought to exploit the  large extracellular domain of nicastrin 
as a novel method of inhibiting nicastrin using monoclonal and polyclonal antibodies against 
nicastrin.  Moreover,  the  DAP  domain,  critical  to  nicastrin  function,  is  exposed  the 
extracellular matrix [47]. This increases the accessibility of monoclonal antibodies to target 




example,  in mitochondria, phagosomes and  lysosomes  [97‐100, 297], andamongst various 










Stemming  from  the  observation  that  inhibition  of nicastrin  reduced  breast  cancer  cell 
growth,  consequent  analysis  of nicastrin  in  tissue  microarrays  by immunohistochemistry 
showed  high  expression  in  47.5%  in  invasive  breast  cancer  patients  (n=1050). 
However, nicastrin was  not  expressed  in  tissue  obtained  from  reduction mammoplasties 
(n=40)  [1]. Furthermore,  it was demonstrated  from preliminary experiments presented  in 
section 3.2.3  show  that, although not  clear‐cut, nicastrin may be up‐regulated during  the 
metastatic process. 
It was therefore postulated that nicastrin may be a putative biomarker of metastatic breast 
cancer.  A  developing  field  of  interest  is  the  use  of CTCs  as  a  prognostic  indicator  in 
metastatic cancer, as these cells can detach from the original primary tumour, extravastate 
and  metastasize  through  the  blood  and  lymphatic  systems  to  other  organs  to  form 












disease  [371].  Detection  methodologies  such  as  the FDA  approved  CellSearch™  system 
enables  a  standardised  technique  to  isolate,  enumerate  and  characterise phenotypical 
features  of CTCs  within  blood  samples.  Thus  this  system  was  used  to  investigate 









pan‐CK.  Furthermore  five  samples  is  a  small  sample  size  to  have  statistical  significance. 
However, the fact that the numbers of nicastrin positive cells in all five samples were similar 
to  the  number  of  pan‐CK  positive  cells  detected  by  immunohistochemistry  in  a  parallel 
analysis is promising. Thus, triple immunofluorescent staining of pan‐CK, nicastrin and CD45 






will  perhaps  strengthen  the  argument  further  that  nicastrin  is  expressed  in  DTCs. 
Nevertheless, the important finding of this experiment illustrates that nicastrin is not widely 
expressed in the bone marrow. If nicastrin proves to be co‐expressed with DTC markers with 





There  were  several  caveats  in  both  isolating CTCs  and  detection  of  nicastrin.  Firstly, 
obtaining  patient  samples  with  enough CTCs  was  problematic.  Although  patients  were 
specifically chosen who had been diagnosed with metastatic breast cancer, some of whom 
had  been  previously  shown  to  have CTCs  using  the  CellSearch™,  it  proved  impossible  to 
detect enough CTCs to be used in downstream applications. This may be due to the paucity 
of  CTCs  or  clinical  treatment  between  sample  acquisition,  such  as  chemotherapy,  or 
hormonal  therapeutic  intervention.  Additionally,  on  average  there  is  approximately  five 
litres of blood  in  the human body. Therefore, by extracting 7.5 mls of blood  to detect an 
already rare population of CTCs makes this task extremely difficult.  
Furthermore, there are very limited commercially available resources for detecting nicastrin. 
The  few  antibodies  that  are  available  are  polyclonal.  Polyclonal  antibodies  tend  to 
incorporate  large amounts of non‐specific antibodies, and as a result generate background 
noise, as well as show variation between batches. This was observed with the first antibody 





was used  (Sigma Aldrich). After rigorous optimisation,  and purification,  this  antibody was 
shown  to have  less background staining. To  further circumvent  this problem, our group  is 
now developing a monoclonal antibody against nicastrin.  
The  added  disadvantage  of  commercially  available  antibodies  is  that  none  are  pre‐




and  validated  by  Veridex  to  be  compatible  with  the  pan‐CK  and  CD45  antibodies 
simultaneously used in the system. Had a pre‐conjugated nicastrin antibody been available, 
then use of  the open‐FITC  channel  could have been exploited  to  test CTCs  all within  the 
CellSearch™ system. This would have also been advantageous, as it would minimise cell loss.  
However,  this was not achievable, mainly due  to  the absence of pre‐conjugated nicastrin 
antibodies. In‐house conjugation of antibodies using commercial kits, have previously been 
unsuccesful  in our  laboratory.  Secondly,  if  this was  achieved,  and  the extra  FITC  channel 




was  considered  the  better  option,  as  immunofluorescence  and microscopy would  allow 









nicastrin  staining  was  achieved,  and  is  compatible  with  the  pan‐CK  used  within  the 
CellSearch™ system. The disadvantage of use with the confocal microscope is that there was 
no  laser  to detect CD45‐APC  in  the particular  instrument used, but where  facilities allow, 
this would not be an  issue  in using the CTC retrieval method  in combination with confocal 
microscopy.  
This method allowed  the detection of pan‐CK positive  cells  that are postulated CTCs  in a 
metastatic breast cancer patient, where nicastrin was expressed in pan‐CK positive cells but 
not in a pan‐CK negative cell. It is acknowledged as only one sample was used, generalised 
conclusions  cannot  be  drawn  about  nicastrin  expression  in  CTCs  as  a whole,  and  larger 
sampling  size  is  required. However,  the  experiment  also  illustrates  that nicastrin may be 
expressed  in  pan‐CK  positive  cells.  This  experiment  does  demonstrate,  like  the  spiking 




recovery percentages would have  to be  conducted, by  spiking varying numbers of  cancer 









Another method was  sought  to  detect  nicastrin  in  CTCs  due  to  the  technical  difficulties 
associated  with  anti‐nicastrin  antibodies.  Flow  cytometry  has  been  previously  used  to 
isolate CTCs, and would have been able  to detect CD45, as well as  the pan‐CK and DAPI, 
unlike  in  confocal  microscopy,  where  the  equipment  was  not  available  to  allow  this. 
However,  the  sample  preparation with multiple washes,  the  acquisition  of  cells  in  flow 




sense  that multiplexing  of markers  allows  simultaneous  detection  of multiple  transcripts 
within a patient  sample. The addition of putative CTC markers  strengthens  the argument 
that  the nicastrin detected  in  that  cell  is  indeed  a CTC. However,  if  the preliminary data 
discussed  in  section 2.2.3 proves  true,  that  there  is a  transcription  regulatory mechanism 






One of  the  issues with CellSearch  is  that  information about  the viability of detected CTCs 
cannot be acquired.  It  is believed that the > 70% of the CTCs detected with CellSearch are 









Nicastrin  protein  was  shown  to  be  expressed  in  PBMCs  in  three  methods‐ 
immunofluorescence, CTCscope and  flow  cytometry. There  is a  low  level of expression  in 
lymphocytes,  and  a  high  expression  in  a  population  of  cells,  which  potentially may  be 
granulocytes, and lower expression in monocytes and lymphocytes. In order to confirm the 
expression  in  the  PBMC  sub‐populations,  dual  staining with  nicastrin  and CD  antigens  to 
detect lymphocytes, granulocytes and monocytes, will have to be conducted. In support of 
these  findings,  nicastrin  expression  has  been  observed  in  T  cells  [373].  Intrerestingly,  a 
recent study compared  the differences between  γ‐secretase expressed  in epithelial  (HeLa, 
HEK293T) and haemopoeitic (Bjab, Jurkat, HL60) cell lines. γ‐secretase activity measured by 
NICD,  Aβ40  and  Aβ42  levels were  all  lower  in  the  heamopoeitic  cell  lines. Western  blot 





In  terms  of  using  nicastrin  as  a  blood‐based  biomarker,  if  nicastrin  is  expressed  in  the 
lymphocytes,  to  a  similar  level  as  CTCs,  then  this  would  be  problematic.  From  the 
immunofluorescence data,  it appears  that  the nucleated  lymphocytes express nicastrin at 
lower levels compared to the MDA‐MB‐231 cells. This may be due to the larger cytoplasm to 
cell ratio  in MDA‐MB‐231 cells compared to  lymphocytes. However, although the confocal 
microscope  parameters  were  consistent  between  the  cancer  cells  and  lymphocytes, 
immunofluorescence  is not a quantitative technique. Therefore a quantitative method, for 
instance,  flow  cytometry  would  have  to  be  employed  to  determine  the  differential 
expression  between  lymphocytes  and  cancer  cells.  It  was  further  demonstrated  that 
nicastrin mRNA  is expressed  in a variety of normal human  tissues. This  is  consistent with 
previous  reports  illustrating  nicastrin  protein  is  expressed  in  numerous mouse,  rat  and 
human tissues.  
In  regards  to  using  nicastrin  as  a  blood‐based marker,  nicastrin  expression  in  blood  sub‐
populations  could  be  problematic.  As  granulocytes, monocytes  and  lymphocytes  are  all 




based marker.  However,  inter‐patient  variability may  play  a  role  in  differential  nicastrin 
expression.  Therfore,  further  investigations  into  clarification  of  differential  expression 






In  summary,  from  the preliminary studies presented here, nicastrin  is expressed  in a  rare 





as  a marker  of metastatic  disease.  The  technique  developed  combining  CellSearch  and 
immunofluorescence  may  be  utilised  as  a  preliminary  measure  to  phenotypically 





(p191),  inhibition of  the proteasome by GSI1  is  the most probable cause of breast cancer 
cell  growth  reduction,  mediated  through  activation  of  apoptosis  and  cytoskeletal 
disorganisation. The observation  that GSI1 additionally  inhibits  the  γ‐secretase complex  is 
also  therapeutically  beneficial,  particularly  as  siRNA  targeting  of  nicastrin  reduced  cell 
growth.  
Although  no  NCSTN mutations  or  splice  variants  were  detected  in  non‐tumourigenic  or 
tumourigenic  breast  cells,  nicastrin may  have  an  oncogenic  role  in  breast  cancer,  as  our 
group  have  demonstrated  high  nicastrin  expression  in  invasive metastatic  breast  cancer. 




antibodies  reduces  the  growth  and  invasive  capacity  of  breast  cancer  cells.  Thus,  the 







rare  population  of  cells  in  bone  marrow  aspirates,  which  may  be  more  promising  for 
nicastrin detection.   Differential nicastrin expression between CTCs/DTCs and  lymphocytes 
could be valuable for phenotypic characterisation of CTCs, and a non‐invasive  liquid biopsy 
for  monitoring  developing  anti‐nicastrin  therapy.  Further  investigations  incorporating 
additional blood  surface antigens  in  larger  sampling  sizes with better nicastrin antibodies 
are  required  before  firm  conclusions  are made. However,  these  data  do  not  negate  the 
potential of using immunohistochemistry to monitor nicastrin expression.  



































































































































































































































































































































































































































































































































































































































was  required  to  inhibit  cell  growth  (GI50),  or  kill  cells  (LC50),  and  were  therefore  less 
sensitive to GSI1 when compared to the overall effect in all cell lines tested. If the mean was 
























MCF-7 MDA-MB-231 ZR-75-1 
% of Parental Gate 
24 
Untreated 
Sub-G0 1.1 0.9 0.5 
G0/G1 59.0 70.0 59.0 
S 17.4 11.1 19.7 
G2/M 22.8 18.0 21.0 
0.75 µM GSI 
Sub-G0 1.0 1.0 0.8 
G0/G1 61.2 73.4 61.4 
S 15.7 8.3 17.2 
G2/M 22.3 17.2 20.9 
5 µm GSI 
Sub-G0 5.1 13.7 2.6 
G0/G1 17.6 37.5 13.4 
S 30.3 17.9 39.7 







MCF-7 MDA-MB-231 ZR-75-1 
% of Parental Gate 
48 
Untreated 
Sub-G0 0.8 1.1 1.0 
G0/G1 68.5 79.8 66.3 
S 12.7 7.3 15.3 
G2/M 18.3 11.8 17.6 
0.75 µM GSI 
Sub-G0 0.8 1.5 1.3 
G0/G1 67.7 81.0 66.8 
S 12.6 6.1 14.2 
G2/M 19.2 11.5 17.8 
5 µm GSI 
Sub-G0 16.5 73.6 58.5 
G0/G1 22.9 9.1 12.8 
S 32.1 4.2 13.6 










































































































































Following  PCR  amplification,  and  sequencing  performed  by  Ivan  Andrews  (MRC), 









































Sequencing  results of Nicastrin  in breast  cancer  cell  lines  (MCF‐7  and MDA‐MB‐231)  and 
non‐tumourigenic breast cell  line  (MCF10A). The PCR product name refers to the name of 
the designated primer region. The colour corresponds to the colour of PCR product depicted 




PCR product Sequencing primer Primer direction MCF-7 MDA-MB-231 MCF-10A
UTR 1 Forward 137-271 124-271 123-271
2 Reverse 49-210 50-212 49-212
NICA1 3 Forward 244-890 249-834 244-977
4 Reverse 69-388 68-408 70-410
5 Forward 662-1090 662-1090 663-1089
6 Reverse 190-805 216-793 80-803
NICA2 7 Forward 1025-1629 1039-1670 1041-1666
8 Reverse 763-1216 763-1207 765-1216
NICA3 9 Forward 1816-2405 1878-2153 1818-2377
10 Reverse 1548-2145 1762-2100 1590-2175
NICA4 11 Forward 2312-2866 2324-2873 2323-2839
12 Reverse 1995-2444 1985-2403 1984-2445
13 Forward 2611-2879 2663-2879 2613-2878
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Inhibition of g-secretase induces G2/M arrest and triggers
apoptosis in breast cancer cells
S Rasul1, R Balasubramanian1, A Filipovic´1, MJ Slade1, E Yagu¨e1 and RC Coombes*,1
1Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Department of Oncology, MRC Cyclotron Building, Imperial College London, London
W12 0NN, UK
g-Secretase activity is vital for the transmembrane cleavage of Notch receptors and the subsequent migration of their intracellular
domains to the nucleus. Notch overexpression has been associated with breast, colon, cervical and prostate cancers. We tested the
effect of three different g-secretase inhibitors (GSIs) in breast cancer cells. One inhibitor (GSI1) was lethal to breast cancer cell lines at
concentrations of 2 mM and above but had a minimal effect on the non-malignant breast lines. GSI1 was also cytotoxic for a wide
variety of cancer cell lines in the NCI60 cell screen. GSI1 treatment resulted in a marked decrease in g-secretase activity and
downregulation of the Notch signalling pathway with no effects on expression of the g-secretase components or ligands. Flow
cytometric and western blot analyses indicated that GSI1 induces a G2/M arrest leading to apoptosis, through downregulation of
Bcl-2, Bax and Bcl-XL. GSI1 also inhibited proteasome activity. Thus, the g-secretase inhibitor GSI1 has a complex mode of action to
inhibit breast cancer cell survival and may represent a novel therapy in breast cancer.
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g-Secretase is an aspartyl protease macromolecular complex
comprising nicastrin (NCSTN), anterior pharynx-defective 1-a/b/c
isoforms, the enzymic component presenilin-1/2 (PSEN) and
presenilin enhancer protein-2 (PSENEN, Pen-2). By providing an
internally hydrophilic environment within the plasma membrane
(Lazarov et al, 2006), g-secretase is responsible for cleaving more
than 30 substrates, including amyloid precursor protein (APP),
Notch (Mumm et al, 2000), ErbB4 (Ni et al, 2001), E-cadherin
(Marambaud et al, 2002), CD44 (Lammich et al, 2002) and p75
(Schluesener et al, 1992), which regulate vital cell functions such
as proliferation, cell cycle, cell adhesion and apoptosis. Interest-
ingly, increased expression of Notch ligands, receptors, and/or
downstream targets are highly associated in the pathogenesis of
breast (Jones et al, 2004; Stylianou et al, 2006; Yamaguchi et al,
2008), brain (Purow et al, 2005), colon (Akiyoshi et al, 2008),
cervical (Liu et al, 2007) pancreatic (Doucas et al, 2008) and skin
cancers (Dang et al, 2006). Thus, the g-secretase complex may be
a potential therapeutic target in a wide array of carcinomas.
Notch signalling is initiated through the interactions between
the plasma-embedded Notch heterodimer receptors and cell
surface ligands (Jagged-1, -2, Delta-like -1, -2 and -4) present on
adjacent cells (Lindsell et al, 1995). This results in a conforma-
tional change in Notch to reveal the site 2 cleavage site for metallo-
proteases (ADAM10, ADAM17), which leaves a 12 amino-acid stub
of the Notch extracellular domain, required for subsequent
recognition and cleavage by the g-secretase complex (Brou et al,
2000; Mumm et al, 2000). g-Secretase cleavage of Notch liberates
the intracellular domain (NICD), which translocates to the nucleus
where it binds to the CSL family of DNA-binding proteins (CBF1/
RBPJ-k in mammalian cells) (Tamura et al, 1995). The NCID–
CBF1 complex initiates recruitment of transcriptional co-activators
Mastermind-like-1, 2, 3, and p300 (Oswald et al, 2001) to enable
gene transcription of Notch downstream targets. These include
Hes, Hey (Iso et al, 2003) c-myc (Klinakis et al, 2006), p21
(Rangarajan et al, 2004) and cyclin D1 (Ronchini and Capobianco,
2001), which regulate proliferation, differentiation and apoptosis.
Notch activation has been observed in a number of malig-
nancies. It was first reported when insertion of mouse mammary
tumour virus within the Notch 4 locus incited tumour formation in
mice (Gallahan et al, 1996). In humans, elevated Notch1 is
observed in Ras-positive breast cancers (Weijzen et al, 2002), while
both increased Notch1 and Jagged1 expression decreases patient
survival (Jones et al, 2004; Reedijk et al, 2005; Dickson et al, 2007).
In addition, Numb, a negative regulator of Notch signalling
(McGill and McGlade, 2003), is significantly reduced in 50% of
breast cancer tissues, inversely correlating with tumour size (Pece
et al, 2004) and correlating with a poor prognosis (Colaluca et al,
2008). Inhibiting Notch signalling by overexpression of Numb
reverts the transformed phenotype of MCF-7 cells (Stylianou et al,
2006), whereas silencing of Notch 3 inhibits proliferation and
promotes apoptosis in ErbB2-negative breast cancer cell lines
(Yamaguchi et al, 2008). Moreover, overexpression of Notch in
non-tumourigenic breast epithelial cells induces transformation
in vitro (Imatani and Callahan, 2000; Stylianou et al, 2006). Thus,
deregulation of Notch signalling plays a significant role in
tumorigenesis.
Synthetic g-secretase inhibitors have been successful in treating
Alzheimer’s disease, where defective g-secretase cleavage of the
substrate molecule APP results in a longer Ab42 variant of Ab40
peptides, consequently leading to plaque formation (Lichtenthaler
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et al, 1997). In breast cancer, the g-secretase inhibitor DAPT
(N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl
ester) has been shown to effectively reduce DCIS-induced
mammosphere formation (Farnie et al, 2007). We therefore
investigated the effects of commercially available g-secretase
inhibitors on the proliferation/survival of normal and malignant
breast cancer cell lines, their effects on g-secretase component
expression and the possible mechanisms involved. We show here
that inhibition of g-secretase activity in breast cancer cell lines
induces G2/M arrest and downregulation of antiapoptotic proteins
leading to cell death.
MATERIALS AND METHODS
Cell culture
Oestrogen receptor-a (ER)-positive (MCF-7, T47D, and ZR-75-1)
and ER-negative (MDA-MB-231 and CAL-51) breast cancer cell
lines were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% foetal calf serum (FCS) and 2 mM
L-glutamine, 100 U ml1 penicillin, 0.1 mg ml1 streptomycin.
Non-tumorigenic 226-L-U19 and 226-L-TS4 breast cell lines were
kindly provided by Parmjit S Jat, Ludwig Institute for Cancer
Research, London, and were cultured in DME/F12 medium
supplemented with 10% FCS containing, 5 mg ml1 insulin,
1 mg ml1 hydrocortisone, 10 ng ml1 epidermal growth factor,
10 ng ml1 cholera toxin and 2 mM L-glutamine, 100 U ml1
penicillin, 0.1 mg ml1 streptomycin.
Effect of c-secretase inhibitors on proliferation assays
The g-secretase inhibitors, DAPT, Compound E ((2S)-2-{[(3,5-
Difluorophenyl)acetyl]amino}-N-[(3S)-1-methyl-2-oxo-5-phenyl-2,
3-dihydro-1H-1,4-benzodiazepin-3-yl]propanamide) and g-secre-
tase inhibitor 1 (GSI1: z-Leu-Leu-Nle-CHO), were purchased from
Merck Biosciences (Darmstadt, Germany). Cells (2.5 103) were
seeded in triplicate and allowed to adhere overnight. The media
was replaced with media containing the inhibitors diluted in
dimethyl sulphoxide (DMSO). After 48 h, the media was removed
and the cells were harvested and counted using a Coulter Counter
(Beckman Coulter, Buckinghamshire, UK).
Sulphorhodamine B assay
The sulphorhodamine B (SRB) assay was used to screen for
GSI1 cytotoxicity (Vichai and Kirtikara, 2006). The assay relies on
the ability of SRB to bind to protein components of cells that
have been fixed to tissue-culture plates by trichloroacetic acid
(TCA). SRB is a bright-pink aminoxanthene dye with two
sulphonic groups that bind to basic amino-acid residues under
mild acidic conditions, and dissociate under basic conditions. As
the binding of SRB is stoichiometric, the amount of dye extracted
from stained cells is directly proportional to the cell mass. To
determine the effect of GSI1 on cell number over time, SRB assays
were performed as described. Cells were seeded with six replicates
in flat-bottomed 96-well plates (3000 cells per well). The cells were
allowed to adhere overnight, and then media containing GSI1 at
different concentrations were added. One plate was assayed at this
time point (time zero) and further plates were assayed at 2-day
intervals until day 10. The cells were fixed by adding 100 ml per well
of ice-cold 40% TCA to each well for 60 min. The plates were
washed five times in running tap water and stained with 100 ml per
well SRB reagent (0.4% w/v SRB (Sigma-Aldrich, Poole, UK)) in
1% acetic acid for 30 min. The plates were washed five times in 1%
acetic acid and allowed to dry overnight. SRB was solubilised with
100ml per well 10 mM Tris-base, shaken for 30 min and the optical
density measured at 492 nm.
c-Secretase activity assay
Cells (1.5 106) were treated with increasing concentrations of
GSI1 (0.75, 2, and 5 mM) and g-secretase activity was measured
after 24 and 48 h using the R&D Systems (R&D, Minneapolis, MN,
USA) g-Secretase Activity Kit following the manufacturer’s
instructions. Briefly, cells were washed twice with ice-cold
phosphate-buffered saline (PBS), harvested in the cell extraction
buffer, and incubated on ice for at least 10 min. Lysates were
centrifuged at 10 000 g for 1 min and supernatants were collected
with a total protein yield of 0.5–1.0 mg ml1. Pierce BCA Protein
Assay (Pierce, Rockford, IL, USA) was used to determine the
protein concentration in each sample. Protein (200 mg) was
incubated with the g-secretase fluorogenic substrate for 2 h at
371C and fluorescence was measured at 355/460 nm.
CBF-1 reporter assay
The ability of the g-secretase-cleaved NICD to bind to CBF1 and
activate gene transcription was measured by the transfection of a
reporter in which four copies of the wild-type CBF1-binding elements
were cloned in front of a simian virus 40 promoter-driven luciferase
gene (4xwtCBF1Luc) (Hsieh et al, 1996). Twenty-four hours after
transfection, cells were treated with GSI1 and luciferase activity was
measured 24 h later using a Promega Luciferase kit (Promega,
Madison, WI, USA) following the manufacturer’s recommendations.
National Cancer Institute Screen of c-secretase inhibitor
The human tumour cell lines of the cancer-screening panel (NCI60)
were cultured in RPMI 1640 medium containing 5% foetal bovine
serum and 2 mM L-glutamine. Cells were inoculated into 96-well
microtiter plates in 100ml at plating densities ranging from 5000 to
40 000 cells per well, depending on the doubling time of individual
cell lines. After cell inoculation, the microtiter plates were incubated
at 371C, 5% CO2 for 24 h before addition of experimental drugs. After
24 h, two plates of each cell line were fixed in situ with TCA to
represent a measurement of the cell population for each cell line at
the time of drug addition (Tz). GSI1 in complete medium containing
50mg ml1 gentamicin was added to the cell lines and the plates were
incubated for an additional 48 h at 371C, 5% CO2, and an SRB assay
was performed. Using the seven absorbance measurements (time zero
(Tz), control growth (C), and test growth in the presence of drug at
the five concentration levels (Ti)), the percentage growth was
calculated at each of the drug concentrations levels. Percentage
growth inhibition was calculated as:
½ðTi  TzÞ=ðC  TzÞ100 for concentrations for which Ti  Tz
½ðTi  TzÞ=TzÞ100 for concentrations for which TioTz:
Three dose–response parameters were calculated for each experi-
mental agent. Growth inhibition of 50% (GI50) was calculated as was
the drug concentration resulting in total growth inhibition (TGI) is
calculated from Ti¼Tz. The LC50 (concentration of drug resulting in a
50% reduction in the measured protein at the end of the drug
treatment as compared with that at the beginning) indicating a net loss
of cells following treatment is calculated from [(TiTz)/
Tz] 100¼50. Values were calculated for each of these three
parameters if the level of activity is reached; however, if the effect is
not reached or is exceeded, the value for that parameter is expressed as
greater or less than the maximum or minimum concentration tested.
Cell cycle analysis
Cells (3 105) were plated out and after 24 h the media was
changed to one containing DMSO, or GSI1 at a concentration of
0.75, 1, or 5 mM. Both adherent and floating cells were harvested
after 24 and 48 h, fixed with ice-cold 70% methanol, washed twice
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with 5 ml PBS, treated with 10 mg RNAse, and stained with 50 mg
propidium iodide, and their DNA content was estimated by flow
cytometry using a Beckton Dickinson FacsCanto flow cytometer
(Beckton Dickinson, Franklin Lakes, NJ, USA) to determine the
proportion of cells at each stage of the cell cycle.
RNA expression
Cells were lysed with 4 M guanidinium isothiocyanate and total RNA
was extracted using RNAeasy (Qiagen Ltd, West Sussex, UK) according
to the manufacturer’s instructions. cDNA was synthesised from 2mg of
RNA with Moloney Murine Leukemia Virus reverse transcriptase and
amplified by PCR on a LightCycler (Roche Diagnostics, Mannheim,
Germany) using the LightCycler DNA FastStart SYBR Green 1 kit
(Roche Diagnostics). Oligonucleotide sequences and PCR conditions
are described in detail in Supplementary Table 1.
Protein expression
Cell lines were harvested and lysed in Lysis buffer (150 mM NaCl,
0.1% SDS, 5 mM EDTA, 10 mM Tris (pH 7.2), 1% Triton-X, and 1%
deoxycholate), containing 1 mM phenylmethanesulphonylfluoride
and protease inhibitor cocktail (Sigma-Aldrich P8340: AEBSF
104 mM, Aprotinin 0.08 mM, Leupeptin 2 mM, Bestatin 4 mM,
Pepstatin A 1.5 mM, E-64 1.4 mM). Whole cell extracts were
denatured at 1001C for 10 min and were electrophoresed on a 10%
SDS–polyacrylamide gel. Primary antibodies Bcl-XL, Bcl-2, Bax and
XIAP (Beckton Dickinson), Notch 1 intracellular domain (Abcam
Plc, Cambridge, UK), and g-tubulin (Sigma-Adrich) were incubated
in 0.1% TBS-Tween overnight. Blots were visualised using chemi-
luminescence (ECL) (Amersham Bioscience, Buckinghamshire, UK),
according to the manufacturer’s instructions.
Proteasome activity
The inhibitory effect of GSI1 and MG132 (z-Leu-Leu-Leu-CHO) on
the 20S proteasomal component (Millipore, Billerica, MA, USA)
was determined in vitro after pre-incubation for 15 min at room
temperature. Then, the enzyme-inhibitor mix was added to 1
assay buffer (25 mM HEPES, 4-(2-hydroxyethyl)-1-piperazineetha-
nesulphonic acid, pH 7.5, 0.5 mM EDTA, 0.05% (v/v) NP-40 and
0.001% (w/v) SDS), and incubated with N-Succinyl-Leu-Leu-Val-
Tyr-7-Amino-4-methylcoumarin (suc-LLVY-AMC, Millipore) for
75 min at 401C. Three replicates were included per treatment.
Fluoresence was measured at 380/460 nm.
The effect of GSI1 and MG132 on proteasomal activity in vivo
was determined after treatment of MDA-MB-231 and MCF-7 cells
(1 106) with the inhibitors for 4 h. Adherent cells were washed
and scraped in cold PBS, collected and centrifuged for 5 min at
170 g and 41C. Cells were resuspended in 50 mM HEPES, pH 7.5,
5 mM EDTA, 150 mM NaCl and 1% Triton X-100, and incubated on
ice for 30 min, with vortexing at 10 min intervals. Samples were
centrifuged at 14 000 g for 15 min at 41C, and the supernatant was
collected. Lysates were incubated with 1 assay buffer and 50 mM
suc-LLVY-AMC at 401C for 75 min. Three replicates were included
per treatment. Fluorescence was measured at 380/460 nm.
Statistical analysis
Where indicated a t-test was performed (two-sided). Statistical
significance was assumed when Po0.05.
RESULTS
Downregulation of the Notch signalling pathway with GSI1
selectively affects the viability of breast cancer cells
The breast cancer cell lines MDA-MB-231, T47D, and MCF-7 were
treated with three g-secretase inhibitors at concentrations in the
range 0.01–50 mM. Compound E had no effect on the MDA-MB-231
cells and only reduced the proliferation of the other cell lines by
less than 50% at a concentration of 50 mM (Figure 1A). The effect of
DAPT on T47D and MCF-7 cell lines was comparable with the
Compound E, but DAPT inhibited proliferation by approximately
50% in the MDA-MB-231 lines at 50mM (Figure 1B). GSI1 had the
most significant effect on all three cell lines at 1 mM reducing
proliferation by approximately 80% (Figure 1C). GSI1 inhibited
g-secretase activity in MCF-7 cells in a dose-dependent manner
and at 5 mM inhibition reached 100% (Figure 2A).
We confirmed that inhibition of g-secretase by GSI1 down-
regulated the Notch pathway by directly detecting the NICD
(which is cleaved by g-secretase) with a specific antibody.
Treatment of MCF-7 cells with 2 and 5 mM GSI1 decreased notably
the levels of NICD (Figure 2B). It is well established that the Notch
intracellular domain interacts with the transcriptional repressor
CBF1 and abolishes CBF1-mediated repression. We used a
surrogate for the activation of Notch by g-secretase consisting of
the transfection of a luciferase reporter containing CBF1-binding
sites (Hsieh et al, 1996). In this system, activation of Notch is
reflected by an increase in luciferase expression. Treatment of
MCF-7 cells with GSI1 reduced the luciferase activity of the
transfected reporter in a dose-dependent manner (Figure 2C).
Interestingly, the effect of GSI1 on Notch-driven luciferase
transcription was always lower than the corresponding inhibition



































































Figure 1 Cytotoxic effect of g-secretase inhibitors on breast cancer cell
lines. Cells were treated with Compound E (A), DAPT (B), and GSI1
(C) for 48 h and their viability was determined using a Coulter counter.
Data represent the average of three independent experiments ±s.d.
c-Secretase in breast cancer
S Rasul et al
1881





















transfection efficiency and activation of CBF1-Luciferase by
Notch-independent mechanisms.
Sulphorhodamine B assays were then carried out on five
tumorigenic and two non-tumorigenic breast cell lines to
investigate the effects of GSI1 over a longer time frame. In
MCF-7, MDA-MB-231, ZR-75-1, T47D and CAL-51 breast cancer
cell lines 1 mM GSI1 and above resulted in cell death (range of IC50
values: 0.6–0.9 mM) (Figure 3A). No effect on the non-tumorigenic
226-L-U19 and 226-L-TS4 cell lines was seen in the range
0.5–40 mM, which showed IC50 values around 50 mM (Figure 3B).
There was no effect on the expression of the g-secretase
components or ligands such as Notch, Jagged, and Numb in
response to the GSI1 treatment (Supplementary Figure 1). Thus,
the effect of GSI1 on breast cancer cells is not due to a differential
expression of g-secretase components or its downstream effectors.
Effect of GSI1 on the NCI 60 panel of cancer cell lines
The effect of GSI1 (10 nm, 100 nM, 1, 10, and 100mM) was tested, in
duplicate, on the NCI panel of 60 cancer cell lines. A decrease in
cell number was seen in all 60 cell lines with the mean log10 GI50 of
6.13±0.007 M (Figure 4). The mean log10 LC50 calculated for all
of the cell lines was 4.41±0.011 M (Supplementary Table 2).
When the screen was repeated the values obtained were
6.41±0.005 M for the log10 GI50, and 4.49±0.12 M for the
log10 LC50.
When the breast cancer cell lines only were examined the mean
log10 GI50 were 6.23±0.063 and 6.58±0.059 M (on the second
run the MDA-MB-468 cell line was included). The mean values of
log10 LC50 were 5.12±0.078 and 4.86±0.12 M in runs 1 and 2,
respectively. GSI1 had a negligible effect on cell number at 100 nM,
but at concentration of 1 mM and higher it had an inhibitory effect
(Figure 4). Interestingly, the multidrug-resistant cell line NCI/
ADR-RES, resistant to adriamycin and other P-glycoprotein
substrates, was less sensitive to GSI1 than the other breast cancer
cell lines tested and than most other cancer cell lines. At 1 mM, GSI1
did not show any decrease in cell number, which was only
noticeable at 10 mM (Figure 4). Thus, GSI1 inhibits the proliferation
of many different cancer cell lines corresponding to a variety of
solid tumours and leukaemia.
GSI1 induces a G2/M arrest resulting in apoptosis
We observed a marked increase in the percentage of cells in G2/M
arrest after 24 h incubation with 5mM GSI1 (Figure 5A). After 48 h
treatment, a large proportion of the ZR-75-1 and MDA-MB-231
cells were apoptotic (58 and 77%, respectively) and only a small
percentage were in G2/M arrest (Figure 5B). Seventeen percent
of MCF-7 cells were apoptotic after treatment with 5 mM GSI1
(Figure 5B), but there was a substantial increase in the percentage
of cells in G2/M arrest. Media replacement experiments indicated
that when fresh medium was added to MDA-MB-231 cells
previously treated with GSI1 for 48 h, the cells recovered their
proliferative capacity when concentration was up to 1mM. However,
at higher concentrations no further proliferation was observed
(data not shown). When the levels of the antiapoptotic protein
Bcl-XL were monitored in MDA-MB-231, ZR-75-1, and MCF-7 cells,
we found a downregulation due to GSI1 treatment (0.75mM for 48 h)
in the two former cell lines (Figure 5C). However, GSI1 treatment in
MDA-MB-231 and ZR-75-1 cell lines also downregulated the level
of g-tubulin (Figure 5C) as well as other proteins tested as loading
controls (eIF4E, RPLP0, ribosomal protein S6, among others). We
then monitored the levels of the antiapoptotic proteins XIAP, Bcl-2,
Bax and Bad after treatment with increasing doses of GSI1 and
found that their levels decreased progressively from 2 to 5mM GSI1
(Figure 5D). Thus, GSI1 triggers apoptosis in breast cancer cells by
downregulating the expression of antiapoptotic proteins.
GSI1 inhibits proteasome activity both in vivo and in vitro
but has less cytotoxic effect on breast cancer cells than
MG132
As GSI1 (z-Leu-Leu-Nle-CHO) is chemically and structurally
similar to proteasomal inhibitor MG132 (z-Leu-Leu-Leu-CHO),
the possibility of GSI1 affecting proteasomal activity was explored.
Proteasomal activity was severely reduced (80-90%) upon incuba-
tion treatment of the isolated proteasome 20S proteolytic core
particle subunit with either compound in vitro (Figure 6A).
Similarly, a strong inhibitory effect was observed in vivo
(Figure 6B), although MG132 was marginally more efficient than
GSI1. However, the cytotoxic effect of both compounds on both
MCF-7 and MDA-MB-231 cells was markedly different (Figure 6C),
MG132 showing a stronger cytotoxic effect than GSI1 (between
1.5- and 2-fold). Thus, despite their similar chemical structure and
protesome inhibition, GSI1 and MG132 affect the growth of breast
cancer cells differently.
DISCUSSION
In this study we endeavoured to determine whether the g-secretase
complex, which has an integral role in signalling of Notch, is a
0 0.75 2 5
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Figure 2 GSI1 downregulates g-secretase activity and the Notch
pathway. (A) Relative g-secretase activity in MCF-7 cells were treated
with GSI1 for 24 h. (B) Western blot analysis of NICD in MCF-7 cells were
treated with GSI1 for 24 h. (C) MCF-7 cells were transfected with a
CBF1-luciferase reporter and the next day treated with GSI1 for 24 h.
Values represent relative luciferase activity with respect to the mock-
transfected and vehicle-treated cells. Bars indicate the average g-secretase
(A) or luciferase activity (C) ±s.d. of three independent experiments (*
indicates Po0.05).
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potential therapeutic target in breast cancer. For this we tested
the effect of commercial g-secretase inhibitors on breast cell lines.
The three g-secretase inhibitors tested had markedly different
effects on different breast cancer cell lines. Both DAPT and
Compound E are chemical inhibitors of the complex. DAPT
reduces ductal carcinoma in situ mammosphere formation
(Farnie et al, 2007) and pancreatic cancer cell growth (Kimura
et al, 2007). Another g-secretase inhibitor, MRK-003, reduces
tumour cell proliferation, inhibits serum independence, and
induces apoptosis of lung cancer cell lines in vitro and in vivo
using mouse xenograft models (Konishi et al, 2007). Thus, the
g-secretase complex is now becoming an accepted target in cancer
therapy, in particular, with regard to Notch signalling (Shih and
Wang, 2007).
Differential responses between tumourigenic and non-tumouri-
genic cell lines may be explained by differential expression of
Numb, a negative regulator of the Notch pathway, and NICD. It has
been shown that non-tumourigenic cells express Numb but
not NICD (Stylianou et al, 2006) indicating that, as expected, the
Notch pathway is not activated in non-cancerous cells. Conversely,
cancer cells have Numb downregulated, NICD upregulated and the
Notch pathway activated (Stylianou et al, 2006), and are sensitive
to the cytotoxic effect of GSI1 by its effect on the
Notch pathway.
We show here that g-secretase inhibition promotes a cell cycle
arrest at G2/M, which further triggers the apoptotic response.
Expression of cyclin B1, which controls the G2/M checkpoint, can
be regulated by the Notch pathway (through putative CBF-1-
binding elements in its promoter). Breast cancer cells in which the
Notch pathway has been targeted, either by an inhibitor of
g-secretase or by Notch-1 RNAi, downregulate cyclin B1 and suffer
G2/M arrest (Rizzo et al, 2008). In addition, in MCF-7 cells another
g-secretase inhibitor triggers the DNA damage response with the
concomitant upregulation of the cell cycle regulators, p53 and
p21, which may promote defective cell division, consequently
abrogating antiapoptotic mechanisms (Alimirah et al, 2007). We
observed a dose-dependent downregulation of Bcl-2, Bax, Bad and
XIAP upon GSI1 treatment (Figure 5) and a corresponding dose-
dependent activation of caspase 3/7 in MDA-MB-231 cells (data
not shown). Increased apoptosis upon treatment with a g-secretase
inhibitor has also been observed in Kaposi sarcoma, multiple
myeloma (Nefedova et al, 2008), melanoma (Leggas et al, 2004)
and tongue carcinoma (Yao et al, 2007). This may be indicative of
a possible mechanism through which inhibition of g-secretase
modulates decreased viability, as observed in the comprehensive
NCI screen.
Notch and APP are probably the best-studied g-secretase
substrates, and we have shown that GSI1 treatment downregulates
IC50 0.85 M
IC50 0.64 M IC50 0.78 M
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Figure 3 Cytotoxic effect of GSI1 on breast cancer cells. The effect of increasing concentrations of GSI1 in breast cancer cell lines (A) and non-
tumorigenic breast cell lines (B) was determined by staining with SRB. Data represents the average ±s.d. of two independent experiments with six
replicates at each time point. The IC50 for each cell line was determined from the corresponding dose–response curves (data not shown) and is indicated.
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the Notch pathway in breast cancer cells. However, as g-secretase
acts upon a large variety of substrates, it is likely that the cytotoxic
effect of GSI1 upon cells will be due to the downregulation of
several downstream targets involved in vital cell functions, which
ultimately affect the survival of cancer cells.
Interestingly, NCI/ADR-RES, multidrug-resistant cells over-
expressing the ABC transporter ABCB1 (P-glycoprotein) (Raguz
et al, 2008) and prostate PC-3 cells, are the least susceptible of all
the cells in the NCI-60 cell panel. As PC-3 cells express also
P-glycoprotein (Rao et al, 2005), and considering the molecular
structure of GSI1, it is possible that GSI1 will be a substrate
of P-glycoprotein (Crivori et al, 2006). This would make GSI1
less effective in cancers from tissues expressing P-glycoprotein
such as those from colon or the adrenal gland, or in those
which have acquired P-glycoprotein-mediated drug resistance
(Burger et al, 2003).
We also showed that GSI1 is a potent proteasomal inhibitor, and
may inhibit breast cancer cell proliferation through dual targets of
the g-secretase complex and the proteasome. Whether GSI1 targets
each specifically, or inhibition occurs through sequential conse-
quence remains uncertain. It is tempting to speculate that
aldehyde-based compounds, such as GSI1 and MG132, may be
able to bind interchangeably between the two complexes. Although
a low-resolution electron microscopy model of the g-secretase
complex has recently been described (Lazarov et al, 2006), only
the complete high-resolution X-ray structure of the g-secretase
complex may suggest putative shared 3D regions to which
aldehyde-based inhibitors bind. In addition, it is possible that
cross-talk between the g-secretase complex and the proteasome
exists, as PSEN may be cleaved into the active C- and N-terminal
fragments by the proteasome (Massey et al, 2005). Furthermore,
it has been suggested that the g-secretase complex can act in a
similar way to the proteasome, as they can recognise, capture
substrates and feed them through the proteolytic-containing cavity
of their respective complexes to produce functional cleaved
fragments (Kopan and Illagan, 2004).
The cytotoxic effect of GSI1 and MG132 on breast cancer cells is
different (Figure 6C). As GSI1, MG132 induces G2/M arrest and
Leukemia
CNS cancer
Renal cancer Prostate cancer Breast cancer
Melanoma Ovarian cancer






















































−9 −8 −7 −6 −5 −4














































































































































Figure 4 Cytotoxic effect of GSI1 on the NCI60 panel of cancer cell lines. The cytotoxic effect of GSI1 (10, 100 nM, 1, 10, 100 mM) on cancer cells was
determined by a SRB assay after 24 h of drug treatment. Although NCI/ADR-RES data are shown within the breast cancer cell panel, recent evidence
suggests that this is an ovarian cancer multidrug-resistant line derived from OVCAR-8 (Liscovitch and Ravid, 2007). Results shown are representative of two
independent experiments.
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apoptosis with loss of Bcl-2 expression (Yan et al, 2007), thus the
therapeutic use of proteasome inhibitors are also being considered
in cancer treatment (Voorhees et al, 2003; Sato et al, 2008).
Whether the uptake of these compounds by breast cancer cells
or their half-lives (either in the culture medium or intracellularly)
is different, and thus modulate their potency, remains to be
established.
Two facts are important from a potential future clinical
application of GSI1: (1) the inhibitor is effective in triggering cell
death of cancer cell lines at much lower concentrations than those
required in non-tumorigenic cell lines, and (2) its effect on breast
cancer cells is irrespective of their ER status. This last point
is particularly important as triple-negative breast tumours
(ER-, progesterone receptor-, and Her-2-negative), which are
particularly aggressive and have a poor prognosis, are currently
only treated with traditional chemotherapy (Haffty et al, 2006;
Cleator et al, 2007). Interestingly, g-secretase inhibitors have the
potential of increasing sensitivity and efficacy of other chemother-
apeutic drugs as well as hormonal and targeted therapeutic agents.
For example, synergistic treatment of breast cancer cells with
a g-secretase inhibitor and trastuzamub (Osipo et al, 2008)
or Tamoxifen (Rizzo et al, 2008) was more effective in reducing
proliferation than the individual treatments. The combined
treatments of g-secretase inhibitors and chemotherapeutic agents
have illustrated a greater extent of antiproliferative effects and/or
apoptosis in multiple myeloma (Nefedova et al, 2008), T-cell acute
lymphoblastic leukaemia (De Keersmaecker et al, 2008), and colon
cancer cell lines (Akiyoshi et al, 2008).
Overall these data indicate that g-secretase is a potential
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Figure 5 GSI1 induces G2/M cell cycle arrest and triggers apoptosis in breast cancer cells. (A, B) Cell cycle analyses of breast cancer cell lines treated with
GSI1 for 24 h (A) and 48 h (B). Cells were stained with propidium iodide and gated according to their fluorescence to differentiate cell cycle phases: 1,
apoptotic cells; 2, cells in G0/G1; 3, cells in S phase; 4, cells in G2-M. Data shown are a representative of two independent experiments. (C, D) Western blot
analyses were used to verify the modulation of the apoptotic response due to GSI1 treatment. (C) Three different breast cancer cell lines treated with a
single GSI1 concentration (0.75 mM) for 48 h. (D) MCF-7 cells treated for 48 h with increasing concentrations of GSI1. Tubulin was used as a loading control.
Note the slight effect of GSI1 on tubulin levels in MDA-MB-231 and ZR-75-1 cells (C).
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Supplementary Figure 1. GSI1 treatment does not change the expression of genes 
coding for γ-secretase components or its targets. Cells were treated with 0.75 µM GSI1 
for 48 h and the expression of the genes monitored by semi-quantitative RT-PCR. 
 
Supplementary Table 1.  Oligonucleotides and PCR conditions used. 
 
Gene Forward primer 
(5’ to 3’) 
Reverse primer 




 °C /s 
Annealing °
C / s 
Elongation  





NOTCH1 gcaacagctccttccacttc ccacgaagaacagaagcaca 3  95/25 59/27 72/25 34 499 
NOTCH2 atgactgccctaaccacagg ctggagtacaggaggcgaag 2  95/15 59/20 72/15 25 264 
APH1A ccgctttgcctactacaagc ccaaaaggtatggagcagga 3  95/20 58/20 72/20 27 265 
NCSTN caaagcaccttcagcatcaa cgagctgccaatgtagtcaa 3  95/25 58/25 72/25+86/2 28 315 
PSEN1 gttccacttcgtatgctggt gcgaggatactgctggaaag 3  95/20 60/15 72/20 23 314 
PSEN2 ctgcccaggagagaaatgag cagtcaagggaggctcaaag 3 95/25 61/25 72/25 25 198 
PEN2 tcccttgtcccagcctacac ggtcctttattgggggatgt 3  95/20 59/20 72/20 32 329 
JAG1 ctcctgtcgggatttgttta ccacagacgttggaggaaat 3 95/30 58/30 72/30 28 414 
JAG2 gtcaaggtggagacggttgt atcctcgtcctcctcatcct 2 95/30 60/30 72/30 25 345 
NUMB agccagcccatactgctcta acaggctgagaggtgaggaa 2 95/30 60/30 72/30 30 346 
GAPDH tctcatcaccatcttcca  catcacgccacagtttcc 2 95/30 54/30 72/30 32 380 
aAn initial step (hot start) of 95°C for 10 min was carried out before amplification cycles. 
 
 
Supplementary Table 2. Summary of results from NCI60 Cell Screen  
____________________________________________________________________________________________________________________ 
          Run 1          Run 2 
     __________________________________                __________________________________ 
Cell Line    Log10 GI50 Log10 TGI Log10 LC50   Log10 GI50 Log10 TGI Log10 LC50 
           (M)       (M)       (M)        (M)          (M)          (M) 
____________________________________________________________________________________________________________________ 
MCF7         -6.21     -4.41     >-4.00      -6.31     -4.95     -4.21 
MDA-MB-231       -6.28     -5.64       -5.11      -6.43       -5.79     -4.02 
HS 578T        -6.35     -4.50     >-4.00      -6.68     -6.26   >-4.00 
MDA-MB-435       -6.56     -6.15       -5.14      -6.79     -6.51     -6.22 
BT-549        -6.29     -5.45     >-4.00      -6.48     -5.72     -5.01 
T47-D         -5.73   >-4.00     >-4.00      -6.60     -6.05   >-4.00 
MDA-MB-468              -6.79     -6.45 
 
Mean Breast Cancer Cell Lines -6.23±0.063 -5.23±0.12 -5.12±0.078  -6.58±0.059 -5.96±0.087 -4.86±0.12 
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Abstract Nicastrin is an essential component of the
gamma secretase (GS) enzyme complex, required for its
synthesis and recognition of substrates for proteolytic
cleavage. The purpose of this study was to investigate
whether nicastrin has prognostic value or potential as a
therapeutic target in breast cancer (BC). The suitability of
nicastrin as a target in BC was assessed using BC tissue
microarrays (TMAs) (n = 1050), and its biological role in
vitro was evaluated in BC cell lines following gene silencing.
Nicastrin blocking antibodies were developed and evaluated
for their suitability as potential clinical therapeutics. TMA
and cell line analysis confirmed that nicastrin expression was
upregulated in BC compared to normal breast cells. In TMA
patient samples, high nicastrin expression was observed in
47.5% of cases and correlated with ERa expression, patient
age, and tumor grade. In pre-defined subset analysis, high
nicastrin expression predicted for worse BC specific survival
in the ERa -ve cohort. In vitro gene silencing of nicastrin
resulted in disruption of the GS complex and a decrease in
notch1 cleavage. This was sufficient to increase E-cadherin
expression and its co-localization with p120 catenin at cell–
cell junctions in MCF7 cells. Nicastrin silencing in invasive
MDA-MB-231 cells resulted in loss of vimentin expression
and a marked reduction in both cell motility and invasion;
which was concomitant with the de novo formation of cell–
cell junctions characterized by the colocalization of p120
catenin and F-actin. These data indicate that nicastrin can
function to maintain epithelial to mesenchymal transition
during BC progression. Anti-nicastrin polyclonal and
monoclonal antibodies were able to decrease notch1 and
vimentin expression and reduced the invasive capacity of BC
cells in vitro. This supports our hypothesis that a nicastrin
blocking antibody could be used to limit metastatic dis-
semination in invasive BC.
Keywords Breast cancer  Nicastrin  Gamma secretase 
Invasion  Monoclonal antibody
Introduction
Tumor progression and metastatic spread involves upreg-
ulation of molecular components that constitute numerous
proteolytic and cell migration pathways that help drive cell
invasion into the surrounding stroma [1]. Gamma secretase
(GS) is a unique multi-protein complex with activity as a
cell surface protease that directly cleaves a variety of
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transmembrane proteins to modify their function. The GS
complex comprises of nicastrin, anterior pharynx defective
1 homolog, presenilin enhancer protein-2, and the aspartyl
protease presenilin [2]. The proteolytic targets of GS
include the amyloid precursor protein [3] and a number of
proteins that function in tumor cell proliferation, adhe-
sion, and migration: including notch 1–4, ErbB4, CD44,
E-cadherin, and EpCAM [4, 5].
The principal rationale behind introducing GS inhibitors
(GSIs) as anti-cancer therapeutics was the discovery of
activating mutations in notch1 in [50% of T-cell acute
lymphoblastic leukemia patients and later data that
described the overexpression and oncogenic function of
notch proteins in solid tumors, including lung, malignant
melanoma, and breast [6]. Activation of the notch pathway
results in binding of the transcription factor CSL to the
promoter of target genes, such as Hes, Hey, Snail, c-myc,
etc., that promote cell survival and can also regulate epi-
thelial to mesenchymal transition (EMT) [7, 8]. E-cadherin
is essential for the stabilization of epithelial cell–cell
adherens junctions and its frequent loss in human cancers is
associated with Snail overexpression [9]. Furthermore,
notch proteins can maintain cancer stem cells [10] that
harbor an EMT-like phenotype: CD24-/CD44?, Snail,
Twist, and vimentin upregulation; and loss of E-cadherin
[8]. Interestingly, E-cadherin and its coregulator p120
catenin (p120ctn) directly interact with the GS complex by
binding to the same domain of presenilin [11]. This indi-
cates that their competitive binding to GS complex could
have an impact on adherens junction stability [12].
Nicastrin provides critical structural support for GS
complex assembly and facilitates molecular recognition of
GS substrates for cleavage. Overexpression of nicastrin
was sufficient to enhance GS activity without altering
presenilin expression [13]. Functional sites of nicastrin
have been identified in its extracellular and transmembrane
domains. Mutations in the transmembrane domain (S632A
and W648A) resulted in the inability of nicastrin to bind
other GS components, disrupting complex formation, and
the proteolytic activity [14]. A Ser to Ala mutation at
position 333 located in the external, DYIGS sequence of
nicastrin (homologous with Domains harboring Amino
Peptidase activity (DAP)), was sufficient to prevent sub-
strate binding [14]. Targeting these functional regions of
nicastrin may confer therapeutic benefit in diseases/condi-
tions that involve nicastrin and/or GS activity.
In this study, we hypothesized that nicastrin is overex-
pressed in breast cancer (BC) and that its large extracellular
domain could represent an antigen target suitable for the
development of a specific therapeutic antibody. Monoclonal
antibodies (McAbs) have emerged as effective therapeutics
that have demonstrated clinical benefit (reducing tumor
burden and increasing disease free and overall survival)
when used alone or in combination with chemotherapy.
Currently, there are four FDA approved McAbs for the
treatment of solid tumors: Trastuzumab, Bevacizumab,
Cetucimab, and Panitumumab, and over one hundred
McAbs are in early and late phase clinical trials [15].
Our data confirm that: (1) nicastrin expression is
upregulated in BC compared to normal breast tissue; (2)
silencing nicastrin at the gene level can prevent BC inva-
sion; and (3) specific anti-nicastrin McAbs inhibit the
invasion of BC cells, which suggests that a similar




MCF-7 and MDA-MB-231 cells were from the American
Type Culture Collection (ATCC). NCSTN?/? and NCSTN-/-
mouse embryonic fibroblasts (MEFs) were obtained from Dr
Philip Wong (Department of Neuropathology, Johns Hopkins
University, ML, USA). Cells were grown in DMEM with 10%
fetal calf serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin
in 5% CO2 at 37C. The non-tumorigenic immortal breast cell
line 184A1 (CRL-8798; ATCC) was cultured in basal
mammary epithelial cell growth medium (Promocell, UK),
supplemented with bovine pituitary extract (13 lg/ml),
epidermal growth factor (10 lg/ml), hydrocortisone
(500 lg/ml), insulin (5 lg/ml), transferrin (0.005 lg/ml),




Patient tissue resource and patient cohort characteristics,
immunohistochemistry (IHC) staining protocol of tissue
microarrays (TMAs) and statistical analysis are described
in the Online Resource 1 and are in line with the REMARK
criteria [16].
RNA interference
Cells were transfected with a final concentration of 40 nM
nicastrin siRNA oligonucleotides (D-008043, Dharmacon,
UK) using HiPerFect (Qiagen, UK). EGFP siRNA
(AM4626, Ambion, UK) was used as a negative control.
Western blotting
Cell lysates were lyzed using buffer (150 mM NaCl, 0.1%
(w/v) sodium dodecyl sulphate, 5 mM EDTA, 10 mM
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Tris–HCl (pH 7.2), 1% (v/v) Triton-X and 1% (w/v)
deoxycholate), containing 1 lM phenylmethanesulfonyl
fluoride and 1% v/v protease inhibitor cocktail (catalog no.
P8340, Sigma, UK). Further steps were as previously
described, only using 10% w/v SDS–polyacrylamide gels
[17]. Primary antibodies and concentrations: 1/500 rabbit
polyclonal anti-nicastrin antibody (pAb) (ab2474); 1/500
mouse anti-human presenilin monoclonal antibody (mAb)
(ab12272); 1/10,000 mouse anti-human b-actin (ab8229)
(Abcam, UK); 1/2,000 mouse anti-human E-cadherin mAb
(610182), 1/1,000 rabbit anti-human p120 pAb (610133)
(BD Transduction Laboratories, UK); and 1/500 mouse
anti-human vimentin mAb (sc-6260, clone V-9) (Santa
Cruz, USA).
RNA isolation and quantitative RT-PCR
Isolation of total RNA was performed using the RNeasy kit
(Qiagen, UK). RNA (1 lg) was reverse transcribed using
oligo dT and Transcriptor First Strand cDNA Synthesis Kit
(Roche, UK). Quantitative PCR was performed using the
SYBR Green PCR mastermix (Applied Biosystems, UK)
on a 7900HT Thermocycler (Applied Biosystems, War-
rington, UK) using primers for nicastrin (NCSTN), E-cad-
herin (CDH1), Snail (SNAI1), vimentin (VIM), presenilin
(PSEN), p120ctn, and GAPDH (Operon, UK). The PCR
cycle number that generated the first fluorescence signal
above a threshold (threshold cycle, CT; 10 standard devi-
ations above the mean fluorescence generated during the
baseline cycles) was determined, and a comparative CT
method was then used to measure relative gene expression.
GS activity assay
GS activity was measured using the R&D Systems Gamma
Secretase Activity Kit following the manufacturer’s
instructions. Briefly, cells were transfected with control or
nicastrin siRNA and harvested after 72 h in cell extraction
buffer and incubation on ice for 10 min. Lysates were
centrifuged at 10,0009g for 1 min and supernatants were
collected with a total protein yield of 0.5–1.0 mg/ml.
Pierce BCA Protein Assay was used to determine protein
concentration. Protein (200 lg) was incubated with the GS
fluorogenic substrate for 1 h at 37C and fluorescence was
measured at 355/460 nm.
Immunofluorescent staining and confocal microscopy
Immunostaining and confocal imaging were carried out as
previously described [18]. 1 9 104 cells were seeded on
13 mm diameter glass cover slips, fixed in 4% w/v para-
formaldehyde at 37C and incubated in immunofluorescent
blocking buffer (2% v/v FCS and 1% BSA) followed by
incubation with 1/100 nicastrin pAb, 1/100 E-cadherin, or
1/100 p120 catenin antibodies. Incubation with 1/1,000
anti-rabbit or anti-mouse-IgG Alexa Fluor-488 or -555 or
phalloidin Alexa Fluor-633 (Molecular Probes, UK).
Nuclear counterstaining was carried out using TO-PRO-3
and coverslips were mounted using Vectashield H-1200
(Vector Laboratories, UK). Images were captured using a
Zeiss LSM 410 confocal microscope (639 lens; 1.40 NA
oil; Leica) using Immersol 518F oil (Zeiss). Image com-
posites of *20 9 0.5 lm z-stacks were obtained using
Axiovision LE software (Zeiss). Photoshop 8.0 (Adobe
Software) was used for post-acquisition editing of images.
Cell migration and invasion
1 9 104 cells were plated on glass bottomed 24-well plates
and imaged by digital recording at a time-lapse interval of
10 min for 16 h in an environmentally controlled Imag-
eXpress Micro microscope (Molecular Devices, UK). The
average speed of cell migration (mean ± s.e.m.; n [ 100
cells) was determined [19]. Cell invasion assays were
performed using Matrigel-coated polycarbonate transwell
filters (8 lm pore size) (Beckton Dickinson, UK). 70 ll
Matrigel (diluted 1:2 in a-MEM) was added to the upper
chamber and allowed to polymerize for 1 h at 37C.
Keratinocyte growth medium consisting of a-MEM sup-
plemented with 10% FCS, 100 IU/ml penicillin, 100 lg/ml
streptomycin, 250 ng/ml amphotericin B (Gibco),
1.8 9 10-4 M adenine, 5 lg/ml insulin, 0.5 lg/ml hydro-
cortisone, 10 ng/ml epidermal growth factor, and
1 9 10-10 M cholera toxin. 500 ll of this medium was
placed in the lower chamber to act as a chemoattractant.
Cells were plated in the upper chamber of quadruplicate
wells at a density of 5 9 104 in 200 ll of a-MEM and
incubated at 37C for 72 h. Cells in the lower chamber
(including those attached to the under surface of the
membrane) were trypsinized and counted using a Casy 1
counter (Sharfe System GmbH, Germany).
Results
Nicastrin expression in BC and correlation
with relevant tumor biomarkers
Nicastrin expression was initially evaluated in a non-
malignant breast cell line and four BC cells lines. A marked
upregulation of nicastrin protein levels was observed in four
BC cell lines (MCF7, MDA-MB-231, BT-474, and SKBR3)
compared to the non-tumorogenic breast cell line, 184A1
(Fig. 1a). Normal breast tissues from reduction mammo-
plasties (n = 40) were examined by IHC. Nicastrin was
absent (IHC score 0) in 30/40 cases, and expressed at very
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low levels (IHC score 1?) in the remaining 10 cases. Nic-
astrin immunostaining in BC TMAs showed predominant
cytoplasmic localization with variable cell membrane
staining. Informative data were obtained in 1050 tissue
cores, of which 52.5% showed low (0 and 1 intensity score)
and 47.5% showed high (2? and 3? score) expression
(Fig. 1b). Nicastrin expression was retained in lymph node
metastasis (n = 15). Specificity of the IHC staining was
verified using pre-incubation with the nicastrin blocking
peptide (N164, Leinco Technologies). High nicastrin
expression positively correlated with hormonal receptors,
estrogen receptor a (ERa) (P \ 0.001), progesterone
receptor (PR). There was a direct correlation with cyto-
keratin 18 (P \ 0.001), and inverse with basal cytokeratines
5/6 (P = 0.01). Nicastrin expression correlated with patient
age (P = 0.031), where patients [50 years were more
likely to have tumors expressing high nicastrin levels.
Nicastrin expression correlated with tumor grade
(P \ 0.001). With respect to tumor type, nicastrin appeared
to be significantly upregulated in tubular carcinomas
(208/1050), with 61% (n = 127/208) showing high nicas-
trin expression, versus 39% (n = 81/208) with low nicastrin
levels (P = 0.002). In patients with invasive ductal carci-
noma (624/1050), 54.3% (n = 339/624) had high and
45.7% (n = 285/624) low nicastrin levels. No correlation
was observed with tumor size. Patient characteristics are
summarized in Table 1.
Fig. 1 Nicastrin expression is upregulated in breast cancer compared
to normal breast. a Western blotting of nicastrin protein levels in a
normal breast cell line 184A1 and four breast cancer cell lines
(MCF7, MDA-MB231, BT474, and SKRB3). b Nicastrin expression
in breast cancer tissue (n = 1050) was analyzed by IHC. Represen-
tative images of nicastrin null, 1?, 2? and 3? staining in breast
tumors. Representative image of normal breast tissue (n = 40),
showing absence of nicastrin expression. Pre-incubation with com-
peting peptide confirms the specificity of the N-1660 antibody.
c Nicastrin expression in a paired tumor/metastatic lymph node
sample (n = 15)
Table 1 Patients’ characteristics and tumor biomarkers showing
nicastrin expression
Variable/biomarker Nicastrin expression P-value
Low (%) High (%)
Patients age (years)
B50 231 (41.8) 173 (35.3) 0.031
[50 321 (58.2) 325 (64.7)
Grade
1 70 (12.8) 96 (19.4) \0.001
2 166 (30.3) 187 (37.7)
3 312 (56.9) 213 (42.9)
Stage
1 337 (51.8) 313 (48.2) 0.827
2 164 (52.9) 146 (47.1)
3 48 (55.2) 39 (44.8)
Tumor type
Tubular 81 (39) 127 (61) 0.002
Invasive ductal 285 (45.7) 339 (54.3)
Estrogen receptor
Negative 170 (61.8) 105 (38.2) \0.001
Positive 355 (49.2) 367 (50.8)
Progesterone receptor
Negative 251 (59.6) 170 (40.4) \0.001
Positive 270 (47.7) 296 (52.3)
Her2 receptor
0/1?/2? 503 (53.4) 439 (46.6) 0.076
3? 33 (42.3) 45 (57.7)
Cytokeratin 18
Negative 67 (13.3) 437 (86.7) \0.001
Positive 30 (6.4) 439 (93.6)
Cytokeratin 5/6
Negative 432 (50.7) 420 (49.3) 0.01
Positive 96 (61.9) 51 (38.1)
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Association of nicastrin expression with clinical
outcome
Kaplan Meyer survival analysis indicated that high nicas-
trin expression was not predictive of BC specific survival
in the whole dataset (P = 0.664) or the ERa ?ve subset of
patients (P = 0.183) (Fig. 2a, b). Further subset analysis in
the ERa -ve patients (275/1050) indicated that high nic-
astrin levels had borderline predictive value for BC specific
survival at 5 years (P = 0.05) (Fig. 2c). Nicastrin expres-
sion did not retain significance in a multivariate analysis
model combined with tumor grade, stage, and size. Nic-
astrin expression did not predict outcome to systemic
adjuvant treatments (endocrine or chemotherapy).
Expression pattern of nicastrin in a panel
of human tissues
We further studied nicastrin expression in normal and
malignant tissue from other human organs. Expression of
nicastrin in normal tissues is summarized in Table 2.
Malignancies found to have nicastrin upregulation (2?)
include colon adenocarcinoma, lung adeno- and squamous
cell-carcinoma, head and neck squamous cell carcinoma,
thyroid papillary and follicular carcinoma, pancreatic
adenocarcinoma and liposarcoma.
Targeting nicastrin disrupts GS complex in BC cells
An siRNA targeting approach was used in MCF7 and
MDA-MB-231 BC cell lines, which represent luminal and
basal BC phenotypes, respectively [20]. A silencing effi-
ciency of [90% was achieved for nicastrin protein
(Fig. 3a), and mRNA (Fig. 3b) levels in both cell types
(P \ 0.0001). Importantly, nicastrin silencing was suffi-
cient to significantly reduce GS complex enzymatic
activity (P \ 0.001) (Fig. 3c) and transcription of its direct
target in the notch signaling pathway, Hes1 (P \ 0.001)
(Fig. 3b). In accordance with a previous report [21], the
concomitant loss of presenilin protein (Fig. 3a) without any
change in mRNA (data not shown) suggests that loss of
nicastrin is sufficient to destabilize GS complex in BC
cells.
Nicastrin regulates breast epithelial cell–cell junctions
through E-cadherin and p120ctn
The GS substrate E-cadherin is required for the formation
of stable cell–cell adhesions in normal breast epithelium.
To investigate whether nicastrin might impact on the sta-
bility of breast epithelium, the E-cadherin positive MCF7
cell line was transfected with nicastrin siRNA. Silencing of
nicastrin in MCF7 monolayers increased the total cellular
Fig. 2 Kaplan–Meier model comparing breast cancer specific survival in breast cancer patients showing nicastrin protein expression. a Entire
analyzed cohort (n = 1050) (P = 0.664). b ERa positive patients (P = 0.183). c *ERa negative patients (P = 0.05)
Table 2 Nicastrin expression in normal tissues




Skin Normal (n = 12) 2?
Liver Normal (n = 7) 1?/2?
Renal tubules Normal (n = 7) 1?/2?
Renal glomeruli Normal (n = 7) 0
Stomach Normal (n = 5) 1?/2?
Heart Normal (n = 2) 2?
Vaginal cervix Normal (n = 2) 2?
Prostate Normal (n = 12) 0/1?
Colon Normal (n = 7) 0/1?
Lung Normal (n = 7) 0
Ovaries Normal (n = 5) 0/1?
Testis Normal (n = 5) 0/1?
Endometrium Normal (n = 5) 1?
Cerebrum Normal (n = 7) 1?
Pancreas Normal (n = 7) 0/1?
Thyroid Normal (n = 5) 0
Lymph nodes Normal (n = 10) 1?
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levels of E-cadherin mRNA and protein (Fig. 3a, d) and
facilitated its enhanced localization to cell–cell junctions
(Fig. 4a). Together with the observation of reduced inter-
cellular spacing (Fig. 4a), this suggests that nicastrin plays
a significant role in the regulation of BC cell–cell adherens
junctions. A potential mechanism might be via the release
of transcriptional repression upon E-cadherin by Snail1,
since levels of this pivotal transcriptional factor in the EMT
program were significantly reduced following nicastrin
silencing (P \ 0.001) (Fig. 3d).
Additional evidence suggests that nicastrin-dependent
regulation of E-cadherin may involve p120ctn, a molecule
that is responsible for regulating E-cadherin turn-over from
the plasma membrane [22], thereby stabilizing E-cadherin
localization to adherens junctions [12, 23]. This regulatory
mechanism may be modulated by the presence of a stable
GS complex at the plasma membrane where it can compete
with p120ctn for binding to E-cadherin [23]. The increase
in p120ctn protein expression (Fig. 3a) and localization to
MCF7 cell–cell junctions (Fig. 5), following nicastrin
Fig. 3 Nicastrin silencing in breast cancer cells disrupts GS complex,
inhibits the notch signaling pathway and affects proteins that regulate
cell adhesion and motility. a Western blotting analysis using indicated
antibodies in control and nicastrin siRNA treated cells. b-actin used as
loading control. b Quantitative RT-PCRs were carried out to
determine fold changes in expression of nicastrin and Hes1 in
nicastrin siRNA treated samples compared with control (eGFP
siRNA) samples. Data are the mean fold change in expression
compared with control siRNA samples from duplicate samples in
three independent experiments. c GS activity assay upon nicastrin
silencing in MCF7 and MDA-MB231 cells. GS inhibitor (GSI1)
(Calbiochem, UK) at 1 lmol concentration was used as a positive
control in this experiment. Nicastrin silencing significantly inhibits
GS activity (P \ 0.001). Degree of inhibition is comparable to that of
a GSI in both cell lines. d Nicastrin silencing regulates transcription
levels of E-cadherin, Snail and vimentin. Quantitative RT-PCRs were
carried out to determine fold changes in expression of E-cadherin
(CDH1), Snail (SNAI1), and vimentin (VIM) in nicastrin siRNA
treated samples compared with control (eGFP siRNA) samples
(P \ 0.001). Data are the mean fold change in expression compared
with control siRNA samples from duplicate samples in three
independent experiments
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silencing, reveals that there may be multiple levels at
which this component of the GS complex can regulate the
stability of luminal epithelial cell–cell adhesions.
Involvement of nicastrin in BC cell migration
and invasion
Genetic silencing of nicastrin
The finding that high nicastrin expression was borderline
predictive of worse BC specific survival in ERa negative
patients, led to the hypothesis that silencing nicastrin in an
ERa negative MDA-MB-231 cell line, which has a typical
mesenchymal-like phenotype and high metastatic potential,
would inhibit their invasiveness. Genetic silencing of nic-
astrin using siRNA in MDA-MB-231 cells fully disrupted
the GS complex, as demonstrated by the loss of presenilin
protein (Fig. 3a) and reduction in GS enzymatic activity
(Fig. 3c). Although p120ctn protein expression following
siRNA targeting nicastrin was not significantly altered
(Fig. 3a), it displayed a marked relocalization from the
cytoplasm to the sites of cell–cell contact, where it became
associated with F-actin fibers (Fig. 4b). This striking phe-
notype in MDA-MB-231 cells signifies that the loss of
nicastrin and subsequent destabilisation of the GS complex
was sufficient for the re-formation of cell–cell junctions in
cells that have undergone progressive transformation
towards a scattered single cell distribution. Genetic
silencing of nicastrin was also sufficient to abolish tran-
scription and expression of the mesenchymal marker and
pro-migratory cytoskeletal protein vimentin (Fig. 3a, d)
[24]. Video time-lapse microscopy of MDA-MB-231 cells
treated with nicastrin siRNA revealed that their marked
decrease in migratory speed (Fig. 4c) was consistent with a
reduced invasive capacity in Matrigel (Fig. 4d). To vali-
date that the phenotypic changes associated with nicastrin
silencing in BC cells were due to a direct impact on the key
components of the genetic program required to maintain a
Fig. 4 a Nicastrin silencing affects E-cadherin in MCF7 breast cancer
cells. Cells were transfected with nicastrin siRNA and after 72 h fixed,
permeabilized and stained with anti-E-cadherin mAb. The antibodies
were labeled with Zenon Alexa Flour 488 (Invitrogen). b Nicastrin
silencing promotes formation of cell junctions in MDA-MB-231 cells.
MB-MDA-231 cells were stained with anti-p120 mAb followed by
Alexa Flour 488 goat anti-mouse IgG (H ? L) (Invitrogen). Polymer-
ized actin was visualized with a tetramethylrhodamine isothiocyanate–
phalloidin conjugate (red). Nuclei were counterstained with TO-PRO-
3 (blue). Bar = 10 lm. *Cell–cell junctions. Nicastrin silencing
regulates cell–cell junction and pro-invasive proteins in breast cancer
cell lines. c Effect of nicastrin silencing on the migration of MDA-MB-
231 cells. d Effect of nicastrin silencing on invasion of MDA-MB-231
cells. Bars represent mean number of invaded cells ± SD from three
separate experiments. Statistical difference from control levels,
P = 0.01
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mesenchymal cell phenotype, we investigated the migratory
behavior and morphology of NCSTN-/- MEFs [21]. Unlike
NCSTN?/? MEFs, which displayed a typical fibroblastic
spindle-like morphology with a scattered distribution
(Online Resource Movie 1), NCSTN-/- MEFs were roun-
ded and formed dense aggregates (Online Resource Movie 2)
with a marked reduction in their migratory speed ([60%,
P \ 0.01) (Online Resource 2). This evidence strengthens
our hypothesis that nicastrin silencing is capable of restoring
an epithelial and/or less invasive phenotype in BC cells that
have progressed via a bona fide EMT program to become
more invasive.
Development of anti-human nicastrin blocking antibodies
A rabbit polyclonal antibody (PcAb) raised against the
extracellular domain of human nicastrin protein was con-
firmed to bind endogenous nicastrin in MCF7 and MDA-
MB-231 using FACS analysis (Online Resource 3). The
efficacy of blocking nicastrin function with PcAb was
confirmed by its strong inhibitory effects on MDA-MB-231
invasion (70%; P \ 0.001) (Fig. 6a). The first phase of
mouse anti-nicastrin monoclonal antibody (McAb) devel-
opment, resulted in the production of supernatants from
twenty-one clones, of which eight had strong affinity for
endogenous nicastrin in MCF-7 and MDA-MB-231 cells
(data not shown). Seven of the eight clones significantly
inhibited the invasion of MDA-MB-231 cells (Fig. 6b).
The two anti-nicastrin McAb clones with the most potent
anti-invasive effects significantly reduced vimentin
expression and notch1 cleavage, to similar levels as anti-
nicastrin PcAb (Fig. 6c). None of the antibodies affected
nicastrin protein levels (Fig. 6d).
Discussion
Most studies to date reported altered expression and
function of GS substrates, such as notch proteins, E-cad-
herin, CD44, and HER4 [25–27]. Limited attention has
Fig. 5 Nicastrin silencing
regulates p120ctn in MCF7
cells. Cells were transfected
with nicastrin siRNA and after
72 h fixed, permeabilized and
stained with anti-p120ctn mAb
followed by Alexa Flour 594
goat anti-mouse IgG (H ? L)
(Invitrogen). Bar = 10 lm
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been given to investigating the expression and function of
individual GS components, with a general notion that the
function of all four proteins: nicastrin, anterior pharynx
defective 1 homolog, presenilin enhancer protein-2, and
presenilin, are united within this enzyme complex. Existing
results are informative predominantly for expression of
presenilin in mouse and rat tissues. Nicastrin and presenilin
were shown to be upregulated in colon cancer cells as
response to treatment with doxorubicine, enhancing notch
activity, which indicated their involvement in developing
resistance to chemotherapeutic agents [28]. One report
reveals though, that levels of nicastrin and presenilin are
not co-ordinately regulated, suggesting for the first time, an
independent function of nicastrin in mouse smooth muscle
tissue [29]. Recent work has revealed that nicastrin can
indeed function independently from its substrate recogni-
tion role within the GS complex. It was shown that nic-
astrin overexpression in HEK293 cells can regulate p53
mediated cell death via a mechanism that does not require
GS complex formation [30].
This study reveals marked upregulation of nicastrin in
human BC compared to normal breast tissue. Its expression
correlated positively with ERa, PR expression and cyto-
keratin 18 expression, and inversely with cytokeratines 5/6,
Fig. 6 Production of anti-nicastrin PcAb and its effects on BC cells
in vitro. Recombinant protein for PcAb generation was produced as
follows: the primers (aa261–aa512): forward: (50-ggatccgaagcctataaa-
tacaactgggac-30); reverse: (50-gcggccgctcactgaactgtgtcgctgaagttg-30)
were used to generate the DAP-domain containing sequence of
nicastrin (amino acids 261–512) by PCR (Qiagen LongRange PCR
kit). This sequence was ligated into the pET-duet plasmid (Novagen)
and transformed into the Rosetta host strain. His-tagged protein was
isolated (soluble and inclusion bodies) using denaturing conditions
(soluble protein conditions: 100 mM Na phosphate, 10 mM Tris, 8 M
urea pH 8.0 with protease inhibitors; inclusion body conditions:
extraction with 20 mM Tris; pH 8.0; 150 mM NaCl; 1% NP40; 1 mg/
ml lysozyme; 0.01% v/v protease inhibitors), purified on a nickel
column and eluted (20 mM Tris; 300 mM imidazole; 300 mM NaCl,
pH 8.0). Protein was dialyzed in PBS and the precipitate collected and
resuspended in PBS (1 mg/ml) then sequenced by mass-spectrometry
prior to use for immunisation. a Anti-nicastrin PcAb inhibits invasion
of MDA-MB231 cells in a dose dependent manner. Doses of 25–
100 lg/ml produce a significant inhibition (25 lg/ml = 40%, P =
0.009; 50 lg/ml = 57%, P \ 0.001; 100 lg/ml = 70%, P \ 0.001).
b Production of the antigen for McAb generation and anti-nicastrin
McAb effects on BC cells in vitro. The primers: forward (50-gc
tagcatggctacggcagggggtggc-30) and reverse (50-gcggccgctcagtatgaca-
cagctcctggc-30), were used to generate full length nicastrin. This
was cloned into pIRES-neo2 vector (Clontech) (1.07 lg/ll). Genetic
immunisation was performed using proprietary immunisation
plasmids (Genovac, GE). Seven McAbs inhibited invasion of
MDA-MB231 cells. Clones 2H6 and 10C5 were most potent
(reduction C 60%, *P \ 0.001). Anti-nicastrin PcAb (100 lg/ll)
was used as a positive control (70% inhibition, *P \ 0.001).
c MDA-MB231 cells were pre-incubated with anti-nicastrin Pc and
Mc antibodies for 30 min at room temperature before plating. After
72 h in culture, cells were lyzed and protein levels were measured by
western blotting. Rabbit IgG was used as a negative control for the
rabbit anti-nicastrin PcAb and a serum from non-immunized rats was
used as a negative control for the rat anti-nicastrin McAbs. GS
inhibitor was used as a positive control, known to inhibit notch1-ICD.
Anti-nicastrin Pc and Ms Abs inhibit notch1 activation equally to a
GSI. Anti-nicastrin Pc and Mc antibodies also reduced vimentin
protein levels, while the GSI had minimal effect. d Anti-nicastrin Pc
and McAbs did not affect nicastrin protein levels. Relative band
intensities, normalized for loading are shown bellow blots
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suggesting that it is predominantly expressed in non-basal
like breast carcinomas. This is in line with our observation
that tubular breast carcinomas are more likely to express
high nicastrin levels. Tubular BC have predominantly ERa
?ve phenotype and favorable prognosis, but carry a risk of
developing contralateral BC of higher grade [31]. The
potential disconcordance between observed co-expression
of nicastrin and ERa on the one hand, and lack of impact of
high nicastrin expression on survival in hormone-depen-
dent BC, can be explained by the fact that anti-hormonal
treatment given to ERa ?ve patients, attenuates the
adverse impact of nicastrin expression over the years.
Hormone-independent BCs represent a subset of tumors
currently being treated with chemotherapy as first line
adjuvant systemic treatment. High nicastrin expression was
observed in 38.2% of ERa -ve in the analyzed cohort
where we observed a borderline impact on BC specific
survival at 5 years (P = 0.05). Our in vitro data generated
in the MDA-MB231, ERa-ve cell line, show that silencing
nicastrin at the gene level, and blocking nicastrin with
specific PcAb and McAb markedly reduced cell invasion,
vimentin levels and GS activity. Taken together, these
observations suggest that anti-nicastrin McAb may be used
in the treatment of invasive BC to prevent cancer cell
dissemination and metastasis. Also, inhibition of vimentin,
a bona fide EMT denominator, has previously been shown
to reduce cellular invasive capacity [24] during the reversal
of an EMT program.
In ERa ?ve, MCF7 cells, nicastrin silencing was suffi-
cient to stabilize cell–cell junctions. The mechanism
underlying this newly identified property of nicastrin
appears to involve the regulation of E-cadherin and
p120ctn localization to cell–cell junctions. The up-regula-
tion of E-cadherin protein and mRNA levels, as well as the
enhanced cell membrane localization upon nicastrin
silencing could involve several mechanisms. The first
mechanism relates to reduced GS cleavage of E-cadherin,
which consequently reduces E-cadherin turn-over from the
cell membrane. A secondary mechanism of regulation
could occur via the activation of pro-transcriptional targets.
Mechanistically, this could represent a direct nicastrin
effect and/or a notch-mediated event. This is corroborated
by reduced transcription of the notch target Hes1 in MCF7
cells upon nicastrin silencing. Notch-mediated effects on
Snail were previously shown in an ovarian cancer model
[7]. Nicastrin dependent E-cadherin regulation could also
involve p120ctn, which stabilizes E-cadherin localization
to adherens junctions by regulating its turnover or com-
peting with presenilin for direct binding to E-cadherin
[12, 23].
Inhibitors of the GS complex used in the treatment of
Alzheimer’s disease [32] are currently being validated in
clinical trials for a number of human malignancies.
Although their exact mechanism of action remains to be
elucidated, the primary target of GSIs is most likely to be
the catalytic component of the GS complex, presenilin
[33]. Whereas in Alzheimer’s disease the target is beta-
amyloid, the primary targets of GSIs in human malignan-
cies are likely to be notch proteins. Targeting the GS
complex may find a role in re-sensitizing cancer cells to
chemotherapy, hormonal and targeted therapies, given the
upregulation of notch 1 upon treatment with oxaliplatin in
colon cancer [28], and tamoxifen and trastuzumab in BC
cell lines [28, 34, 35]. The lack of tissue specificity of
GSIs, however, results in significant gastrointestinal tox-
icity and lethargy [36], limiting their clinical appeal. Tar-
geting nicastrin may provide an alternate therapeutic way
to achieve more stringent tissue specificity. Further, evi-
dence exists to suggest that nicastrin can function inde-
pendently of the GS complex [30], and therefore targeting
nicastrin may represent a valid therapeutic approach. Our
proof of principle studies using an anti-human nicastrin
PcAb and McAbs confirm that cell surface nicastrin can be
blocked to impart anti-invasive effects on BC cells. This
suggests that developing a humanized McAb against nic-
astrin may help in the future design of personalized ther-
apeutic strategies for the treatment of invasive BC.
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 ESM_1. Detailed description of: a) clinical specimens’ resource and characteristics; b) immunohistochemistry 
staining protocol and, c) statistical analysis. 
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a) Clinical specimens and tissue microarrays. Tissue microarrays (TMAs) containing 1050 primary 
operable BC cases from the Nottingham Tenovus Primary Breast Carcinoma Series (26) were 
employed. The cohort comprised women aged up to 70 years, who presented between 1986 and 1999. 
This well- characterized resource contains information on patients’ clinical and pathological data 
including histological tumor type, primary tumor size, lymph node status, histological grade and data 
on other BC relevant biomarkers. Patients within the good prognosis group (Nottingham Prognostic 
Index (NPI) ≤ 3.4) did not receive adjuvant therapy (AT). Hormonal therapy (HT) was prescribed to 
patients with ERα +ve tumors and NPI scores > 3.4 (moderate and poor prognostic groups). Pre-
menopausal patients within the moderate and poor prognosis groups were candidates for 
cyclophosphamide, metotrexate and 5-fluorouracil (CMF) chemotherapy. Conversely, postmenopausal 
patients with moderate or poor NPI and ERα +ve were offered HT, while ERα -ve patients received 
CMF chemotherapy. Data collected included overall survival, breast cancer specific survival (BCSS), 
disease-free interval (DFI) and time to development of loco-regional and distant metastasis (DM). 
Clinical datawere maintained on a prospective basis. Median follow-up was 124 months (range 1 to 
233). Breast cancer specific survival (BCSS) was defined as the time (in months) from date of the 
primary surgical treatment to the time of death from BC. DFI was defined as the interval (in months) 
from the date of the primary surgery to the first loco-regional or distant metastasis. Human tissue was 
used in accordance with the regulations of the local Research Ethics Committee of Imperial College 
NHS Healthcare Trust without patient identifiers being provided. Archival formalin-fixed, paraffin-
embedded blocks from reduction mammoplasty (n = 40) were obtained from the Pathology 
Department, Charing Cross Hospital, London. TMAs containing normal (BN481) and malignant breast 
(MC5001) tissue cores were purchased from US Biomax Inc., (USA). 
  
b) Immunohistochemistry. Anti-nicastrin pAb N-1660 (Sigma, UK) was optimised to a working 
concentration of 1:200 on full-face excisional BC tissue sections. Subsequently, a 13-slide series BC 
TMA (n = 1050 cases) comprising 4 m thick formalin fixed paraffin embedded tissue cores were 
immunostained using this anti-nicastrin pAb for 3h at room temperature without antigen retrieval. 
Secondary labelling using indirect streptavidin-avidin-biotin was performed followed by detection with 
diaminobenzidine chromogen. Negative controls were performed by omission of the primary antibody. 
Immunostained sections were counterstained with hematoxilin. Nicastrin immunoreactivity was 
detected in the cytoplasm and cell membrane in breast epithelial cells, and was scored based on 
staining intensity ranging from 0 to +3; 0 = null, +1 = low, +2 = intermediate and +3 = high level of 
staining intensity. The percentage of nicastrin positive tumor cells scored as high (+2 or +3 in at least 
66% of cells) or low/none was calculated for each tissue core on the TMAs by two independent 
investigators (AF and JW). High resolution digital imaging (NanoZomer, Hamamatsu Photonics, 
Welwyn Garden City, UK) at 20x magnification with a web-based interface (Distiller, SlidePath Ltd., 
Dublin, Ireland) was used. All cases were scored without prior knowledge of the clinicopathological or 
outcome data.   
 
c) Statistical Analysis. Statistical analysis was performed using SPSS 16.0 statistical software (SPSS 
Inc., Chicago, IL, USA). Cut-off values for different biomarkers included in the study were chosen 
before statistical analysis. Analysis of categorical variables was performed with the appropriate 
statistical test. Survival curves were analysed using the Kaplan-Meier method with significance 
determined by the Log Rank test. Multivariate analysis was performed by Cox hazard analysis. A P 
value ≤ 0.05 (two-sided) was considered significant. 
 
ESM_2.  Effects of the stable nicastrin depletion in mouse embryonic fibroblast cells (MEFs). 
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ESM_2. Stable nicastrin knock-down in mouse embryonic fibroblast cells induces profound morphological and 




 MEFs. b, Cell migration assay 




 MEFs.  
 
 
 ESM_3. FACS analysis of anti-nicastrin PcAb. 
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ESM_3. Polyclonal anti-nicastrin Ab recognizes endogenous nicastrin in breast cancer cells. MDA-MB231 
and MCF7 cells were detached from the culture flasks using EDTA only, palleted and resuspended in PBS. 
Cells were not permeabilized before incubation with the developed PcAb (100µg/ml) for 1 h. Cells were then 
washed in PBS x 3, incubated with the secondary anti-rabbit-FITC Ab for 1 h, washed x 2 and resuspended in 
the final volume of 500ul of PBS. All steps were performed at 4˚C. Rabbit IgG (100µg/ml) was used as the 
negative control. FACS analysis confirm that PcAb against nicastrin recognises endogenously expressed 
nicastrin on the surface of breast cancer cells.  
 
 
Supplementary real-time video microscopy  
 
Online Resource Movie 1  NCSTN +/+ MEFs. Video represents 10 h time-lapse 
microscopy with image collected 1 frame/10 min. 
 
Online Resource Movie 2  NCSTN −/− MEFs. Video represents 10 h time-lapse 
microscopy with image collected 1 frame/10 min. Display rate is 10 frames per 
second. 
 
Information is available from: 
http://www.springerlink.com/content/h4243855l5g26224/10549_2010_Article_823_E
SM.html 
